Crosslinked antibodies

By introducing non-natural amino acid residues into the targeting domain, using covalent bonding technology to achieve targeted binding and payload delivery of proteins, the problem of improving protein function and diversity in the prior art is solved, and is suitable for the treatment of various diseases. .

CN118922209APending Publication Date: 2024-11-08ENLAZA THERAPEUTICS INC
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202280092390.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-07-11
Filing Date
2022-12-22
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art has difficulty effectively leveraging covalent bonds between proteins to enhance protein diversity and function, especially in the identification of proteins, drug discovery and payload delivery in vivo.

Method used

Conjugates containing targeting domains and payloads are developed, where the targeting domains contain non-natural amino acid residues capable of forming covalent bonds with the targets for targeting cell surface molecules for targeting targeted binding and payload delivery.

Benefits of technology

Through the formation of covalent bonds, the binding stability of the conjugate to the target and the delivery efficiency of the payload are enhanced, and is suitable for the treatment of a variety of cancers and other diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922209A_ABST
    Figure CN118922209A_ABST
Patent Text Reader

Abstract

Provided herein are compositions and methods for cross-linking a single domain antibody to a target with a conjugate. Further provided herein are conjugates comprising a targeting domain, wherein the targeting domain comprises a non-natural amino acid. Further provided herein are methods of treating disease with cross-linked single domain antibodies and multispecific antibodies.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references

[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 293,025, filed on December 22, 2021; U.S. Provisional Patent Application No. 63 / 346,799, filed on May 27, 2022; and U.S. Provisional Patent Application No. 63 / 388,072, filed on July 11, 2022, which are incorporated herein by reference in their entireties. Background Art

[0003] Proteins primarily use non-covalent interactions within or between proteins, as the amino acid side chains of proteins are generally unable to form covalent bonds with each other, with the exception of cysteine, which produces relatively weak reversible disulfide bonds. Therefore, potentially bioactive unnatural amino acids (UAAs) that can react specifically with multiple natural amino acid residues on target proteins will expand the diversity of proteins that can be covalently bonded in vivo, which can enhance existing protein properties or evolve new functions by utilizing new covalent bonds. In addition, covalent bonds between proteins will allow for irreversible capture of protein-protein interactions in vivo, which can be used for protein identification, drug discovery, irreversible antagonists, and payload delivery. Summary of the invention

[0004] Provided herein is a conjugate comprising a targeting domain and a payload, wherein the targeting domain comprises at least one non-natural amino acid (UAA) residue, wherein the targeting domain is configured to be bound to a target, and wherein when the targeting domain is bound, the UAA residue is close enough to form a covalent bond with the target. Further provided herein is a conjugate wherein the payload is attached to an amino acid in position n+x relative to the UAA residue, wherein n is the position of the amino acid, and x is at least 1. Further provided herein is a conjugate wherein the payload is attached to an amino acid in position nx relative to the UAA residue, wherein n is the position of the amino acid, and x is at least 1. Further provided herein is a conjugate wherein the UAA residue is within 5-20 angstroms of the target when the targeting domain is bound to the target. Further provided herein is a conjugate wherein the targeting domain is bound to a cell surface molecule. Further provided herein is a conjugate wherein the UAA residue is configured to form a covalent bond with the histidine, lysine or tyrosine residue of the target. Further provided herein is a conjugate wherein the UAA residue comprises a fluorosulfate moiety. Further provided herein is a conjugate wherein the UAA residue comprises an aryl fluorosulfate moiety. Further provided herein are wherein the UAA residue comprises Formula I: Further provided herein are conjugates wherein the UAA residue has the structure: Further provided herein are conjugates wherein the UAA residue has the structure: Further provided herein are conjugates wherein the UAA residue comprises Formula II: Further provided herein are conjugates wherein the UAA residue has the structure: Further provided herein are conjugates wherein the UAA residue has the structure: Further provided herein are conjugates wherein the UAA residue comprises Formula III: Further provided herein are conjugates wherein the UAA residue has the structure: Further provided herein are conjugates wherein the UAA residue has the structure: conjugate.

[0005] Further provided herein are conjugates wherein the UAA of the UAA residue has the structure of Formula (IA):

[0006]

[0007] in,

[0008] Each X is independently O or NR';

[0009] Y is a bond, -O-, -NR- or -N=;

[0010] A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4;

[0011] When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl;

[0012] R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl;

[0013] L is -(CH2) p -or-C(O)NH-(CH2) p -; p is an integer from 1 to 6; and

[0014] When Y is -O- or -NR-, m is 1; when Y is -N=, m is 2.

[0015] Further provided herein are wherein the UAA of formula (IA) has formula (IA-a): Further provided herein is a conjugate of a structure of wherein the UAA of formula (IA) has formula (IA-b): Further provided herein is a conjugate of a structure of wherein the UAA of formula (IA) has formula (IB): Further provided herein is a conjugate of a structure of wherein the UAA of formula (IA) has formula (IC): Conjugate of the structure.

[0016] Further provided herein are wherein the UAA of Formula (IA) has Formula (ID): Conjugate of the structure,

[0017] in:

[0018] Each X is independently O or NR';

[0019] Y is a bond, -O-, -NR- or -N=;

[0020] A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4;

[0021] When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl;

[0022] R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and

[0023] When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

[0024] Further provided herein are conjugates wherein the UAA of Formula (IA) has the structure of Formula (IE):

[0025]

[0026] in:

[0027] Each X is independently O or NR';

[0028] Y is a bond, -O-, -NR- or -N=;

[0029] A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4;

[0030] When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl;

[0031] R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and

[0032] When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

[0033] Further provided herein are conjugates wherein the UAA of Formula (IA) has the structure of Formula (IIA):

[0034]

[0035] in:

[0036] X is independently O or NR'; and

[0037] When present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

[0038] Further provided herein are conjugates wherein the UAA of Formula (IA) has the structure of Formula (IIB):

[0039]

[0040] in:

[0041] X is independently O or NR'; and

[0042] When present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

[0043] Further provided herein is a UAA wherein the UAA residue has the formula (IV) Conjugate of the structure,

[0044] in,

[0045] Each X is independently O or NR';

[0046] Y is a bond, -O-, -NR- or -N=;

[0047] A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4;

[0048] When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl;

[0049] Ring A is a 5- to 6-membered aryl or heteroaryl group;

[0050] Each R A are independently -OH, -OR X , halogen, NHR X 、N(R X )2 or optionally substituted alkyl; each R X is an optionally substituted alkyl group;

[0051] L is -(CH2) p -or-C(O)NH-(CH2) p -; p is an integer from 1 to 6; and

[0052] When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

[0053] Further provided herein are conjugates wherein the payload comprises an imaging agent, a radioligand agent, or a cytotoxic agent. Further provided herein are conjugates wherein the cytotoxic moiety comprises a small molecule drug or a chemotherapeutic drug. Further provided herein are conjugates wherein the radioligand agent is selected from 153 Sm, 177 Lu, 90 Y. 131 I. 149 Tb, 211 At 212 Pb / 212 Bi, 213 Bi, 223 Ra, 225 Ac and 227 Further provided herein are conjugates wherein the radioligand agent further comprises a chelating agent. Further provided herein are conjugates wherein the radioligand agent is selected from 99m Tc, 131 I. 201 Tl, 111 In and 67Ga conjugate. Further provided herein is a conjugate, wherein the payload is attached to the conjugate with a linker. Further provided herein is a conjugate wherein the linker includes a polymer. Further provided herein is a conjugate wherein the linker is a cleavable or non-cleavable linker. Further provided herein is a conjugate wherein the linker is 0.01kDa to 2.5kDa. Further provided herein is a conjugate wherein the linker is 0.01kDa to 2.5kDa. Further provided herein is a conjugate wherein the linker is a linear, branched, polymer or dendrimer. Further provided herein is a conjugate wherein the linker is a bifunctional or multifunctional linker or a bifunctional or multifunctional polymer. Further provided herein is a conjugate wherein the linker includes a water-soluble polymer. Further provided herein is a conjugate wherein the water-soluble polymer is polyethylene glycol (PEG). Further provided herein is a conjugate wherein the molecular weight of PEG is between 0.1kDa and 2.5kDa. Further provided herein is a conjugate wherein PEG comprises 1-8 monomers. Further provided herein is a conjugate wherein the targeting domain includes an antibody, an antibody fragment or an antigen binding domain. Further provided herein are conjugates wherein the targeting domain comprises an antigen binding domain, the conjugate comprises a CDR region, and at least one UAA residue is within or near the CDR region. Further provided herein are conjugates wherein the UAA residue is contained within the CDR region. Further provided herein are conjugates wherein the targeting domain comprises a single domain antibody (sdAb).Further provided herein is a method wherein the cell surface molecule is selected from the group consisting of PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPa, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3 rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, C D73, ITGaVb3, ITGaVb6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD25 , 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47 and EpCAM conjugates.

[0054] Also provided herein are conjugates comprising (i) a payload and (ii) an engineered single domain antibody (sdAb), the engineered single domain antibody comprising an sdAb having a CDR region and at least one unnatural amino acid (UAA) residue within or near the CDR region, wherein the sdAb comprises any one of SEQ ID NOs: 1-4 or 16-64. Further provided herein are conjugates wherein the UAA residue comprises a fluorosulfate moiety. Further provided herein are conjugates wherein the UAA residue comprises an aryl fluorosulfate moiety. Further provided herein are conjugates wherein the UAA residue comprises Formula I: Further provided herein are conjugates wherein the UAA residue has the structure: Further provided herein are conjugates wherein the UAA residue has the structure: Further provided herein are conjugates wherein the UAA residue comprises Formula II: Further provided herein are conjugates wherein the UAA residue has the structure: Further provided herein is a conjugate wherein UAA has the structure: Further provided herein are conjugates wherein the UAA residue comprises Formula III: Further provided herein are conjugates wherein the UAA residue has the structure: Further provided herein are conjugates wherein the UAA residue has the structure: conjugate.

[0055] Further provided herein are conjugates wherein the UAA of the UAA residue has the structure of Formula (IA):

[0056]

[0057] in,

[0058] Each X is independently O or NR';

[0059] Y is a bond, -O-, -NR- or -N=;

[0060] A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4;

[0061] When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl;

[0062] R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl;

[0063] L is -(CH2) p -or-C(O)NH-(CH2) p -; p is an integer from 1 to 6; and

[0064] When Y is -O- or -NR-, m is 1; when Y is -N=, m is 2.

[0065] Further provided herein are wherein the UAA of formula (IA) has formula (IA-a): Further provided herein is a conjugate of a structure of wherein the UAA of formula (IA) has formula (IA-b): Further provided herein is a conjugate of a structure of wherein the UAA of formula (IA) has formula (IB): Further provided herein is a conjugate of a structure of wherein the UAA of formula (IA) has formula (IC): Conjugate of the structure.

[0066] Further provided herein are wherein the UAA of Formula (IA) has Formula (ID): Conjugate of the structure,

[0067] in:

[0068] Each X is independently O or NR';

[0069] Y is a bond, -O-, -NR- or -N=;

[0070] A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4;

[0071] When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl;

[0072] R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and

[0073] When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

[0074] Further provided herein are wherein the UAA of Formula (IA) has Formula (IE): The structure of the conjugate:

[0075] in:

[0076] Each X is independently O or NR';

[0077] Y is a bond, -O-, -NR- or -N=;

[0078] A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4;

[0079] When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl;

[0080] R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and

[0081] When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

[0082] Further provided herein are engineered sdAbs wherein the UAA of Formula (IA) has Formula (IIA): The structure,

[0083] in:

[0084] X is independently O or NR'; and

[0085] When present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

[0086] Further provided herein are engineered sdAbs wherein the UAA of Formula (IA) has Formula (IIB): The structure of which:

[0087] X is independently O or NR'; and

[0088] When present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

[0089] Further provided herein is a UAA wherein the UAA residue has the formula (IV) Conjugate of the structure,

[0090] in,

[0091] Each X is independently O or NR';

[0092] Y is a bond, -O-, -NR- or -N=;

[0093] A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4;

[0094] When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl;

[0095] Ring A is a 5- to 6-membered aryl or heteroaryl group;

[0096] Each R A are independently -OH, -OR X , halogen, NHR X 、N(R X )2 or optionally substituted alkyl; each R X is an optionally substituted alkyl group;

[0097] L is -(CH2)p -or-C(O)NH-(CH2) p -; p is an integer from 1 to 6; and

[0098] When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

[0099] Further provided herein are conjugates, wherein the engineered sdAb comprises SEQ ID NO: 1, and wherein the UAA residue is contained in any one of SEQ ID NOs: 5, 6, and 7. Further provided herein are conjugates, wherein the UAA residue is present at an amino acid position selected from 26, 28, 29, 30, 99, 102, 103, 105, 108, 110, 111, 112, 113, 114, and 115 relative to SEQ ID NO: 1. Further provided herein are conjugates, wherein the engineered sdAb comprises SEQ ID NO: 2, and wherein the UAA residue is contained in any one of SEQ ID NOs: 8, 9, and 10. Further provided herein are conjugates, wherein the UAA residue is present at an amino acid position selected from 50, 52, 53, 54, 56, 58, and 100 relative to SEQ ID NO: 2. Further provided herein are conjugates, wherein the engineered sdAb comprises SEQ ID NO: 3, and wherein the UAA residue is contained in any one of SEQ ID NOs: 11, 12, and 13. Further provided herein are conjugates, wherein the UAA residue is present at an amino acid position selected from 58, 62, 101, 103, and 107 relative to SEQ ID NO: 3. Further provided herein are conjugates, wherein the engineered sdAb comprises SEQ ID NO: 16, and wherein the UAA is present at an amino acid position 109 relative to SEQ ID NO: 16. Further provided herein are conjugates, wherein the engineered sdAb comprises SEQ ID NO: 23, and wherein the UAA is present at an amino acid position selected from 52, 53, 54, 55, 56, 58, 60, 62, and 64 relative to SEQ ID NO: 23. Further provided herein are conjugates, wherein the engineered sdAb comprises SEQ ID NO: 24, and wherein the UAA is present at an amino acid position selected from 53, 55, 56, 57, 58, 60, 64, and 67 relative to SEQ ID NO: 24.

[0100] Further provided herein are conjugates wherein the payload is not attached via the side chain of a UAA residue. Further provided herein are conjugates wherein the payload comprises an imaging agent, a radioligand agent, or a cytotoxic agent. Further provided herein are conjugates wherein the cytotoxic moiety comprises a small molecule drug or a chemotherapeutic drug. Further provided herein are conjugates wherein the radioligand agent is selected from 153 Sm,177 Lu, 90 Y. 131 I. 149 Tb, 211 At 212 Pb / 212 Bi, 213 Bi, 223 Ra, 225 Ac and 227 Further provided herein are conjugates wherein the radioligand agent further comprises a chelating agent. Further provided herein are conjugates wherein the imaging agent comprises a fluorophore or selected from 99m Tc, 131 I. 201 Tl, 111 In and 67 Conjugate of a radioligand reagent with Ga.

[0101] Provided herein are methods comprising administering a conjugate as described herein, wherein the conjugate covalently binds to a target on the surface of a cell. Further provided herein are methods wherein the cell comprises a tumor cell. Further provided herein are methods wherein the conjugate kills a tumor cell or inhibits tumor cell growth. Further provided herein are methods wherein the target is selected from PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPa, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3 rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, C D73, ITGaVb3, ITGaVb6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD2 5, 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47 and EpCAM. Provided herein are methods of treating a disease or condition comprising administering a conjugate described herein.Further provided herein are methods wherein the disease comprises one or more of PCa (prostate cancer), CRPCa (castration-resistant prostate cancer), solid tumors (neovasculature), NSCLC (non-small cell lung cancer), HNSCC (head and neck squamous cell carcinoma), ESCC (esophageal cancer), GC (gastric cancer), CRC (colorectal cancer), SCLC (small cell lung cancer), MPM (mesothelioma), PDAC (ductal pancreatic adenocarcinoma), ALL (acute lymphoblastic leukemia), AML (acute myeloid leukemia), MDS (myelodysplastic syndrome), MSI-high tumors, melanoma, DLBCL (diffuse large B-cell lymphoma), endometrial cancer, cervical cancer, bladder cancer, BrCa (breast cancer), TNBC (triple negative breast cancer), NE-PCa (neuroendocrine prostate cancer), GBM (glioblastoma) and RCC (renal cell carcinoma).

[0102] Provided herein are methods for making the conjugates described herein, comprising: generating a targeting domain comprising at least one unnatural amino acid; and optionally conjugating the targeting domain to a payload via a linker. Further provided herein are methods wherein a targeting domain comprising at least one unnatural amino acid is synthesized in vivo. Further provided herein are methods wherein generation comprises using an orthogonal tRNA synthetase / suppressor tRNA pair. Further provided herein are methods wherein generation comprises an orthogonal tRNA synthetase / suppressor tRNA pair (derived from pyrrolysine tRNA synthetase / tRNA Pyl ). Further provided herein are methods wherein the orthogonal tRNA synthetase comprises SEQ ID NO: 84, 87, 92 or a variant thereof.

[0103] Provided herein is a method for delivering a cytotoxic payload to a cell, comprising administering a conjugate as described herein, wherein the conjugate covalently binds to a target on the surface of the cell, thereby delivering the cytotoxic payload. Further provided herein is a method wherein the cell is a tumor cell. Further provided herein is a method wherein the cell is contained in a tumor microenvironment. Further provided herein is a method wherein the cell is contained in a mammalian subject. Further provided herein is a method wherein the cell is contained in a human subject. Further provided herein is a method wherein the conjugate kills tumor cells or inhibits tumor cell growth. Further provided herein is a method wherein the target is selected from PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPa, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3 rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, C D73, ITGaVb3, ITGaVb6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD2 5, 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47, and EpCAM.Further provided herein are methods wherein the human subject has or is diagnosed with a disease or condition selected from the group consisting of PCa (prostate cancer), CRPCa (castration-resistant prostate cancer), solid tumors (neovasculature), NSCLC (non-small cell lung cancer), HNSCC (head and neck squamous cell carcinoma), ESCC (esophageal cancer), GC (gastric cancer), CRC (colorectal cancer), SCLC (small cell lung cancer), MPM (mesothelioma), PDAC (ductal pancreatic adenocarcinoma), ALL (acute lymphoblastic leukemia), AML (acute myeloid leukemia), MDS (myelodysplastic syndrome), MSI-high tumors, melanoma, DLBCL (diffuse large B-cell lymphoma), endometrial cancer, cervical cancer, bladder cancer, BrCa (breast cancer), TNBC (triple negative breast cancer), NE-PCa (neuroendocrine prostate cancer), GBM (glioblastoma) and RCC (renal cell carcinoma).

[0104] Provided herein is a conjugate comprising (i) a first targeting domain, (ii) a second targeting domain, and (iii) a payload, wherein the first targeting domain comprises at least one first unnatural amino acid (UAA), whereby the first targeting region can be covalently bound to the first target at the site of the UAA, and the second targeting domain is configured to bind to the second target. In some embodiments, the first target and the second target are located on the same cell. In some embodiments, the first targeting domain comprises an antibody, an antibody fragment, or an antigen binding domain. In some embodiments, the first targeting domain comprises a single domain antibody (sdAb). In some embodiments, the first UAA is contained in or near the region of the first targeting domain that is connected to the first target. In some embodiments, the second targeting domain comprises an antibody, an antibody fragment, or an antigen binding domain. In some embodiments, the second targeting domain comprises a single domain antibody (sdAb). In some embodiments, the first targeting domain and the second targeting domain are connected to form a fusion protein. In some embodiments, the first targeting domain and the second targeting domain are connected by chemical conjugation. In some embodiments, the first targeting domain and the second domain are connected by a connector. In some embodiments, the first targeting domain and the second targeting domain bind to the same target. In some embodiments, the first targeting domain and the second targeting domain bind to different epitopes of the same target. In some embodiments, the first targeting domain and the second targeting domain bind to the same epitope of the same target. In some embodiments, the same target is a monomer. In some embodiments, the same target is a multimeric molecule. In some embodiments, the first targeting domain and the second targeting domain bind to different targets. In some embodiments, the first target is a first cell surface molecule. In some embodiments, the second target is a second cell surface molecule. In some embodiments, at least one first UAA comprises a fluorosulfate moiety. In some embodiments, at least one UAA comprises an aryl fluorosulfate moiety. In some embodiments, at least one first UAA comprises Formula I: In some embodiments, at least one first UAA has the structure: In some embodiments, at least one first UAA has the structure: (FSY). In some embodiments, at least one first UAA comprises Formula II: In some embodiments, at least one first UAA has the structure: In some embodiments, at least one first UAA has the structure: In some embodiments, at least one first UAA comprises Formula III: In some embodiments, at least one first UAA has the structure: In some embodiments, at least one first UAA has the structure: In some embodiments, at least one first UAA has Formula (IA): The structure of wherein each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; when present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; L is -(CH2) p -or-C(O)NH-(CH2) p -; p is an integer from 1 to 6; and wherein when Y is -O- or -NR-, m is 1; when Y is -N=, m is 2. In some embodiments, at least one first UAA has formula (IA-a): In some embodiments, at least one first UAA has formula (IA-b): In some embodiments, at least one first UAA has formula (IB): In some embodiments, at least one first UAA has formula (IC): In some embodiments, at least one first UAA has formula (ID): The structure of wherein: each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n-; m is 1 or 2; n is an integer from 1 to 4; when present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and wherein when Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2. In some embodiments, at least one first UAA has formula (IE): The structure of wherein: each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; when present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and wherein when Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2. In some embodiments, at least one first UAA has formula (IIA): wherein: X is independently O or NR'; and when present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl. In some embodiments, at least one first UAA has formula (IIB): wherein: X is independently O or NR'; and when present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl. In some embodiments, at least one first UAA has formula (IV) The structure of wherein each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; when present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycloalkyl; Ring A is a 5- to 6-membered aryl or heteroaryl group; each R A are independently -OH, -OR X , halogen, NHR X 、N(R X)2 or optionally substituted alkyl; p is 0, 1, 2, 3 or 4; each R X is an optionally substituted alkyl group; L is -(CH2) p -or-C(O)NH-(CH2) p-; p is an integer from 1 to 6; and wherein when Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2. In some embodiments, the first cell surface molecule is selected from PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPa, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3 rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, CD73, ITGaVb3, ITGaVb6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD 25, 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47, and EpCAM.In some embodiments, the second cell surface molecule is selected from PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPa, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3 rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, CD73, ITGaVb3, ITGaVb6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD 25, 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47 and EpCAM. In some embodiments, the second domain comprises a second UAA, whereby the second domain can be covalently bound to the second target at the site of the second UAA. In some embodiments, the second UAA is different from at least one UAA contained in the first targeting domain. In some embodiments, the second UAA is the same as at least one UAA contained in the first targeting domain. In some embodiments, the second UAA comprises a fluorosulfate moiety. In some embodiments, the second UAA comprises an aryl fluorosulfate moiety. In some embodiments, the second UAA comprises Formula I:. In some embodiments, the second UAA has the structure: In some embodiments, the second UAA has the structure: In some embodiments, the second UAA comprises Formula II: In some embodiments, the second UAA has the structure: In some embodiments, the second UAA has the structure: In some embodiments, the second UAA comprises Formula III: In some embodiments, the second UAA has the structure: In some embodiments, the second UAA has the structure: In some embodiments, the second UAA has Formula (IA): The structure of wherein each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; when present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; L is -(CH2) p -or-C(O)NH-(CH2) p -; p is an integer from 1 to 6; and wherein when Y is -O- or -NR-, m is 1; when Y is -N=, m is 2. In some embodiments, the second UAA has formula (IA-a): In some embodiments, the second UAA has formula (IA-b): In some embodiments, the second UAA has formula (IB): In some embodiments, the second UAA has formula (IC): In some embodiments, the second UAA has formula (ID): The structure of wherein: each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; when present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and wherein when Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2. In some embodiments, the second UAA has formula (IE): The structure of wherein: each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n-; m is 1 or 2; n is an integer from 1 to 4; when present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and wherein when Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2. In some embodiments, the second UAA has formula (IIA): wherein: X is independently O or NR'; and when present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl. In some embodiments, the second UAA has formula (IIB): wherein: X is independently O or NR'; and when present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl. In some embodiments, the second UAA has formula (IV) The structure of wherein each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; when present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycloalkyl; Ring A is a 5- to 6-membered aryl or heteroaryl group; each R A are independently -OH, -OR X , halogen, NHR X 、N(R X )2 or optionally substituted alkyl; p is 0, 1, 2, 3 or 4; each R X is an optionally substituted alkyl group; L is -(CH2) p -or-C(O)NH-(CH2) p-; p is an integer from 1 to 6; and wherein when Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2. In some embodiments, the first targeting domain comprises any one of SEQ ID NOs: 1-4 or 16-64. In some embodiments, the first targeting domain comprises a sequence having at least 70% sequence identity with any one of SEQ ID NOs: 1-4 or 16-64. In some embodiments, the second targeting domain comprises any one of SEQ ID NOs: 1-4 or 16-64. In some embodiments, the second targeting domain comprises a sequence having at least 70% identity with any one of SEQ ID NOs: 1-4 or 16-64. In some embodiments, the conjugate comprises SEQ ID NOs: 66-72. In some embodiments, the conjugate comprises a sequence having at least 70% sequence identity with SEQ ID NOs: 66-72. In some embodiments, the conjugate comprises any one of SEQ ID NOs: 1-4 or 16-64. In some embodiments, the conjugate comprises a sequence having at least 70% sequence identity to any one of SEQ ID NOs: 1-4 or 16-64. In some embodiments, the conjugate comprises a sequence having at least 70% sequence identity to SEQ ID NOs: 66-72. In some embodiments, at least one of the first targeting domain and the second targeting domain comprises SEQ ID NO: 1. In some embodiments, the UAA is present at an amino acid position selected from 26, 28, 29, 30, 99, 102, 103, 105, 108, 110, 111, 112, 113, 114, and 115 relative to SEQ ID NO: 1. In some embodiments, at least one of the first targeting domain and the second targeting domain comprises SEQ ID NO: 2. In some embodiments, the UAA is present at an amino acid position selected from 50, 52, 53, 54, 56, 58, and 100 relative to SEQ ID NO: 2. In some embodiments, at least one of the first targeting domain and the second targeting domain comprises SEQ ID NO: 3. In some embodiments, the UAA is present at an amino acid position selected from 58, 62, 101, 103, and 107 relative to SEQ ID NO: 3. In some embodiments, at least one of the first targeting domain and the second targeting domain comprises SEQ ID NO: 16. In some embodiments, at least one of the first targeting domain and the second targeting domain comprising SEQ ID NO: 16 further comprises an unnatural amino acid at position 109 relative to SEQ ID NO: 16. In some embodiments, at least one of the first targeting domain and the second targeting domain comprises SEQ ID NO: 18. In some embodiments, the payload comprises an imaging agent, a radioligand agent, or a cytotoxic agent.In some embodiments, the cytotoxic moiety comprises a small molecule drug or a chemotherapeutic drug. In some embodiments, the radioligand agent is selected from the group consisting of. 153 Sm, 177 Lu, 90 Y. 131 I. 149 Tb, 211 At 212 Pb / 212 Bi, 213 Bi, 223 Ra, 225 Ac and 227 Th. In some embodiments, the radioligand agent further comprises a chelating agent. In some embodiments, the radioligand agent is selected from 99m Tc, 131 I. 201 Tl, 111 In and 67Ga. In some embodiments, the payload is attached to the conjugate with a connector. On the other hand, provided herein is a method comprising administering a conjugate provided herein, wherein the conjugate covalently binds to a first target on the surface of a first cell. In some embodiments, the conjugate binds to a second target on the surface of a first cell. In some embodiments, the first targeting domain and the second targeting domain bind to the same target. In some embodiments, the first targeting domain and the second targeting domain bind to the same epitope of the same target. In some embodiments, the first targeting domain and the second targeting domain bind to different epitopes of the same target. In some embodiments, the first targeting domain and the second targeting domain bind to different targets on the surface of the first cell. In some embodiments, the second domain comprises a second UAA, and wherein the second UAA is covalently bound to the second target. In some embodiments, the first cell is a tumor cell. In some embodiments, when bound to the first target, the conjugate kills the tumor cell or inhibits the growth of the tumor cell. In some embodiments, when bound to the second target, the conjugate kills the tumor cell or inhibits the growth of the tumor cell. In some embodiments, when bound to the first target and the second target, the conjugate kills the tumor cell or inhibits the growth of the tumor cell.In some embodiments, the first target is selected from PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPa, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3 rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, CD73, ITGaVb3, ITGaVb6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD 25, 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47, and EpCAM.In some embodiments, the second target is selected from PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPα, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, CD73, ITGaVb3 , ITGaVb6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD25, 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47, and EpCAM. In some embodiments, the payload is a radiolabeling agent or a cytotoxic agent. In some embodiments, the payload is an imaging agent. In some embodiments, when the conjugate is bound to the first target and the second target on the first cell, the method images or identifies the first cell. On the other hand, there is provided herein a method for manufacturing a conjugate provided herein, including: (a) synthesizing a first targeting domain comprising at least one non-natural amino acid in vivo; and (b) optionally conjugating the payload to the first targeting domain or the second targeting domain via a connector. In some embodiments, the method further includes synthesizing the second targeting domain in vivo as a fusion protein with the first targeting domain. In some embodiments, the synthesis includes using an orthogonal tRNA synthetase / suppressive tRNA pair. In some embodiments, the synthesis includes an orthogonal tRNA synthetase / suppressive tRNA pair, which is derived from pyrrolysine tRNA synthetase / tRNA. Pyl .

[0105] Incorporation by reference

[0106] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. BRIEF DESCRIPTION OF THE DRAWINGS

[0107] The novel features of the present invention are particularly set forth in the appended claims. The features and advantages of the present invention will be better understood by reference to the following detailed description and accompanying drawings, in which illustrative embodiments utilizing the principles of the present invention are set forth, wherein:

[0108] Figures 1A-1E Various SDS-PAGE analyses of cross-linking between FSY-modified sdAbs with FSY at different positions and PSMA at 37°C are shown, wherein the molar ratio of sdAb to PSMA is about 7:1 (PSMA final concentration is 0.125 mg / mL, 1.25 uM). Figure 1A Depicted is a gel showing the C1 construct containing FSY in the presence or absence of target PSMA. PSMA-C1-FSY crosslinks, PSMA and C1-FSY are labeled. Figure 1B Depicted is a gel showing the C1 construct containing FSY in the presence or absence of target PSMA. PSMA-C1-FSY crosslinks, PSMA and C1-FSY are labeled. Figure 1C Depicted is a gel showing the C1 construct containing FSY in the presence or absence of target PSMA. PSMA-C1-FSY crosslinks, PSMA and C1-FSY are labeled. Figure 1D Depicted is a gel showing the C1 construct containing FSY in the presence or absence of target PSMA. PSMA-C1-FSY crosslinks, PSMA and C1-FSY are labeled. Figure 1E Depicted is a gel showing the C1 construct containing FSY in the presence or absence of target PSMA. PSMA-C1-FSY crosslinks, PSMA and C1-FSY are labeled.

[0109] Figure 2A-2C Various SDS-PAGE analyses of cross-linking between C2 (PSMA-specific sdAb) and PSMA at 37°C, where the molar ratio of sdAb:PSMA was 8:1, are shown. Figure 2A Depicted is a gel showing a C2 construct containing FSY at positions 50-61 in the presence of target PSMA as well as PSMA and wild-type C2-CDR2 library controls. Thick arrows indicate the presence of cross-linked products. PSMA and C2 are marked with thin arrows. Figure 2B Depicted is a gel showing the C2 construct containing FSY in the presence of target PSMA. Figure 2CDepicted is a gel showing a C2 construct containing FSY in the presence of target PSMA and a wild-type C2-CDR3 library control. Thick arrows indicate the presence of cross-linked products. PSMA and C2-FSY are marked with thin arrows.

[0110] Figure 3A Shown is SDS-PAGE analysis of the cross-linking kinetics between FSY-modified sdAb (FSY at position 28 or 102 of C1) and PSMA at a molar ratio of 5:1 (PSMA final concentration 0.125 mg / mL, 1.25 uM) at 37°C for 180 min.

[0111] Figure 3B Shown is a kinetic graph of the percentage of PSMA cross-linking versus time for a cross-linking experiment between FSY-modified sdAb and PSMA. The y-axis is labeled as cross-linked PSMA% (0 to 60, 10 units apart), and the x-axis is labeled as time (min, 0 to 180, 30 min apart). The constructs tested were C1-28FSY (circles), C1-102FSY (squares), C1-112FSY (triangles), C1-113FSY (inverted triangles).

[0112] Figure 4 Diagrams of monomeric C1-related sdAb constructs are shown. C1 (wild-type sequence containing two cysteine ​​disulfide bonds), C39 (C1-C101A / C104A, one cysteine ​​disulfide bond replaced by two alanines, thereby removing the disulfide bond), C1-102FSY (construct C1, histidine 102 replaced by the unnatural amino acid FSY), and C39-102FSY (C1-C101A / C104A / H102 (FSY), both C101 and C104 cysteines replaced by alanines, histidine 102 replaced by FSY).

[0113] Figure 5A Shown is an SDS-PAGE analysis of the cross-linking kinetics of the biparatopic construct C40-102FSY (generated by ligating the C39-102FSY sequence to a copy of C39 without FSY) or a monoparatopic construct of C39-102FSY to PSMA over 180 minutes at 37° C. Bands corresponding to C39-102FSY, C40-102FSY, receptor, and cross-linking species are labeled. The coupling rate of the biparatopic construct is increased compared to the monoparatopic construct.

[0114] Figure 5B The kinetics of PSMA cross-linking versus time are shown for cross-linking between the biparatopic construct C40-102FSY or the monoparatopic construct C39-102FSY and PSMA.

[0115] Fig. 6A and 6B SDS-PAGE analysis of cross-links between various FSY-modified C3 constructs is shown. Fig. 6A Results are shown for C3 constructs with FSY at positions 26-35 and 50-60; the cross-linked product of construct C3-58FSY is indicated with an asterisk. Figure 6B Results are shown for C3 constructs with FSY at positions 61-66 and 99-113); cross-linking products were observed for at least constructs C3-62FSY, C3-101FSY, C3-103FSY, C3-107FSY.

[0116] Fig. 7A Shown is SDS-PAGE analysis of cross-links between various pooled FSK-modified C8 constructs and the FAP receptor. Figure 7B Shown is SDS-PAGE analysis of cross-links between various single FSK-modified C8 constructs and the FAP receptor.

[0117] Figure 7C Shown is an SDS-PAGE analysis of the cross-linking kinetics between various FSK-modified C8 constructs and the FAP receptor.

[0118] Figures 8A-8D SDS-PAGE analysis of cross-linking between various FSY-modified C9 constructs and Her3 receptor is shown. Fig. 8A Results are shown for a library of C9 constructs with FSY at various positions and the Her3 receptor. Figure 8B Results are shown for a C9 construct with FSY at positions 52-68 and the Her3 receptor. Figure 8C Results are shown for C9 constructs with FSY at position 53, 55, 56, 57, 58, 60, 64 or 67 and the Her3 receptor. Fig.8D Shown is SDS-PAGE analysis of the cross-linking kinetics between the FSY-modified C9 construct (C9-55FSY) and the Her3 receptor.

[0119] Fig. 9 Shown are the results of binding assays of C2-54FSY and C2-54TYR sdAbs to human prostate tumor cell lines LNCaP (PSMA+) and PC3 (PSMA-) using flow cytometry.

[0120] Fig. 10A and 10B SDS-PAGE analysis of FSY-modified sdAb cross-linked to cells is shown. Fig. 10AWestern blots using LNCaP cells and C2-54 FSY incubated at different concentrations and time points are shown. Blots were analyzed using anti-PSMA antibody (upper panel), anti-sdAb antibody (middle panel) and anti-GAPDH (lower panel) as loading controls. Fig. 10B A western blot using LNCaP cells and C2-54TYR is shown and shows no cross-linking to PSMA. The rightmost lane is a control showing a sample of C2-54FSY incubated with LNCaP cells at 1 uM for 9 hours. Fig. 10C Shown are graphs of the cross-linking kinetics of different concentrations of C2-54FSY at different time points.

[0121] Fig.11A Western blot analysis of the cross-linking kinetics of C2-54FSY and C3-101FSY with PSMA at 1 uM and 24 nM in LNCaP cells at different times is shown. The upper panel shows the blot of anti-PSMA antibody, while the lower panel shows the anti-GAPDH control. Fig. 11B Shown are the cross-linking kinetics of C2-54FSY and C3-101FSY with PSMA on LNCaP cells.

[0122] Fig. 12A and 12B Study design and results of in vivo cross-linking assays are shown. Fig. 12A Study design and Western blots of LNCaP and PC3 tumor tissue samples from mice administered C2-54 TYR and C2-54 FSY are shown. The upper panel shows the PSMA region of a gel blotted with an anti-VHH antibody, the middle panel shows the free VHH region of a gel blotted with an anti-VHH antibody, and the lower panel shows an anti-GAPDH blot. The left panel shows samples from LNCaP tumor-bearing animals, while the right panel shows PC3 samples. Cross-linking was observed only in LNCaP (PSMA+) tumors and in the presence of C2-54FSY. Fig. 12B A graph showing the plasma concentrations of C2-54 TYR and C2-54 FSY after administration is shown.

[0123] Fig.13 SDS-PAGE analysis of the cross-linking kinetics of C8-54FSY, C8-55FSY and C8-56FSY is shown (from left to right). The band positions representing cross-linking and C8-FSY are marked. For each construct, the lanes represent (from left to right) 0, 15, 30, 60, 120, 180 minutes and ladder.

[0124] Fig.14SDS-PAGE analysis of cross-linking of various C15-FSY-containing constructs is shown. Left gel: lanes (from left to right) represent constructs with FSY replacement at positions: 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 33, 34, 35, ladder and Her2. Right gel: lanes (from left to right) represent constructs with FSY replacement at positions: 36, 37, 66, 67, 68, 69, wt ladder and Her2. Markers represent cross-linked band positions and constructs containing FSY.

[0125] Fig.15 SDS-PAGE analysis of the biparatopic construct C38-FSY cross-linked with Her2-Fc is shown. Lanes (from left to right) are 0, 0.5, 1.5, 2.5, 3.5, 4.5, 5.5 hours of time, Her2 and ladder. Markers indicate the band positions of cross-linking, Her2-Fc and C38-FSY.

[0126] Fig.16 Depicted is a graph of fluorescence versus concentration from binding studies of constructs in A431 and Colo320DM cells by flow cytometry: A431-C23-TYR, solid squares; A431-C23-FSY, solid triangles; Colo320DM-C23-TYR, "x" symbols; and Colo320DM-C23-FSY, open circles. The y-axis is labeled with the AF680 GeoMean from 0 to 200,000 in 40,000 unit intervals. The x-axis is labeled with a base 10 logarithmic scale from 10 -11 Up to 10 -5 The concentration (M).

[0127] Fig.17 Shown are the intratumoral free and EGFR cross-linked AF680-labeled compounds C23-TYR and C23-FSY in a time-dependent manner in A431 (EGFR+) and COLO320DM (EGFR-) tumors. Free AF-680-labeled C23-TYR and C23-FSY were detected in the approximately 15kD region (lower figure), and the EGFR cross-linked sdAb band was detected in the approximately 175kD region (upper figure). Time-dependent cross-linking of EGFR with C23-FSY was observed in EGFR+A431 tumors, but time-dependent cross-linking of EGFR with C23-TYR was not observed. Free sdAb retention and cross-linking were not observed in EGFR-COLO320DM tumors.

[0128] Fig.18ADepicted are graphs of photons / s / g tissue from three biological replicates of A431 tumors from animals administered C23-TYR or C23-FSY test articles. Values ​​from individual animals are shown, the center bar shows the mean intensity, and the error bars represent the SEM (* represents p=0.024, ** represents p=0.002 by paired t-test). At the 8 hour and 24 hour time points, C23-FSY was present at significantly higher levels in A431 tumors compared to C23-TYR protein without FSY. The y-axis is 0.5x10 10 The intervals are marked from 0 to 1.5x10 10 Photons / s / g tissue. The x-axis is labeled as time (hr) at 8 and 24 hours after administration. Asterisks indicate statistical significance (*=p≤0.05, **=p≤0.005) via paired t-test (two-tailed).

[0129] Fig.18B Depicted are graphs of quantitative ex vivo fluorescence intensity of A431 and COLO320DM tumors from animals administered C23-FSY at 8 and 24 hours post-dose. Graphs show photons / s / g tissue from three biological replicates. Values ​​from individual animals are shown, center bars show mean intensity, error bars represent SEM. At the 8 and 24 hour time points, levels of C23-FSY in A431 tumors were significantly higher than in EGFR-COLO320DM tumors, demonstrating the specificity of tumor targeting of the C23-FSY protein. The y-axis is plotted at 0.5x10 10 The intervals are marked from 0 to 1x 10 10 Photons / s / g tissue. For each group of bar graphs, the x-axis is labeled as time (hr) at 8 and 24 hr after administration. The left group is A431 model tumor, and the right group is Colo320DM model tumor.

[0130] Fig.19 Fluorescence images of SDS PAGE gels are shown, showing free sdAb and PSMA cross-linked sdAb associated with tumors in a time-dependent manner. Mice carrying LNCaP tumors are administered C30-TYR or C30-FSY in triplicate. At the designated time point after treatment, tumors are harvested and gel electrophoresis is performed to detect the sdAb test article conjugated with fluorophores. Free (non-cross-linked) sdAb-AF680 (figure below) is detected in about 20kD regions, and the PSMA cross-linked sdAb-AF680 species of C30-FSY migrate in 100kD regions (figure above). Lanes marked with * show vehicle samples.

[0131] Fig. 20Quantitative analysis of tumor-associated free and PSMA-crosslinked test products C30-TYR and C30-FSY is shown. The fluorescence band intensity of the free and PSMA-crosslinked species bands in the above gels was quantified via densitometry and compared with the standard curve. A graph of the total concentration of the test product in the tumor (free and PSMA-crosslinked, pg / mg tumor tissue) versus time (h) was plotted. The data points indicated with * represent samples below the detection and quantification limits. Compared to non-covalent C30-TYR, the tumor exposure of C30-FSY increased to about 3x.

[0132] Fig.21A Depicted is a comparison of the cytotoxicity of the C26-54TYR and C26-54FSY test articles in PC3PIP (PSMA positive) and PC3flu (PSMA negative) cell lines, showing the concentration of sdAb conjugated to MMAE versus cell viability curves. The y-axis is labeled with 20 unit intervals from 0 to 120% viability. The x-axis is labeled with a logarithmic interval from 10 to 10. -11 Up to 10 -6 The test article concentration (M).

[0133] Fig.21B Depicted is a comparison of the cytotoxicity of the C28-101TYR and C28-101FSY test articles in PC3PIP (PSMA positive) and PC3flu (PSMA negative) cell lines, showing the concentration of sdAb conjugated to MMAE versus cell viability curves. The y-axis is labeled with 20 unit intervals from 0 to 120% viability. The x-axis is labeled with a logarithmic interval from 10 to 10. -11 Up to 10 -6 The test article concentration (M).

[0134] Fig. 22 Depicted is an SDS-PAGE analysis of FSY cross-linking kinetics, where the 52FSY and 54FSY variants of C17 were incubated with the Her2 receptor and the cross-linking efficiency was examined. Lanes 1-5 represent C17-52FSY at 0, 30, 60, 120, and 180 min; lanes 6-10 represent C17-54FSY at 0, 30, 60, 120, and 180 min; lanes 11 and 12 are FcHer2 and ladder, respectively. The band positions corresponding to C17-FSY, receptor, and cross-linked products are marked.

[0135] Fig.23ADepicted is a comparison of cytotoxicity after 5 hours washout using C33-52TYR, C33-52FSY, C33-54TYR and C33-54FSY test articles, showing the concentration of sdAb conjugated to MMAE versus cell viability curves in BT474 cells. The y-axis is labeled with viability % at 20 unit intervals from -20 to 120. The x-axis is labeled with logarithmic intervals from 10 to 10. -3 Up to 10 3 The test article concentration (nM).

[0136] Fig. 23B Depicted is a comparison of cytotoxicity using 6 consecutive days of exposure to C33 test article, showing the concentration of sdAb conjugated to MMAE versus cell viability curves in BT474 cells. The y-axis is labeled with viability % at 20 unit intervals from -20 to 120. The x-axis is labeled with logarithmic intervals from 10 to 10. -2 Up to 10 2 The test article concentration (nM).

[0137] Fig.24A Depicted are PSMA cross-linking plots for monoparatopic and biparatopic constructs (C3-101FSY, squares; C34-FSY, triangles; C36-FSY, circles). The y-axis is labeled with cross-linked PSMA (total %) at 20 unit intervals from 0 to 100. The x-axis is labeled with test article concentration (nM) at logarithmic intervals from 0.01 to 1000 to base 10. The graph corresponds to cross-linking at 1 hour.

[0138] Fig. 24B Depicted are PSMA crosslinking plots for monoparatopic and biparatopic constructs (C3-101FSY, squares; C34-FSY, triangles; C36-FSY, circles). The y-axis is labeled with crosslinked PSMA (total %) at 20 unit intervals from 0 to 100. The x-axis is labeled with test article concentration (nM) at logarithmic intervals from 0.01 to 1000 to base 10. The graph corresponds to crosslinking at 6 hours.

[0139] Fig.25AWestern blot analysis of FSY cross-linking kinetics at 1 hour and 6 hour time points for C3-101FSY and C34-FSY constructs of different concentrations is described. Lanes 1-6 represent C3-101FSY at 1 hour; Lanes 7-12 represent C34-FSY at 1 hour; Lanes 13-18 represent C3-101FSY at 6 hours, and Lanes 19-24 represent C34-FSY at 6 hours. Each group of six lanes depicts the increase in construct concentration (from left to right): UTC, 0.1, 1, 10, 100, 1000 nM. The top blot group depicts a-PSMA, and the bottom blot group depicts a-GAPDH. The band positions of GAPDH, PSMA, cross-linked monomers, and cross-linked dimers are marked.

[0140] Fig.25B Western blot analysis of FSY cross-linking kinetics at 1 hour and 6 hour time points for different concentrations of C3-101FSY and C36-FSY constructs is described. Lanes 1-6 represent C3-101FSY at 1 hour; Lanes 7-12 represent C36-FSY at 1 hour; Lanes 13-18 represent C3-101FSY at 6 hours, and Lanes 19-24 represent C36-FSY at 6 hours. Each group of six lanes depicts an increase in construct concentration (from left to right): UTC, 0.1, 1, 10, 100, 1000 nM. The top blot group depicts a-PSMA, and the bottom blot group depicts a-GAPDH. The band positions of GAPDH, PSMA, cross-linked monomers, and cross-linked dimers are marked.

[0141] Fig.26A Describe the SDS-PAGE analysis of cross-linking kinetics between EGFR and single paratope construct C4-109FSY. The half maximum time is about 120 minutes. The band corresponding to the cross-linked product, EGFR and sdAb monomer is marked. The right side shows the illustration of the receptor engaged with the sdAb monomer containing FSY.

[0142] Fig.26B Describes the SDS-PAGE analysis of the cross-linking kinetics between EGFR and the biparatopic construct C37-FSY. The bands corresponding to the cross-linked products, EGFR and sdAb dimers are labeled. An illustration depicting a receptor engaged with a sdAb biparatopic construct containing FSY is shown on the right.

[0143] Fig. 27 Depicted are graphs of EGFR cross-linking kinetics for the monoparatopic construct C4-109FSY (squares) or the biparatopic construct C37-FSY (circles). The y-axis is labeled EGFR cross-linking % from 0 to 100% and the x-axis is labeled time (min) from 0 to 400 at 100-min intervals.

[0144] Fig.28A -C describes an exemplary conjugate described herein, comprising a first targeting domain (e.g., constructs C1-C4) and a second targeting domain (e.g., constructs C1-C4), wherein the conjugate comprises an unnatural amino acid (e.g., FSY). An exemplary conjugate further comprises a payload. An exemplary conjugate may include an unnatural amino acid on the first targeting domain, the second targeting domain, or both targeting domains. DETAILED DESCRIPTION

[0145] Antibodies, antibody fragments and antibody-related constructs, such as antibody drug conjugates (ADCs), can be useful tools for research and clinical applications. However, in some cases, the use of these molecules is limited by the on / off rate and stability of the target. Provided herein are compositions and methods for specifically and covalently binding a conjugate to a target. In some cases, the conjugate includes at least one targeting domain, having at least one non-natural amino acid (UAA) residue near the interface between the target and the targeting domain, so that when the targeting domain is combined with the target, a covalent bond is formed between the target and the UAA residue. In some cases, the conjugate includes at least one targeting domain and at least one payload. In some cases, the targeting domain includes at least one non-natural amino acid (UAA) residue near the interface between the target and the targeting domain, so that when the targeting domain is combined with the target, a covalent bond is formed between the target and the UAA residue. In some cases, once the conjugate reaches its target cell / tumor, the payload is now covalently bound to the target via the targeting domain. In some cases, covalent interactions eliminate or reduce the rate at which the conjugate is bound to the target, increasing contact with the attached payload.

[0146] In some cases, the conjugate comprises (i) a first targeting domain and (ii) a second targeting domain, wherein the first targeting domain or the second targeting domain comprises at least one unnatural amino acid (UAA). In some cases, the first targeting domain or the second targeting domain comprises at least one UAA present near the interface between the target and the first targeting domain or the second targeting domain, and when the first targeting domain or the second targeting domain binds to the target, a covalent bond is formed between the target and at least one UAA. In some cases, the conjugate also comprises a payload. In some cases, when the conjugate reaches its target cell, such as a cell in a tumor or a tumor microenvironment, the payload is now covalently bound to the target via one of the targeting domains (e.g., the first targeting domain or the second targeting domain).

[0147] In some cases, covalent interactions eliminate or reduce the rate at which the conjugate binds to the target, or otherwise stabilizes contact with the target. In further cases, the first targeting domain and the second targeting domain in the conjugate provided herein target the same or different targets. In some cases, only the second targeting domain, rather than the first targeting domain, comprises UAA. In some cases, only the first targeting domain, rather than the second targeting domain, comprises UAA. In some cases, both the first targeting domain and the second targeting domain comprise UAA. In some cases, a payload can be attached to the first targeting domain or the second targeting domain. In some cases, a payload is attached to the first targeting domain. In some cases, a payload is attached to the second targeting domain.

[0148] Conjugate

[0149] The conjugate can include a targeting domain and a payload. In some embodiments, the payload is attached to the conjugate with a connector. In some cases, the conjugate includes at least one non-natural amino acid. In some cases, the targeting domain is configured to bind to the target, and a non-natural amino acid in the targeting domain forms a covalent bond with the target.

[0150] The conjugate provided herein may include (i) a first targeting domain and (ii) a second targeting domain. The conjugate provided herein may include (i) a first targeting domain, (ii) a second targeting domain and (iii) a payload. The conjugate herein may include a first targeting domain and a second targeting domain, wherein the first targeting domain and the second targeting domain are configured to be bound to the same cell. In some cases, the conjugate includes at least one non-natural amino acid (UAA), which is contained in the first targeting domain, in the second targeting domain, or each of the first targeting domain and the second targeting domain includes at least one UAA. In some cases, the targeting domain is configured to be bound to the target, and one of the UAAs in the targeting domain (e.g., the first and / or second targeting domain) forms a covalent bond with the target. In some cases, the first targeting domain includes UAA, and is configured to form a covalent bond with the first target, so that at least one UAA is present in the first targeting domain, near the interface between the first target and the first targeting region. In some cases, the first target is combined with the first targeting domain, and a covalent bond is formed between the UAA in the first targeting domain of the first target and the conjugate. In some cases, the second targeting domain comprises a UAA and is configured to form a covalent bond with the second target such that at least one UAA is present in the second targeting domain near the interface between the second target and the second targeting domain. In some cases, the second target binds to the second targeting domain and a covalent bond is formed between the second target and the UAA in the second targeting domain of the conjugate. In some cases, the first target is the same as the second target. In some cases, the first target and the second target are located on the surface of the same cell.

[0151] In some embodiments, the first targeting domain and the second targeting domain bind to the same target, such as on the surface of a cell, and the engagement of one of the targeting domains brings the other targeting domain into proximity with its corresponding target. In some cases, the first targeting domain binds to the first target and the second targeting domain binds to the second target, and at least one of the first and second targeting domains comprises a UAA, and the UAA forms a covalent bond with the corresponding target. In some cases, one targeting domain forms a covalent bond with its corresponding target, and the other targeting domain non-covalently binds to its corresponding target. In some cases, both the first targeting domain and the second targeting domain covalently bind to their corresponding targets.

[0152] The conjugates provided herein can be configured to bind more than one target. In some cases, the second targeting domain can bind to a target different from the first targeting domain. In some cases, the conjugate comprises at least 2, 3, 4, 5, 6 or more than 7 targeting domains. In some cases, the targeting domains (e.g., the first targeting domain and the second targeting domain) are attached to each other via a connector (e.g., a chemical connector, a fusion protein or other connectors provided herein). In some cases, a plurality of targeting domains (e.g., the first targeting domain and the second targeting domain) in the conjugates provided herein can provide a single paratope or a double paratope construct. In some cases, the first targeting domain and the second targeting domain bind to the same target. In some cases, the first targeting domain and the second targeting domain bind to different epitopes of the same target. In some cases, the first targeting domain and the second targeting domain bind to different targets. In some cases, the first targeting domain and the second targeting domain are connected to form a fusion protein.

[0153] The targeting domain (e.g., the first targeting domain or the second targeting domain) can guide the payload attached to the conjugate to the target. In some cases, the targeting domain includes an antibody or a fragment thereof. In some cases, the targeting domain includes monospecific Fab2, bispecific Fab2, trispecific Fab3, monovalent IgG, scFv, bispecific double antibody, trispecific triple antibody, scFv-Fc, nano antibody (i.e., single domain antibody, sdAb), micro antibody, IgNAR, V-NAR, hcIgG, VhH or peptibody, Darpin, monomer / FN3, VNAR, Repebody, Darpin. In some cases, the targeting domain includes nano antibody. In some embodiments, the targeting domain includes a single domain antibody (sdAb). In some cases, the targeting domain includes one or more CDR regions. In some embodiments, the targeting domain binds to a cell surface molecule. In some cases, the conjugate is biparatopic. In some embodiments, the first targeting domain and the second targeting domain each include an antibody or an antigen binding fragment, and the structure of this antibody or antigen binding fragment may be the same or different. In some cases, the first targeting domain can be a single chain (e.g., Fv) antibody fragment and the second targeting domain can be a sdAb, or in other cases, the first targeting domain can be a sdAb and the second targeting domain can be a sdAb.

[0154] In some cases, the targeting domain (eg, the first targeting domain and / or the second targeting domain) is an antibody mimetic, such as an affibody, a DARPin, or a minibinder.

[0155] In some cases, the target includes a cell surface protein. In some cases, the target includes PSMA. In some cases, the targeting domain (e.g., the first targeting domain and / or the second targeting domain) includes SEQ ID: 1-4 or any one of 16-64. In some cases, the targeting domain includes a sequence with at least 99%, 98%, 97%, 95%, 90%, 85%, 80%, 70% or at least 65% identity to any one of SEQ ID: 1-4 or 16-64. In some cases, the targeting domain includes a sequence with at least 99%, 98%, 97%, 95%, 90%, 85%, 80%, 70% or at least 65% identity to any one of SEQ ID: 1-4 or 16-64 and at least one non-natural amino acid.

[0156] Non-natural amino acids can be located at any position in the conjugate. In some cases, one or both (e.g., the first targeting domain or the second targeting domain) of the first targeting domain or the second targeting domain include non-natural amino acids. In some cases, the targeting domain is an antibody or antigen binding fragment comprising one or more complementary determining regions (CDRs). In some cases, one or more non-natural amino acids are included in or near the CDR in only one or two targeting domains. In some cases, the targeting domain includes non-natural amino acids. In some cases, the targeting domain includes C1, C2 or C3. In some cases, the conjugate includes C1, which has non-natural amino acids in CDR1, CDR2 or CDR3. In some cases, the conjugate includes C1, which has non-natural amino acids in any one of positions 26, 28, 29, 30, 99, 102, 103, 105, 108, 110, 111, 112, 113, 114 and 115. In some cases, the conjugate comprises C1 having a non-natural amino acid at any one of positions 28, 102, 112, and 113. In some cases, the conjugate comprises C2 having a non-natural amino acid in CDR1, CDR2, or CDR3. In some cases, the conjugate comprises C2 having a non-natural amino acid at any one of positions 50, 52, 53, 54, 56, 58, or 100. In some cases, the conjugate comprises C4 having a non-natural amino acid in CDR1, CDR2, or CDR3. In some cases, the conjugate comprises C4 having a non-natural amino acid at position 109. In some cases, the conjugate comprises C3 having a non-natural amino acid in CDR1, CDR2, or CDR3. In some cases, the conjugate comprises C3 having a non-natural amino acid at any one of positions 58, 62, 101, 103, or 107. In some cases, the conjugate comprises a C8 with an unnatural amino acid at any one of positions 52, 53, 54, 55, 56, 58, 60, 62, 64. In some cases, the conjugate comprises a C9 with an unnatural amino acid at any one of positions 53, 55, 56, 57, 58, 60, 64, 67. In some cases, the conjugate comprises a single domain antibody (sdAb) comprising an sdAb having a CDR region and at least one unnatural amino acid (UAA) residue within or near the CDR region, wherein the sdAb comprises any one of SEQ ID No. 1-4 or 16-64. In some cases, the conjugate comprises a single domain antibody (sdAb) comprising a sdAb having a CDR region and at least one unnatural amino acid (UAA) residue within or near the CDR region, wherein the sdAb comprises a sequence having 99%, 98%, 97%, 95%, 90%, 85%, 80%, 70% or at least 65% identity to any one of SEQ ID No. 1-4 or 16-64.In some embodiments, the CDR region comprises one or more SEQ ID No. 5- 13. In some embodiments, the CDR region comprises a sequence that is at least 99%, 98%, 97%, 95%, 90%, 85%, 80%, 70% or at least 65% identical to one or more SEQ ID No. 5-13.

[0157] In some cases, the conjugate comprises a tag, such as a tag for purification (e.g., a His6 tag). In some cases, the conjugate does not comprise a tag, or the tag is removed before administration. In some cases, the conjugate comprises a leader sequence, such as for expression or secretion. In some cases, the conjugate does not comprise a leader sequence, or the leader sequence is removed from the first targeting domain or the second targeting domain before forming the conjugate, before attaching a payload, or before administering the conjugate.

[0158] In some cases, the conjugate comprises a signal sequence. The signal sequence may allow the conjugate to be expressed, folded or oxidized in a bacterial cell. In some cases, the signal sequence may allow the conjugate expressed in a bacterial cell to be transported to another location or environment to facilitate the folding or function of the conjugate. In some cases, the signal sequence may be a PelB sequence. In some cases, the signal sequence may allow the conjugate to be transported to the periplasm of a bacterial cell. In some cases, the environment may be oxidizing or reducing to allow the formation of a disulfide or the reduction of a disulfide.

[0159] Target

[0160] The conjugates provided herein can be configured to be combined with one or more targets. In some cases, the conjugate is configured to have a single targeting domain comprising UAA, and the conjugate is bound to the target. In some cases, the conjugate is configured to have two (or at least two) targeting domains, and the first targeting domain and the second targeting domain are bound to one or more targets. In some cases, the first targeting domain is bound to the first target, and the second targeting domain is bound to the second target. In some cases, the UAA contained in the targeting domain (e.g., a single targeting domain or the first targeting domain or the second targeting domain) forms a covalent bond between the targeting domain (e.g., a single targeting domain, or the first targeting domain or the second targeting domain) and the target (the corresponding target of the targeting domain, for example, the first or second target). In some cases, the conjugate comprises a first targeting domain comprising the first UAA and a second targeting domain comprising the second UAA. These UAAs are identical in some cases, or different in other cases. In some cases, the target is a cell surface molecule (i.e., present in whole or in part on the extracellular surface). In some cases, the first targeting domain and the second targeting domain are bound to the same target, such as the same cell surface molecule. In some cases, the first targeting domain and the second targeting domain each bind to a different target, such as to a different cell surface molecule. The different cell surface molecules can be on the same cell.

[0161] In some cases, the target is a cell surface molecule present on a tumor cell. In some cases, the target is a monomer. In some cases, the target is contained in a multimeric structure of homogeneous or heterogeneous units. In some cases, the target is selected from PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPα, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, CD73, ITGaVb3, I TGaVb6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD25, 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47 and EpCAM.

[0162] In some cases, the conjugate comprises a first targeting domain and a second targeting domain, and both targeting domains bind to the same target, wherein the target is a cell surface molecule on a tumor cell. For example, both targeting domains bind to a target selected from the group consisting of PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPa, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, CD73, ITG4b3, I Targets of TGaVb6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD25, 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47 and EpCAM. In some cases, the conjugate comprises a first targeting domain and a second targeting domain that bind to different targets, wherein the one or more different targets are cell surface molecules on tumor cells.For example, the first targeting domain and the second targeting domain bind to different targets, each target is selected from PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPa, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3 rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, CD73, ITGaVb3, ITGaVb6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD 25, 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47 and EpCAM. In some cases, when the first or second target (or both) is combined, the conjugate carries the payload to the cell surface. In some cases, the conjugate has no payload, and when covalently bound to the first target, the second target or the first and second targets, the conjugate acts as a blocker or antagonist.

[0163] In some cases, the conjugate comprises a single targeting domain, and the targeting domain binds to a target, wherein the target is a cell surface molecule on a tumor cell. For example, the targeting domain binds to a molecule selected from the group consisting of PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPa, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3 rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, C D73, ITGaVb3, ITGaVb6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD2 5, 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47 and EpCAM targets. In some cases, a single targeting domain carries the payload of the target. In some cases, a single targeting domain has no payload, and the conjugate acts as a blocker or antagonist when covalently bound to the target.

[0164] The target engaged by the targeting domain can include various structures. In some cases, the target includes one or more epitopes that can be engaged by the targeting domain. In some cases, the target includes multiple epitopes and can be engaged by multiple targeting domains, for example, such as being bound to the first epitope by the first targeting domain and being bound to the second epitope by the second targeting domain. In some cases, the target includes a monomer. In some cases, the target includes a single-chain peptide. In some cases, the target includes a polymer molecule. In some cases, the polymer molecule includes two or more subunits. In some cases, the subunits have the same structure. In some cases, the subunits are different structures, or a combination of the same and different structures. In some cases, the polymer molecule includes two or more molecules in the complex. In some cases, the polymer molecule includes two proteins that are compounded or interact with each other.

[0165] Exemplary Targeting Domains and Exemplary Conjugates

[0166] The conjugates provided herein include a targeting domain that can be assembled by a molecule that is engaged with a target. In some cases, the targeting domain (single targeting domain or the first targeting domain and / or the second targeting domain) includes an antigen binding region, wherein the antigen binding region is engaged with a specific target. Such antigen binding regions may include CDRs, such as 3 CDRs commonly found in the heavy or light chains of antibodies. In some cases, the targeting domain includes an antigen binding fragment, which includes CDRs, such as VHH (also referred to as nano antibodies or single domain antibodies). In some cases, single domain antibodies include one or more UAAs. In some cases, a single targeting domain or for a conjugate with multiple targeting domains, one of the targeting domains (e.g., the first targeting domain or the second targeting domain) is selected from the single domain antibodies of Table 1, such as C1, C2, C3, C4 or C5. In some cases, if conjugated to more than one targeting domain, each targeting domain (e.g., a first targeting domain and a second targeting domain) is independently selected from a single domain antibody of Table 1, such as any one of C1, C2, C3, C4, or C5, and one or more UAAs are present in or near the CDR of the single domain antibody. In some cases, the first targeting domain is selected from a single domain antibody of Table 1, such as any one of C1, C2, C3, C4, or C5. In some cases, the second targeting domain is selected from a single domain antibody of Table 1, such as any one of C1, C2, C3, C4, or C5.

[0167] In some cases, the conjugate comprises a single targeting domain, a first targeting domain, a second targeting domain, or two targeting domains comprising construct C1. In some cases, the conjugate comprises construct C1 with non-natural amino acids in CDR1, CDR2, or CDR3. In some cases, the conjugate comprises construct C1 with non-natural amino acids at any one of positions 26, 28, 29, 30, 99, 102, 103, 105, 108, 110, 111, 112, 113, 114, and 115 in SEQ ID NO: 1, 4, 19, or 73. In some cases, the conjugate comprises construct C1 with non-natural amino acids at any one of positions 28, 102, 112, and 113 in SEQ ID NO: 1, 4, 19, or 73. In some cases, the conjugate comprises a single domain antibody (sdAb) and at least one non-natural amino acid (UAA) in or near a CDR region in the sdAb. In some cases, this sdAb comprises SEQ ID NO: 1. In some cases, the conjugate comprises a single domain antibody (sdAb) and at least one unnatural amino acid (UAA) within or near a CDR region within the sdAb, wherein the sdAb comprises a sequence having at least 99%, 98%, 97%, 95%, 90%, 85%, 80%, 70%, or at least 65% sequence identity to SEQ ID NO: 1. In some cases, the conjugate comprises a single targeting domain, a first targeting domain, or a second targeting domain, or both, having at least 99%, 98%, 97%, 95%, 90%, 85%, 80%, 70%, or at least 65% identity to SEQ ID NO: 1.

[0168] In some cases, the conjugate comprises a single targeting domain, a first targeting domain, a second targeting domain, or two targeting domains comprising construct C2. In some cases, the conjugate comprises construct C2 having an unnatural amino acid in CDR1, CDR2, or CDR3. In some cases, the conjugate comprises construct C2 having an unnatural amino acid at any one of positions 50, 52, 53, 54, 56, 58, or 100 of SEQ ID NO: 2 or 22. In some cases, the conjugate comprises a single domain antibody (sdAb) comprising an sdAb and at least one unnatural amino acid (UAA) within or near a CDR region within the sdAb, wherein the sdAb comprises SEQ ID NO: 2. In some cases, the conjugate comprises a single domain antibody (sdAb) and at least one unnatural amino acid (UAA) within or near a CDR region within the sdAb, wherein the sdAb comprises a sequence having at least 99%, 98%, 97%, 95%, 90%, 85%, 80%, 70%, or at least 65% sequence identity to SEQ ID NO: 2. In some cases, the conjugate comprises a single targeting domain, a first targeting domain, or a second targeting domain, or both, having at least 99%, 98%, 97%, 95%, 90%, 85%, 80%, 70%, or at least 65% sequence identity to SEQ ID NO: 2.

[0169] In some cases, the conjugate comprises a single targeting domain, a first targeting domain, a second targeting domain, or two targeting domains comprising construct C3. In some cases, the conjugate comprises a construct C3 having an unnatural amino acid in CDR1, CDR2, or CDR3. In some cases, the conjugate comprises a construct C3 having an unnatural amino acid in any one of positions 58, 62, 101, 103, or 107 of SEQ ID NO:3. In some cases, the conjugate comprises an unnatural amino acid in CDR1, CDR2, or CDR3 of C3. In some cases, the conjugate comprises an unnatural amino acid at position 109. In some cases, the conjugate comprises a single domain antibody (sdAb) and at least one unnatural amino acid (UAA) in or near a CDR region within the sdAb, wherein the sdAb comprises SEQ ID NO:3. In some cases, the conjugate comprises a single domain antibody (sdAb) and at least one unnatural amino acid (UAA) within or near a CDR region within the sdAb, wherein the sdAb comprises a sequence having at least 99%, 98%, 97%, 95%, 90%, 85%, 80%, 70%, or at least 65% sequence identity to SEQ ID NO: 3. In some cases, the conjugate comprises a single targeting domain, a first targeting domain, or a second targeting domain, or both, having at least 99%, 98%, 97%, 95%, 90%, 85%, 80%, 70%, or at least 65% sequence identity to SEQ ID NO: 3.

[0170] In some cases, the conjugate comprises a single targeting domain, a first targeting domain, a second targeting domain, or two targeting domains comprising construct C4. In some cases, the conjugate comprises a construct C4 with an unnatural amino acid in CDR1, CDR2, or CDR3. In some cases, the conjugate comprises a single domain antibody (sdAb) and at least one unnatural amino acid (UAA) within or near a CDR region within the sdAb, wherein the sdAb comprises SEQ ID NO: 16. In some cases, the conjugate comprises a single domain antibody (sdAb) and at least one unnatural amino acid (UAA) within or near a CDR region within the sdAb, wherein the sdAb comprises a sequence having at least 99%, 98%, 97%, 95%, 90%, 85%, 80%, 70% or at least 65% sequence identity with SEQ ID NO: 16. In some cases, the conjugate comprises a single targeting domain, the first targeting domain, or the second targeting domain, or both, having at least 99%, 98%, 97%, 95%, 90%, 85%, 80%, 70%, or at least 65% sequence identity to SEQ ID NO:16.

[0171] In some cases, the conjugate comprises a single targeting domain, a first targeting domain, a second targeting domain, or two targeting domains comprising construct C5. In some cases, the conjugate comprises a construct C5 with an unnatural amino acid in CDR1, CDR2, or CDR3. In some cases, the conjugate comprises a single domain antibody (sdAb) and at least one unnatural amino acid (UAA) within or near a CDR region within the sdAb, wherein the sdAb comprises SEQ ID NO: 18. In some cases, the conjugate comprises a single domain antibody (sdAb) and at least one unnatural amino acid (UAA) within or near a CDR region within the sdAb, wherein the sdAb comprises a sequence having at least 99%, 98%, 97%, 95%, 90%, 85%, 80%, 70% or at least 65% sequence identity with SEQ ID NO: 18. In some cases, the conjugate comprises a single targeting domain, the first targeting domain, or the second targeting domain, or both, having at least 99%, 98%, 97%, 95%, 90%, 85%, 80%, 70%, or at least 65% sequence identity to SEQ ID NO:18.

[0172] The conjugates described herein may include two or more targeting domains. In some cases, two or more targeting domains (e.g., a first targeting or a second targeting) are attached to each other via a connector. In some cases, the conjugate is a fusion protein. In some cases, the connector includes a connector L1 (SEQ ID NO: 14). In some cases, the conjugate includes any one of SEQ ID NO: 65-72. In some cases, the conjugate has at least 99%, 98%, 97%, 95%, 90%, 85%, 80%, 70% or at least 65% sequence identity with any one of SEQ ID NO: 65-72.

[0173] In some cases, the first targeting domain comprises any one of SEQ ID NOs: 1-4 or 16-64. In some cases, the first targeting domain comprises a sequence having at least 70% sequence identity to any one of SEQ ID NOs: 1-4 or 16-64. In some cases, the second targeting domain comprises any one of SEQ ID NOs: 1-4 or 16-64. In some cases, the second targeting domain comprises a sequence having at least 70% sequence identity to any one of SEQ ID NOs: 1-4 or 16-64. In some cases, the conjugate is configured with a single targeting domain, and the single targeting domain comprises any one of SEQ ID NOs: 1-4 or 16-64. In some cases, the single targeting domain comprises a sequence having at least 70% sequence identity to any one of SEQ ID NOs: 1-4 or 16-64.

[0174] In some cases, the conjugate comprises SEQ ID NO: 65-72. In some cases, the conjugate comprises a sequence having at least 70% sequence identity to any one of SEQ ID NO: 65-72. In some cases, the conjugate comprises any one of SEQ ID NO: 1-4 or 16-64. In some cases, the conjugate comprises a sequence having at least 70% sequence identity to any one of SEQ ID NO: 1-4 or 16-64. In some cases, the conjugate comprises a sequence having at least 70% sequence identity to any one of SEQ ID NO: 65-72.

[0175] In some cases, the amino acid sequences associated with the conjugates described herein are in Table 1A.

[0176] Table 1A: Amino Acid Sequences

[0177]

[0178]

[0179]

[0180]

[0181]

[0182]

[0183]

[0184]

[0185] X indicates the position of the FSY incorporation site. Sequences in the table with a His6 purification tag and / or a PeIB leader sequence are also reflected herein.

[0186] In some cases, the DNA sequences associated with the conjugates described herein are in Table 2.

[0187] Table 2: DNA sequences

[0188]

[0189]

[0190]

[0191]

[0192]

[0193]

[0194]

[0195]

[0196]

[0197] Payload

[0198] The conjugate may comprise a payload. In some cases, a targeting domain (e.g., a single targeting domain or a first targeting domain or a second targeting domain) contained in the conjugate may direct the payload to a target. In some cases, the targeting domain (e.g., a single targeting domain or a first targeting domain or a second targeting domain) comprises an antibody or fragment thereof that directs the payload to a cell (such as a tumor cell). In some embodiments, the payload comprises an imaging agent, a radioligand agent, or a cytotoxic agent. In some embodiments, the cytotoxic moiety comprises a small molecule drug, a peptide, a protein, or a chemotherapeutic drug. In some embodiments, the payload comprises a radioligand agent. In some embodiments, the radioligand agent is selected from35 S. 3 H. 111 In, 112 In, 14 C. 186 Re, 188 Re, 32 P. 153 Sm, 177 Lu, 86 Y. 88 Y. 90 Y. 131 I. 123 I. 124 I. 125 I. 149 Tb, 211 At 212 Pb / 212 Bi, 213 Bi, 223 Ra, 225 Ac, 64 Cu, 67 Cu and 227 Th. In some embodiments, the radioligand agent further comprises a chelating agent. Examples of chelating agents include DOTA, DOTAGA, NOTA, MACROPA, THP, and TRAP. In some embodiments, the radioligand agent is selected from 99m Tc, 131 I. 201 Tl, 111 In and 67 Ga. In some cases, the imaging agent comprises a dye. In some cases, the conjugate comprises two or more payloads. For example, the conjugate comprises a payload dye for visualizing tissue penetration and a payload chemotherapeutic agent for killing tumors.

[0199] Payload can be attached to conjugate. Payload can be covalently attached to conjugate. In some cases, payload is not attached to conjugate via non-natural amino acid (UAA) residue. In some embodiments, payload is attached to amino acid n+x (towards C-terminal) relative to UAA residue. In some embodiments, the site of attachment is defined as the position of x amino acid at distance n from non-natural amino acid position. In some embodiments, payload is attached to amino acid nx (towards n-terminal) relative to UAA residue. In some embodiments, UAA residue is included in or near the region of the targeting domain (for example, single targeting domain or the first targeting domain or the second targeting domain) connected to the target. In some cases, payload is at least 2, 5, 10, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100 or at least 125 amino acids away from the non-natural amino acid in the conjugate.

[0200] Unnatural Amino Acids (UAA)

[0201] Unnatural amino acids (UAA) can be incorporated into conjugates described herein. In some cases, UAA residues are present in the targeting domain of the conjugate. In some cases, UAA is configured to covalently bind to the target. In some cases, UAA is configured to covalently bind to the amino acid present in the target. In some cases, the conjugate comprises one, two, three, four or more UAA. In some cases, the conjugate comprises a first targeting domain comprising the first UAA and a second targeting domain comprising the second UAA. In some cases, UAA is configured in the targeting domain (e.g., when the first targeting domain or the second targeting domain) to covalently bind to the amino acid present in the target when the targeting domain is engaged with the target. In some cases, such amino acids include nucleophilic amino acids. In some cases, UAA residues form covalent bonds with lysine, histidine or tyrosine. In some cases, UAA residues are located in the target binding domain. In some cases, once incorporated into the conjugate, UAA is located in the CDR of the targeting domain, such as a targeting domain comprising an antibody or antigen-binding fragment, such as a single domain antibody. In some embodiments, the UAA residue comprises an aryl fluorosulfate moiety. In some cases, the UAA residue is genetically encoded into the conjugates described herein. In some cases, the UAA residue comprises a variant of tyrosine or lysine. In some embodiments, the non-natural amino acid residue comprises Formula I: In some embodiments, the non-natural amino acid residue comprises Formula II: In some embodiments, the UAA residue is derived from the incorporation of a UAA as described herein. In some embodiments, the unnatural amino acid is 2-amino-3-(4-((fluorosulfonyl)oxy)phenyl)propanoic acid In some embodiments, the unnatural amino acid is fluorosulfonyltyrosine (FSY): In some embodiments, the unnatural amino acid is N6-(4-((fluorosulfonyl)oxy)benzoyl)lysine: In some embodiments, the unnatural amino acid is fluorosulfonyloxybenzoyl-L-lysine (FSK): In some embodiments, the non-natural amino acid residue comprises Formula III: In some embodiments, the unnatural amino acid is In some embodiments, the unnatural amino acid is

[0202] In some embodiments, the unnatural amino acid (UAA) of the UAA residue has the structure of Formula (IA):

[0203] (IA),

[0204] in,

[0205] Each X is independently O or NR';

[0206] Y is a bond, -O-, -NR- or -N=;

[0207] A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4;

[0208] When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl;

[0209] R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl;

[0210] L is -(CH2) p -or-C(O)NH-(CH2) p -; p is an integer from 1 to 6; and

[0211] When Y is -O- or -NR-, m is 1; when Y is -N=, m is 2.

[0212] In some embodiments, the UAA of Formula (IA) has Formula (IA-a): In some embodiments, the UAA of formula (IA) has formula (IA-b): structure.

[0213] In some embodiments, the UAA of Formula (IA) has Formula (IB): structure.

[0214] In some embodiments, the UAA of Formula (IB) has Formula (IB-a): In some embodiments, the UAA of formula (IB) has formula (IB-b): structure.

[0215] In some embodiments, the UAA of Formula (IA) has Formula (IC): The structure:

[0216] In some embodiments, the UAA of Formula (IC) has Formula (IC-a): In some embodiments, the UAA of formula (IB) has formula (IB-b): In some preferred embodiments, R is hydrogen.

[0217] In some embodiments, the UAA of Formula (IA) has Formula (ID): The structure,

[0218] wherein each X is independently O or NR';

[0219] Y is a bond, -O-, -NR- or -N=;

[0220] A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4;

[0221] When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl;

[0222] R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and

[0223] When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

[0224] In some embodiments, the UAA of formula (ID) has formula (ID-a): In some embodiments, the UAA of formula (ID) has formula (ID-b): structure.

[0225] In some embodiments, the UAA of Formula (IA) has Formula (IE): The structure,

[0226] wherein each X is independently O or NR';

[0227] Y is a bond, -O-, -NR- or -N=;

[0228] A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4;

[0229] When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl;

[0230] R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and

[0231] When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

[0232] In some embodiments, the UAA of Formula (IE) has Formula (IE-a): In some embodiments, the UAA of Formula (IE) has Formula (IE-b): structure.

[0233] In some embodiments, Y is a bond, -O- or -NR-, and m is 1. In other embodiments, Y is -N= and m is 2. In certain preferred embodiments, Y is -O- and m is 1. In other embodiments, Y is -NR- and m is 1. In other embodiments, Y is a bond and m is 1. In other embodiments, Y is O- or -NR-, and m is 1.

[0234] In some embodiments, the UAA of Formula (IA) has Formula (IIA): The structure,

[0235] in:

[0236] X is independently O or NR'; and

[0237] When present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

[0238] In some embodiments, the UAA of Formula (IIA) has Formula (IIA-a): In some embodiments, the UAA of formula (IIA) has formula (IIA-b): structure.

[0239] In some embodiments, the UAA of Formula (IA) has Formula (IIB): The structure,

[0240] in:

[0241] X is independently O or NR'; and

[0242] When present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

[0243] In some embodiments, the UAA of Formula (IIB) has Formula (IIB-a): In some embodiments, the UAA of formula (IIB) has formula (IIB-b): structure.

[0244] In some embodiments, the unnatural amino acid (UAA) has the formula (IV) The structure,

[0245] in,

[0246] Each X is independently O or NR';

[0247] Y is a bond, -O-, -NR- or -N=;

[0248] A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4;

[0249] When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl;

[0250] Ring A is a 5- to 6-membered aryl or heteroaryl group;

[0251] Each R A are independently -OH, -OR X , halogen, NHR X 、N(R X )2 or optionally substituted alkyl; each R X is an optionally substituted alkyl group;

[0252] L is -(CH2) p -or-C(O)NH-(CH2) p -; p is an integer from 1 to 6; and

[0253] When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

[0254] In some embodiments, A is a bond. In other embodiments, A is -(CH2) n -. In some embodiments, n is 1, 2, 3, or 4. In one embodiment, n is 1. In another embodiment, n is 2. In another embodiment, n is 3. In another embodiment, n is 4.

[0255] In some embodiments, Ring A is a 5-membered ring. In some embodiments, Ring A is a 6-membered ring. In some embodiments, Ring A is an aryl group. In some embodiments, Ring A is a heteroaryl group. In some embodiments, Ring A is a 6-membered aryl group. In some embodiments, Ring A is a 6-membered heteroaryl group. In a preferred embodiment, Ring A is a phenyl group.

[0256] In some embodiments, p is 0. In some embodiments, p is an integer from 1 to 4. In some embodiments, p is an integer from 1 to 3. In one embodiment, p is 1. In another embodiment, p is 2. In another embodiment, p is 3. In another embodiment, p is 4.

[0257] In some embodiments, each R A are independently -OH, -OR X , halogen, NHR X 、N(R X )2 or optionally substituted alkyl; each R X is an optionally substituted alkyl. A is independently -OH, halogen, or optionally substituted alkyl. A is independently halogen or optionally substituted alkyl. A is independently -OH or optionally substituted alkyl. A is independently optionally substituted alkyl. A is independently substituted alkyl. A is independently unsubstituted alkyl. A In another embodiment, each R A In one embodiment, wherein p is 1, R A In another specific embodiment, wherein p is 2, each R A It is methyl.

[0258] In some embodiments, Y is a bond, -O-, -NR-, or -N=. In some embodiments, Y is -O-, -NR-, or -N=. In some embodiments, Y is a bond, -O-, or -NR-. In some embodiments, Y is a bond, -O-, or -N=. In some embodiments, Y is a bond, -NR-, or -N=. In some embodiments, Y is -O-, or -NR-. In some embodiments, Y is -O-, or -N=. In some embodiments, Y is -NR-, or -N=. In one embodiment, Y is a bond. In another embodiment, Y is -O-. In another embodiment, Y is -NR-. In another embodiment, Y is -N=.

[0259] In some embodiments, L is -(CH2) p -. In other embodiments, L is -C(O)NH-(CH2) p-. In some embodiments, p is an integer from 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2. In one embodiment, p is from 1 to 4. In another embodiment, p is 1 or 2. In another embodiment, p is 1 or 4. In a preferred embodiment, L is -CH2-. In another preferred embodiment, L is -C(O)NH-(CH2)4-.

[0260] In some embodiments, R is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl. In some embodiments, R is hydrogen or substituted or unsubstituted alkyl. In a preferred embodiment, R is hydrogen. In another embodiment, R is substituted or unsubstituted C 1-6 In another embodiment, R is an unsubstituted C 1-6 In one embodiment, R is methyl. In another preferred embodiment, R is hydrogen or methyl.

[0261] In some embodiments, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl. In some embodiments, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In some embodiments, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl. In some embodiments, R' is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted aryl. In embodiments, R' is hydrogen. In another embodiment, R' is substituted or unsubstituted. In another embodiment, R' is substituted or unsubstituted aryl.

[0262] In some embodiments, R 1 In some embodiments, R 1 In some embodiments, R 1 In some embodiments, R 2 In other embodiments, R 2 In some embodiments, R 1 is hydrogen and R 2 In some embodiments, R 1 is fluorine and R 2 In some embodiments, R 1 is hydrogen and R 2 In some embodiments, R 1 is iodine and R2 For hydrogen.

[0263] Connector

[0264] In some embodiments, the conjugate provided herein comprises more than one connector. In some embodiments, the targeting domain (e.g., the first targeting domain and the second targeting domain) is connected via the first connector. The first connector and the second connector can be any connector described herein. In some embodiments, the payload is connected to one (the first or second targeting domain) in the targeting domain via the second connector. In a preferred embodiment, the first connector is a peptide connector. In another preferred embodiment, the second connector is formed by chemical conjugation. In some embodiments, the second connector is a bifunctional connector for chemical conjugation. In another preferred embodiment, the second connector is a non-peptide connector.

[0265] In some embodiments, useful functional reactive groups for conjugating or binding the targeting domain to the payload described herein include, for example, zero or higher order connectors. In some cases, the conjugated moiety includes a functional reactive group that reacts with a connector as described herein (optionally pre-attached to other parts of the payload, targeting domain, or conjugate). In some embodiments, the connector includes a reactive group that reacts with a natural amino acid in a payload or targeting domain as described herein. The targeting domain (e.g., the first targeting domain and the second targeting domain) or one of the targeting domains (e.g., the first targeting domain or the second targeting domain) and the payload can be conjugated together by reacting the nucleophilic reactive moiety on the first targeting domain with the electrophilic reactive moiety on the second targeting domain, or by reacting the nucleophilic reactive moiety on the targeting domain with the electrophilic reactive moiety on the payload. In alternative embodiments, the first and second targeting domains, or the targeting domains (e.g., the first or second targeting domains) and the payload are conjugated together by reacting an electrophilic reactive portion on the first targeting domain with a nucleophilic portion on the second targeting domain, or by reacting an electrophilic reactive portion on the targeting domain with a nucleophilic portion on the payload. In some embodiments, an amide bond may be formed when an amine on the targeting domain (e.g., the ε-amine of a lysine residue) reacts with a carboxyl group on another targeting domain, or an amine on the targeting domain reacts with a carboxyl group on the payload. In alternative embodiments, the targeting domain and or the payload are derivatized with a derivatizing agent prior to conjugation.

[0266] In some cases, the higher-order linker includes a bifunctional linker, such as a homobifunctional linker or a heterobifunctional linker. Exemplary homobifunctional linkers include, but are not limited to, Lomant reagent dithiobis(succinimidyl propionate) DSP, 3′3′-dithiobis(sulfosuccinimidyl propionate) (DTSSP), disuccinimidyl suberate (DSS), bis(sulfosuccinimidyl) suberate (BS), disuccinimidyl tartrate (DST), disulfosuccinimidyl tartrate (sulfoDST), ethylene glycol bis(succinimidyl succinate) (EGS), disuccinimidyl glutarate (DSG), N,N′-disuccinimidyl carbonate (DSC), dimethyl adipate (DMA), dimethyl pimelate (DMP), dimethyl suberate (DMS), dimethyl-3,3′-dithiobispropionimidate (DTBP) , 1,4-di-3′-(2′-pyridyldithio)propionamido)butane (DPDPB), bismaleimidohexane (BMH), a compound containing an aromatic halide (DFDNB) such as 1,5-difluoro-2,4-dinitrobenzene or 1,3-difluoro-4,6-dinitrobenzene, 4,4′-difluoro-3,3′-dinitrobenzene sulfone (DFDNPS), bis-[β-(4-azidosalicylicylamido)ethyl]disulfide (BASED), formaldehyde, glutaraldehyde, 1,4-butanediol diglycidyl ether, adipic acid dihydrazide, carbohydrazide, o-toluidine, 3,3′-xylidine, benzidine, α,α′-p-diaminobenzidine, diiodo-p-xylenesulfonic acid, N,N′-ethylenebis(iodoacetamide), or N,N′-hexamethylenebis(iodoacetamide).

[0267] In some embodiments, the bifunctional linker includes a heterobifunctional linker. Exemplary heterobifunctional linkers include, but are not limited to, amine-reactive and sulfhydryl crosslinkers such as 3-(2-pyridyldithio) propionic acid N-succinimidyl ester (sPDP), long-chain 3-(2-pyridyldithio) propionic acid N-succinimidyl ester (LC-sPDP), water-soluble long-chain 3-(2-pyridyldithio) propionic acid N-succinimidyl ester (sulfo-LC-sPDP), succinimidyloxycarbonyl-α-methyl-α-(2-pyridyldithio) toluene (sMPT), sulfosuccinimidyl-6-[α-methyl-α-(2-pyridyldithio) toluamido] hexanoate (sulfo-LC-sMPT), succinimidyl-4-(N-maleimidomethyl) Cyclohexane-1-carboxylate (sMCC), sulfosuccinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulfo-sMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBs), m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester (sulfo-MBs), N-succinimidyl (4-iodoacetyl) aminobenzoate (sIAB), sulfosuccinimidyl (4-iodoacetyl) aminobenzoate (sulfo-sIAB), succinimidyl-4-(p-maleimidophenyl) butyrate (sMPB), sulfosuccinimidyl-4-(p-maleimidophenyl) butyrate (sulfo-sMPB ), N-(γ-maleimidobutyryloxy)succinimide ester (GMBs), N-(γ-maleimidobutyryloxy)sulfosuccinimide ester (sulfo-GMBs), succinimide 6-((iodoacetyl)amino)hexanoate (sIAX), succinimide 6-[6-(((iodoacetyl)amino)hexanoyl)amino]hexanoate (sIAXX), succinimide 4-(((iodoacetyl)amino)methyl)cyclohexane-1-carboxylate (sIAC), succinimide 6-((((4-iodoacetyl)amino)methyl)cyclohexane-1-carbonyl)amino)hexanoate (sIACX), p-nitrophenyl iodoacetate (NPIA), carbonyl-reactive and sulfhydryl-reactive Responsive crosslinkers such as 4-(4-N-maleimidophenyl)butyric acid hydrazide (MPBH), 4-(N-maleimidomethyl)cyclohexane-1-carboxy-hydrazide-8 (M2C2H), 3-(2-pyridyldithio)propionylhydrazide (PDPH), amine-reactive and photoreactive crosslinkers such as N-hydroxysuccinimidyl-4-azidosalicylic acid (NHs-AsA), N-hydroxysulfosuccinimidyl-4-azidosalicylic acid (sulfo-NHs-AsA), sulfosuccinimidyl-(4-azidosalicylic acidamido)hexanoate (sulfo-NHs-LC-AsA), sulfosuccinimidyl-2-(ρ-azidosalicylic acidamido)ethyl-1,3′-dithiopropionate (sAsD), N-hydroxysuccinimidyl-4-azidobenzoate (HsAB), N-hydroxysulfosuccinimidyl-4-azidobenzoate (sulfo-HsAB), N-succinimidyl-6-(4′-azido-2′-nitrophenylamino)hexanoate (sANPAH), sulfosuccinimidyl-6-(4-azido-2′-nitrophenylamino)hexanoate (sulfo-sANPAH), N-5-azido-2-nitrobenzoyloxysuccinimidyl azobenzene imide (ANB-NOs), sulfosuccinimidyl-2-(m-azido-o-nitrobenzamido)-ethyl-1,3′-dithiopropionate (sAND), N-succinimidyl-4-(4-azidophenyl)-1,3′-dithiopropionate (sADP), N-sulfosuccinimidyl-(4-azidophenyl)-1,3′-dithiopropionate (sulfo-sADP), sulfosuccinimidyl-4-(ρ-azidophenyl)butyrate (sulfo-sAPP), 2-(7-azidophenyl)-1,3′-dithiopropionate (sADP), sulfosuccinimidyl-4-(p-azidophenyl)butyrate (sulfo-sAPP), sAED), 7-azido-4-methylcoumarin-3-acetate sulfosuccinimidyl ester (sulfo-sAMCA), p-nitrophenyl diazopyruvate (pNPDP), p-nitrophenyl-2-diazo-3,3,3-trifluoropropionate (PNP-DTP), sulfhydryl-reactive and photoreactive crosslinkers such as 1-(p-azidosalicylamido)-4-(iodoacetamido)butane (AsIB), N-[4-(ρ-azido salicylamido) butyl]-3′-(2′-pyridyldithio) propionamide (APDP), benzophenone-4-iodoacetamide, benzophenone-4-maleimide carbonyl reactive and photoreactive crosslinkers such as p-azidobenzohydrazide (ABH), carboxylate reactive and photoreactive crosslinkers such as 4-(ρ-azido salicylamido) butylamine (AsBA) and arginine reactive and photoreactive crosslinkers such as p-azidophenylglyoxal (APG).

[0268] In some cases, the reactive functional group includes a nucleophilic group that reacts with an electrophilic group present on a binding moiety (e.g., on a payload moiety or on a targeting domain). Exemplary electrophilic groups include carbonyls, such as aldehydes, ketones, carboxylic acids, esters, amides, enones, acyl halides, or anhydrides. In some embodiments, the reactive functional group is an aldehyde. Exemplary nucleophilic groups include hydrazides, oximes, amino groups, hydrazine, thiosemicarbazones, hydrazine carboxylates, and aromatic hydrazides. In some embodiments, the non-natural amino acid incorporated into the conjugates described herein includes an electrophilic group.

[0269] In some embodiments, the linker is a cleavable linker. In some embodiments, the cleavable linker is a dipeptide linker. In some embodiments, the dipeptide linker is valine-citrulline (Val-Cit), phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala) and valine-lysine (Val-Lys). In some embodiments, the dipeptide linker is valine-citrulline. The linker may comprise a cleavable sequence or a sequence recognized by a protease.

[0270] In various embodiments, the targeting domain (e.g., the first targeting domain and the second targeting domain) comprises a polypeptide connector sequence. The connector can be at the C-terminus of the targeting domain. The connector can be expressed via recombinant technology and can be encoded using a nucleic acid sequence together with the expression of the targeting domain. The connector can connect the targeting domain to form a fusion protein. The presence of the connector in the conjugate can make the targeting domain play a role appropriately without being disturbed by the space of other targeting domains. The connector can connect the targeting domain to a tag, such as an expression tag or a purification tag. The connector can be a flexible connector. The flexibility of the connector can allow the targeting domain to adopt an independent conformation, with minimal interference from other targeting domains. In some embodiments, the connector is a peptide connector, which comprises, for example, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 35, 40, 45, 50 or more amino acids. In some cases, the peptide connector comprises at most 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 35, 40, 45, 50 or less amino acids. In other cases, the peptide connector comprises about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 35, 40, 45 or 50 amino acids. In other cases, the polypeptide connector comprises about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 35, 40, 45 or 50 amino acids. In some cases, the polypeptide connector comprises (GGGGSGGGS)x (SEQ ID NO: 14), wherein x is 1-10. In some embodiments, the connector is a polypeptide connector of 1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 1-11, 1-12 amino acids and longer in length. The connector may comprise SPSTPPTPSPSTPP, and the polypeptide connector may be a repeat of (GGGGS)x, (GGGS)x. The connector may comprise glycine, serine, threonine or proline. In some embodiments, the N-terminus of one targeting domain is fused to the C-terminus of the connector polypeptide, and the N-terminus of the connector polypeptide is fused to the N-terminus of another targeting domain.

[0271] In various embodiments, the targeting domains (e.g., the first targeting domain and the second targeting domain) are connected or separated by a connector. The connector can be a polypeptide connector. The connector can be expressed via recombinant technology and can be encoded using a nucleic acid sequence together with the expression of the targeting domain. The connector can connect the targeting domains to form a fusion protein. The presence of the connector in the conjugate can allow the targeting domain to function properly without being disturbed by the space of other targeting domains. The connector can be a flexible connector. The flexibility of the connector can allow the targeting domain to adopt an independent conformation with minimal interference from other targeting domains. In some embodiments, the connector is a peptide connector comprising, for example, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 35, 40, 45, 50 or more amino acids. In some cases, the peptide connector comprises at most 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 35, 40, 45, 50 or less amino acids. In other cases, the peptide connector comprises about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 35, 40, 45 or 50 amino acids. In other cases, the polypeptide connector comprises about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 20, 25, 30, 35, 40, 45 or 50 amino acids. In some cases, the polypeptide connector comprises (GGGGSGGGS)x (SEQ ID NO: 14), wherein x is 1-10. In some embodiments, the connector is a polypeptide connector of 1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 1-11, 1-12 amino acids and longer in length. The connector may include SPSTPPTPSPSTPP, and the polypeptide connector may be a repeat of (GGGGS)x, (GGGS)x. The connector may include glycine, serine, threonine or proline. In some embodiments, the N-terminus of one targeting domain is fused to the C-terminus of the connector polypeptide, and the N-terminus of the connector polypeptide is fused to the N-terminus of another targeting domain.

[0272] In some embodiments, the linker includes a self-immolative linker portion. In some embodiments, the self-immolative linker portion includes p-aminobenzyl alcohol (PAB), p-aminophenyloxycarbonyl (PABC) or a derivative or analog thereof. In some embodiments, the linker includes a dipeptide linker portion and a self-immolative linker portion. In some embodiments, the self-immolative linker portion is as described in U.S. Patent No. 9089614 and WIPO Application No. WO2015038426.

[0273] In some embodiments, the cleavable linker is a glucuronide. In some embodiments, the cleavable linker is an acid cleavable linker. In some embodiments, the acid cleavable linker is a hydrazine. In some embodiments, the cleavable linker is a reducible linker.

[0274] In some embodiments, the linker includes a maleimide group. In some cases, the maleimide group is also referred to as a maleimide spacer. In some cases, the maleimide group also includes the caproic acid forming maleimidocaproyl (mc). In some cases, the linker includes maleimidocaproyl (mc). In some cases, the linker is maleimidocaproyl (mc). In other cases, the maleimide group includes a maleimidomethyl group, such as succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sMCC) or sulfosuccinyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulfo-sMCC).

[0275] In some embodiments, the maleimide group is a self-stabilized maleimide. In some cases, the self-stabilized maleimide utilizes diaminopropionic acid (DPR) to be incorporated into the basic amino group adjacent to the maleimide, so as to provide intramolecular catalysis for the hydrolysis of the sulfosuccinimide ring, thereby eliminating the elimination reaction of the maleimide by the reverse Michael reaction. In some cases, the self-stabilized maleimide is Lyon et al., "Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates," Nat.Biotechnol.32 (10): 1059-1062 (2014) described maleimide group. In some cases, the linker includes a self-stabilized maleimide. In some cases, the linker is a self-stabilized maleimide.

[0276] In some cases, the linker comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or ten or more of a carbonyl or dicarbonyl, an oxime, a hydroxylamine, or a protected form thereof. The TLR agonist linker derivative or targeting domain may be the same or different, for example, there may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more different sites in the derivative comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more different reactive groups.

[0277] As described herein, the present disclosure provides a targeting domain coupled to another molecule having the formula "targeting domain-L-payload", wherein L is a linker or a chemical bond. In some embodiments, L is stable in vivo. In some embodiments, L is hydrolyzable in vivo. In some embodiments, L is metastable in vivo.

[0278] The targeting domain and the payload can be linked together by L using standard linkers and procedures known to those skilled in the art. In some aspects, the targeting domain is directly fused to the payload, and L is a key. In other aspects, the targeting domain and the payload are fused by a linking group L. For example, in some embodiments, the targeting domain and the payload are linked together via a peptide bond, optionally linked together by a peptide or amino acid spacer. In some embodiments, the targeting domain and the payload are linked together by chemical conjugation, optionally linked together by a linking group (L). In some embodiments, L is directly conjugated to each of the targeting domain and the payload.

[0279] Chemical conjugation can occur by reacting the nucleophilic reactive group of one compound with the electrophilic reactive group of another compound. In some embodiments, when L is a bond, the targeting domain is conjugated to the payload by reacting the nucleophilic reactive part on the targeting domain with the electrophilic reactive part on the linker, or by reacting the electrophilic reactive part on the targeting domain with the nucleophilic reactive part on the payload. In an embodiment, when L is a group connecting the targeting domain and the payload together, the targeting domain and / or the payload can be conjugated to L by reacting the nucleophilic reactive part on the targeting domain and / or the payload with the electrophilic reactive part on L, or by reacting the electrophilic reactive part on the targeting domain and / or the payload with the nucleophilic reactive part on L. Non-limiting examples of nucleophilic reactive groups include amino, thiol and hydroxyl. Non-limiting examples of electrophilic reactive groups include carboxyl, acyl chloride, anhydride, ester, succinimidyl ester, alkyl halide, sulfonate, maleimido, haloacetyl and isocyanate. In embodiments where the targeting domain and payload are conjugated together by reacting a carboxylic acid with an amine, an activating agent may be used to form an activated ester of the carboxylic acid.

[0280] The activated ester of the carboxylic acid can be, for example, N-hydroxysuccinimide (NHS), tosylate (Tos), mesylate, triflate, carbodiimide or hexafluorophosphate. In some embodiments, the carbodiimide is 1,3-dicyclohexylcarbodiimide (DCC), 1,1'-carbonyldiimidazole (CDI), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) or 1,3-diisopropylcarbodiimide (DICD). In some embodiments, the hexafluorophosphate is selected from benzotriazol-1-yl-oxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), benzotriazol-1-yl-oxytripyrrolidinephosphonium hexafluorophosphate (PyBOP), 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), and o-benzotriazole-N,N,N',N'-tetramethyluronium-hexafluorophosphate (HBTU).

[0281] In some embodiments, the targeting domain (e.g., the first targeting domain and the second targeting domain) comprises a nucleophilic reactive group (e.g., an amino group, a thiol or a hydroxyl group of a side chain of lysine, cysteine ​​or serine) that can be conjugated to an electrophilic reactive group on a payload or L. In some embodiments, the targeting domain comprises an electrophilic reactive group (e.g., a carboxylate group of a side chain of Asp or Glu) that can be conjugated to a nucleophilic reactive group on a payload or L. In some embodiments, the targeting domain is chemically modified to include a reactive group that can be directly conjugated to a payload or L. In some embodiments, the targeting domain is modified at the N-terminus or C-terminus to include a natural amino acid with a nucleophilic side chain. In an exemplary embodiment, the N-terminus or C-terminus amino acid of the targeting domain is selected from lysine, ornithine, serine, cysteine ​​and homocysteine. For example, the N-terminus or C-terminus amino acid of the targeting domain can be modified to include a lysine residue. In some embodiments, the targeting domain is modified at the N-terminus or C-terminus amino acid to include a natural amino acid with an electrophilic side chain, such as, for example, Asp and Glu. In some embodiments, the internal amino acids in the targeting domain are replaced by natural amino acids with nucleophilic side chains, as described herein above. In exemplary embodiments, the internal amino acids in the replaced targeting domain are selected from lysine, ornithine, serine, cysteine ​​and homocysteine. For example, the internal amino acids in the targeting domain can be replaced by lysine residues. In some embodiments, the internal amino acids in the targeting domain are replaced by natural amino acids with electrophilic side chains, such as, for example, Asp and Glu.

[0282] In some embodiments, the payload includes a reactive group that can be directly conjugated to the targeting domain or L. In some embodiments, the payload comprises a nucleophilic reactive group (e.g., amine, thiol, hydroxyl) that can be conjugated to an electrophilic reactive group on the targeting domain or L. In some embodiments, the payload comprises an electrophilic reactive group (e.g., carboxyl, activated form of carboxyl, compound with a leaving group) that can be conjugated to a nucleophilic reactive group on the targeting domain or L. In some embodiments, the payload is chemically modified to include a nucleophilic reactive group that can be conjugated to an electrophilic reactive group on the targeting domain or L. In some embodiments, the payload is chemically modified to include an electrophilic reactive group that can be conjugated to a nucleophilic reactive group on the targeting domain or L.

[0283] In some embodiments, conjugation can be performed via organosilanes, e.g., aminosilanes treated with glutaraldehyde, carbonyldiimidazole (CDI) activation of silanol groups, or using dendrimers. A variety of dendrimers are known in the art and include poly(amidoamine) (PAMAM) dendrimers, which are synthesized by a divergent approach starting from an ammonia or ethylenediamine initiator core reagent; a subclass of PAMAM dendrimers based on a triaminoethyleneimine core; radially layered poly(amidoamine-organosilicon) dendrimers (PAMAMOS), which are inversely layered structures consisting of a hydrophilic, nucleophilic polyamidoamine (PAMAM) interior and a hydrophobic organosilicon (OS) exterior. Unimolecular micelles; poly(propyleneimine) (PPI) dendrimers, which are generally polyalkylamines with primary amines as end groups, while the interior of the dendrimer is composed of many tertiary tripropyleneamines; poly(propyleneamine) (POPAM) dendrimers; diaminobutane (DAB) dendrimers; amphiphilic dendrimers; micellar dendrimers, which are unimolecular micelles of water-soluble hyperbranched polyphenylenes; polylysine dendrimers; and dendrimers based on polybenzyl ether hyperbranched backbones.

[0284] In some embodiments, conjugation can be carried out by olefin metathesis. In some embodiments, the payload and the targeting domain, the payload and L or the targeting domain and L both contain an olefin or alkyne moiety capable of metathesis. In some embodiments, a suitable catalyst (e.g., copper, ruthenium) is used to accelerate the metathesis reaction. Suitable methods for carrying out olefin metathesis reactions are described in the art. See, for example, Schafmeister et al., J.Am.Chem.Soc.122:5891-5892 (2000), Walensky et al., Science 305:1466-1470 (2004) and Blackwell et al., Angew, Chem., Int.Ed.37:3281-3284 (1998).

[0285] In some embodiments, click chemistry can be used for conjugation. The "click reaction" is wide-ranging, easy to implement, uses only readily available reagents, and is insensitive to oxygen and water. In some embodiments, the click reaction is a cycloaddition reaction between an alkynyl group and an azido group to form a triazole group. In some embodiments, the click reaction uses a copper or ruthenium catalyst. Suitable methods for performing click reactions are described in the art. See, for example, Kolb et al., Drug Discovery Today 8:1128 (2003); Kolb et al., Angew. Chem. Int. Ed. 40:2004 (2001); Rostovtsev et al., Angew. Chem. Int. Ed. 41:2596 (2002); Tornoe et al., J. Org. Chem. 67:3057 (2002); Manetsch et al., J. Am. Chem. Soc. 126:12809 (2004); Lewis et al., J. Am. Chem. Soc. 126:12809 (2004); s et al., Angew. Chem. Int. Ed. 41:1053 (2002); Speers, J. Am. Chem. Soc. 125:4686 (2003); Chan et al. Org. Lett. 6:2853 (2004); Zhang et al., J. Am. Chem. Soc. 127:15998 (2005); and Waser et al., J. Am. Chem. Soc. 127:8294 (2005).

[0286] Indirect conjugation via high affinity specific binding partners (eg, streptavidin / biotin or avidin / biotin or lectin / carbohydrate) is also contemplated.

[0287] Reactive residues for conjugation

[0288] In some embodiments, the targeting domain and / or the effective load are functionalized to include nucleophilic reactive groups or electrophilic reactive groups with organic derivatizing agents. This derivatizing agent can react with the selected side chain or N or C-terminal residue of the functional group on the targeting amino acid and the effective load on the targeting domain. The reactive groups on the targeting domain and / or the effective load include, for example, aldehydes, amino groups, esters, thiols, α-haloacetyl groups, maleimido groups or hydrazino groups. Derivatizing agents include, for example, maleimidobenzoyl sulfosuccinimide esters (conjugated by cysteine ​​residues), N-hydroxysuccinimide (by lysine residues), glutaraldehyde, succinic anhydride or other reagents known in the art. Alternatively, the targeting domain and / or the effective load can be indirectly connected to each other through an intermediate carrier (such as a polysaccharide or polypeptide carrier). Examples of polysaccharide carriers include aminodextran. Examples of suitable polypeptide carriers include polylysine, polyglutamic acid, polyaspartic acid, copolymers thereof, and mixed polymers of these amino acids and other amino acids (eg, serine) to impart the desired solubility on the resulting loaded carrier.

[0289] Cysteine ​​residues are most commonly reacted with α-haloacetates (and corresponding amines) such as chloroacetic acid or chloroacetamide to give carboxymethyl or carboxamidomethyl derivatives. Cysteine ​​residues are also derivatized by reaction with bromotrifluoroacetone, α-bromo-β-(5-imidazolyl)propionic acid, chloroacetyl phosphate, N-alkylmaleimide, 3-nitro-2-pyridyl disulfide, methyl 2-pyridyl disulfide, p-chloromercurybenzoate, 2-chloromercury-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-1,3-diazole.

[0290] Histidine residues are derivatized by reaction with diethyl pyrocarbonate at pH 5.5-7.0, as this reagent is relatively specific for histidyl side chains. P-Bromophenylacetyl bromide is also useful; the reaction is preferably carried out in 0.1 M sodium cacodylate at pH 6.0.

[0291] Lysyl and amino terminal residues react with succinic anhydride or other carboxylic anhydrides. Derivatization with these reagents has the effect of reversing the charge of the lysyl residues. Other suitable reagents for derivatizing residues containing α-amino groups include iminoesters, such as methyl pyridine imine methyl ester, pyridoxal phosphate, pyridoxal, chloroborohydride, trinitrobenzenesulfonic acid, O-methylisourea, 2,4-pentanedione and transaminase-catalyzed reactions with glyoxylate.

[0292] Arginine acyl residues are modified by reaction with one or more conventional reagents, including phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Due to the high pKa of the guanidine functional group, derivatization of arginine residues requires the reaction to be performed under alkaline conditions. In addition, these reagents can react with groups of lysine as well as the arginine epsilon amino group.

[0293] Specific modifications can be made to tyrosyl residues, in particular the introduction of spectral labels into tyrosyl residues by reaction with aromatic diazo compounds or tetranitromethane. Most commonly, N-acetylimidazole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively.

[0294] The carboxyl side groups (aspartyl or glutamyl) are selectively modified by reaction with carbodiimide (RN=C=N-R'), wherein R and R' are different alkyl groups, such as 1-cyclohexyl-3-(2-morpholinyl-4-ethyl)carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl)carbodiimide. In addition, aspartyl and glutamyl residues are converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.

[0295] Other modifications include hydroxylation of proline and lysine, phosphorylation of the hydroxyl groups of seryl or threonyl residues, methylation of the α-amino groups of lysine, arginine and histidine side chains (TECreighton, Proteins: Structure and Molecular Properties, WH Freeman & Co., San Francisco, pp. 79-86 (1983)), deamidation of asparagine or glutamine, acetylation of the N-terminal amine and / or amidation or esterification of the C-terminal carboxylic acid group.

[0296] Another type of covalent modification involves chemically or enzymatically coupling glycosides to peptides. Sugars can be attached to (a) arginine and histidine, (b) free carboxyl groups, (c) free sulfhydryl groups, such as the sulfhydryl groups of cysteine, (d) free hydroxyl groups, such as the hydroxyl groups of serine, threonine or hydroxyproline, (e) aromatic residues, such as the residues of tyrosine or tryptophan, or (f) the amide group of glutamine. These methods are described in WO1987 / 05330 and Aplin and Wriston CRC Crit. Rev. Biochem., pp. 259-306 (1981).

[0297] In some embodiments, L is a bond. In these embodiments, the targeting domain and the payload are conjugated together by reacting the nucleophilic reactive moiety on the targeting domain with the electrophilic reactive moiety on the payload. In an optional embodiment, the targeting domain and the payload are conjugated together by reacting the electrophilic reactive moiety on the targeting domain with the nucleophilic moiety on the payload. In an exemplary embodiment, L is an amide bond formed when an amine on the targeting domain (e.g., the ε-amine of a lysine residue) reacts with a carboxyl group on M. In an optional embodiment, the targeting domain and or the payload are derivatized with a derivatizing agent before conjugation.

[0298] In some embodiments, L is a linking group. In some embodiments, L is a bifunctional linker, and only two reactive groups are included before being conjugated with the targeting domain and the payload. In the embodiment where the targeting domain and the payload both have electrophilic reactive groups, L includes two identical or two different nucleophilic groups (e.g., amine, hydroxyl, thiol) before being conjugated with the targeting domain and the payload. In the embodiment where the targeting domain and the payload both have nucleophilic reactive groups, L includes two identical or two different electrophilic groups (e.g., carboxyl, activated form of carboxyl, compound with leaving group) before being conjugated with the targeting domain and the payload. In the embodiment where one in the targeting domain or the payload has a nucleophilic reactive group and another in the targeting domain or the payload has an electrophilic reactive group, L includes a nucleophilic reactive group and an electrophilic group before being conjugated with the targeting domain and the payload.

[0299] L can be any molecule having at least two reactive groups capable of reacting with each of the targeting domain and the payload (before conjugation with the targeting domain and the payload). In some embodiments, L has only two reactive groups and is bifunctional. L (before conjugation with the peptide) can be represented by Formula VI: ALB, wherein A and B are independently nucleophilic or electrophilic reactive groups. In some embodiments, both A and B are nucleophilic groups or both are electrophilic groups. In some embodiments, one of A or B is a nucleophilic group, and the other of A or B is an electrophilic group.

[0300] In some embodiments, A and B may include olefins and / or alkyne functional groups suitable for olefin metathesis reactions. In some embodiments, A and B include parts suitable for click chemistry (e.g., olefins, alkynes, nitrile, azide). Other non-limiting examples of reactive groups (A and B) include pyridyl dimercapto, aryl azide, diaziridine, carbodiimide and hydrazide.

[0301] In some embodiments, L is hydrophobic. Hydrophobic linkers are known in the art. See, for example, Bioconjugate Techniques, GT Hermanson (Academic Press, San Diego, CA, 1996), which is incorporated herein by reference in its entirety. Suitable hydrophobic linking groups known in the art include, for example, 8-hydroxyoctanoic acid and 8-mercaptooctanoic acid. Prior to conjugation with the peptide of the composition, the hydrophobic linking group comprises at least two reactive groups (A and B), as described herein and as follows: A-(hydrophobic linking group)-B.

[0302] In some embodiments, hydrophobic linking group includes maleimido or iodoacetyl, and carboxylic acid or activated carboxylic acid (such as NHS ester) as reactive group.In these embodiments, maleimido or iodoacetyl can be coupled with thiol moiety on targeting domain or effective load, and carboxylic acid or activated carboxylic acid can be coupled with amine on targeting domain or effective load with or without coupling reagent.Any coupling agent known to those skilled in the art can be used for coupling carboxylic acid with free amine, such as DCC, DIC, HATU, HBTU, TBTU and other activators described herein.In specific embodiments, hydrophilic linking group includes aliphatic chain of 2 to 100 methylene groups, wherein A and B are carboxyl or its derivatives (such as succinic acid).In other specific embodiments, L is iodoacetic acid.

[0303] In some cases, prior to conjugation to the peptide of the composition, the hydrophilic linking group includes at least two reactive groups (A and B), as described herein and as follows: A-(hydrophilic linking group)-B. In specific embodiments, the linking group is polyethylene glycol (PEG). In certain embodiments, the molecular weight of PEG is from about 100 Daltons to about 10,000 Daltons, for example, from about 500 Daltons to about 5000 Daltons. In some embodiments, the molecular weight of PEG is from about 10,000 Daltons to about 40,000 Daltons.

[0304] In some embodiments, hydrophilic linking group includes maleimido or iodoacetyl, and carboxylic acid or activated carboxylic acid (such as NHS ester) as reactive group.In these embodiments, maleimido or iodoacetyl can be coupled with sulfhydryl moiety on targeting domain or effective load, and carboxylic acid or activated carboxylic acid can be coupled with amine on targeting domain or effective load with or without coupling reagent.Any suitable coupling agent known to those skilled in the art can be used for coupling carboxylic acid with amine, such as, for example, DCC, DIC, HATU, HBTU, TBTU and other activators described herein.In some embodiments, linking group is maleimido-polymer (0.1-2.5kDa)-COOH, iodoacetyl-polymer (0.1-2.5kDa)-COOH, maleimido-polymer (0.1-2.5kDa)-NHS or iodoacetyl-polymer (0.1-2.50kDa)-NHS.

[0305] In some embodiments, the linking group consists of an amino acid, a dipeptide, a tripeptide, or a polypeptide, wherein the amino acid, dipeptide, tripeptide, or polypeptide comprises at least two activating groups, as described herein. In some embodiments, the linking group (L) comprises a moiety selected from amino, ether, thioether, maleimide, disulfide, amide, ester, thioester, olefin, cycloolefin, alkyne, triazole, carbamate, carbonate, cathepsin B cleavable and hydrazone.

[0306] In some embodiments, L comprises an atomic chain of 1 to about 60, or 1 to 30 or longer, 2 to 5, 2 to 10, 5 to 10 or 10 to 20 atoms. In some embodiments, the chain atoms are all carbon atoms. In some embodiments, the chain atoms in the skeleton of the linker are selected from C, O, N and S. In some cases, the chain atoms and the linker are selected according to their expected solubility (hydrophilicity) to provide a more soluble conjugate. In some embodiments, L provides a functional group that can be cut by an enzyme or other catalyst or by hydrolysis conditions found in a target tissue or organ or cell. In some embodiments, the length of L is sufficient to reduce the possibility of steric hindrance.

[0307] In some embodiments, L is stable in biological fluids such as blood or blood components. In some embodiments, L is stable in serum for at least 5 minutes, for example, when incubated in serum for a period of 5 minutes, less than 25%, 20%, 15%, 10% or 5% of the conjugate is cut. In other embodiments, L is stable in serum for at least 10, or 20, or 25, or 30, or 60, or 90, or 120 minutes, or 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18 or 24 hours. In these embodiments, L does not include a functional group that can be hydrolyzed in vivo. In some exemplary embodiments, L is stable in serum for at least about 72 hours. Non-limiting examples of functional groups that cannot be significantly hydrolyzed in vivo include amides, ethers and thioethers.

[0308] In some embodiments, L is hydrolyzable in vivo. In these embodiments, L comprises a functional group capable of being hydrolyzed in vivo. Non-limiting examples of functional groups capable of being hydrolyzed in vivo include esters, anhydrides, and thioesters.

[0309] In some exemplary embodiments, L is unstable and undergoes extensive hydrolysis in 3 hours and complete hydrolysis in 6 hours in plasma at 37° C. In some exemplary embodiments, L is not unstable.

[0310] In some embodiments, L is metastable in vivo. In these embodiments, L comprises a functional group (e.g., an acid-labile, reduction-labile, or enzyme-labile functional group) that can be chemically or enzymatically cleaved in vivo, optionally over a period of time. In these embodiments, L may include, for example, a hydrazone moiety, a disulfide moiety, or a cathepsin-cleavable moiety. When L is metastable, and without intending to be bound by any particular theory, the targeting domain-LM conjugate is stable in an extracellular environment, such as in serum over the above time period, but is unstable in an intracellular environment or under conditions simulating an intracellular environment so that it will cleave when entering a cell. In some embodiments, when L is in a metastable state, L is stable in serum for at least about 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 42, or 48 hours, e.g., at least about 48, 54, 60, 66, or 72 hours, or about 24-48, 48-72, 24-60, 36-48, 36-72, or 48-72 hours.

[0311] In some cases, suitable polymer backbones have the formula X-polymer-LY, wherein the polymer is polyethylene glycol, and X is a functional group that does not react with the azide group, and Y is a suitable leaving group. Examples of suitable functional groups include, but are not limited to, hydroxyl, protected hydroxyl, acetal, alkenyl, amine, aminooxy, protected amine, protected hydrazide, protected thiol, carboxylic acid, protected carboxylic acid, maleimide, dithiopyridine and vinylpyridine, and ketone. Examples of suitable leaving groups include, but are not limited to, chloride, bromide, iodide, mesylate, tresylate and tosylate.

[0312] Connectors can have a wide range of molecular weights or molecular lengths. Connectors of larger or smaller molecular weights can be used to provide desired spatial relationships or conformations between a targeting domain and a connected entity or between a connected entity and its binding partner (if any). Connectors with longer or shorter molecular lengths can also be used to provide desired space or flexibility between a targeting domain and a connected entity or between a connected entity and its binding partner.

[0313] In some embodiments, the linker includes a water-soluble bifunctional linker having a dumbbell structure including: a) a carbonyl-containing moiety on at least the first end of an azide, an alkyne, a hydrazine, a hydrazide, a hydroxylamine, or a polymer backbone; and b) at least a second functional group on the second end of the polymer backbone. The second functional group may be the same or different from the first functional group. In some embodiments, the second functional group does not react with the first functional group. In some embodiments, the water-soluble compound includes at least one arm of a branched molecular structure. For example, the branched molecular structure may be dendritic.

[0314] In an exemplary embodiment, the polymer is linked to the targeting domain or modified targeting domain via a linker. For example, the linker may comprise one or two amino acids, one end of which is bound to the polymer, such as an albumin binding moiety, and the other end is bound to any available position on the polypeptide backbone. Additional exemplary linkers include hydrophilic linkers, such as a chemical moiety comprising at least 5 non-hydrogen atoms, wherein 30-50% of these are N or O.

[0315] Optionally, multiple targeting domains or modified targeting domain molecules can be connected by a linker polypeptide, wherein the length of the linker polypeptide is optionally 1, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 1-11, 1-12 amino acids, and longer, wherein optionally, the N-terminus of one targeting domain is fused to the C-terminus of the linker polypeptide, and the N-terminus of the linker polypeptide is fused to the N-terminus of another targeting domain.

[0316] As used herein, the terms "electrophilic group", "electrophile", etc. refer to an atom or group of atoms that can accept an electron pair to form a covalent bond. As used herein, "electrophilic group" includes, but is not limited to, halides, carbonyl groups, and epoxide-containing compounds. Common electrophiles include halides such as thiophosgene, dichloroglycerol, phthaloyl chloride, succinyl chloride, chloroacetyl chloride, chlorosuccinyl chloride, etc.; ketones such as chloroacetone, bromoacetone, etc.; aldehydes such as glyoxal, etc.; isocyanates such as hexamethylene diisocyanate, toluene diisocyanate, m-xylyl diisocyanate, cyclohexylmethane-4,4-diisocyanate, and derivatives of these compounds.

[0317] As used herein, the terms "nucleophilic group", "nucleophile" and the like refer to an atom or group of atoms having an electron pair capable of forming a covalent bond. This type of group can be an ionizable group that reacts as an anionic group. As used herein, "nucleophilic group" includes, but is not limited to, hydroxyl, primary amine, secondary amine, tertiary amine and thiol.

[0318] In general, carbon electrophiles are susceptible to attack by complementary nucleophiles, including carbon nucleophiles, wherein the attacking nucleophile donates an electron pair to the carbon electrophile to form a new bond between the nucleophile and the carbon electrophile.

[0319] Non-limiting examples of carbon nucleophiles include, but are not limited to, alkyl, alkenyl, aryl and alkynyl Grignard reagents, organolithium, organozinc, alkyltin reagents, alkenyltin reagents, aryltin reagents and alkynyltin reagents (organotins), alkylborane reagents, alkenylborane reagents, arylborane reagents and alkynylborane reagents (organoboranes and organoboronates); these carbon nucleophiles have the advantage of being kinetically stable in water or polar organic solvents. Other non-limiting examples of carbon nucleophiles include phosphorus ylides, enols and enolate reagents; these carbon nucleophiles have the advantage of being relatively easy to generate from precursors well known to those skilled in the art of synthetic organic chemistry. When a carbon nucleophile is used in combination with a carbon electrophile, a new carbon-carbon bond is generated between the carbon nucleophile and the electrophile.

[0320] Non-limiting examples of non-carbon nucleophiles suitable for coupling to carbon electrophiles include, but are not limited to, primary and secondary amines, thiols, thiolates and thioethers, alcohols, alkoxides, azides, semicarbazides, etc. When used in conjunction with a carbon electrophile, these non-carbon nucleophiles typically generate a heteroatom bond (CXC) where X is a heteroatom including, but not limited to, oxygen, sulfur, or nitrogen.

[0321] In some cases, the polymer used herein terminates at one end with a hydroxyl or methoxy group, i.e., X is H or CH3 ("methoxy PEG"). Alternatively, the polymer can terminate with a reactive group to form a bifunctional polymer. Typical reactive groups may include those reactive groups commonly used to react with the functional groups found in 20 common amino acids (including but not limited to maleimide groups, activated carbonates (including but not limited to p-nitrophenyl esters), activated esters (including but not limited to N-hydroxysuccinimide, p-nitrophenyl esters) and aldehydes), and functional groups (including but not limited to azide groups, alkyne groups) that are inert to 20 common amino acids but specifically react with complementary functional groups. It is worth noting that the other end of the polymer (represented by Y in the above formula) will be directly or indirectly attached to the targeting domain via amino acids. For example, Y is an amide, carbamate or urea connected to an amine group (including but not limited to the epsilon amine or N-terminal of lysine) of a polypeptide. Alternatively, Y is a maleimide connected to a thiol group (including but not limited to the thiol group of cysteine). Alternatively, the alkynyl groups on the polymer can react with the azide groups present in the targeting domain to form similar products. In some embodiments, strong nucleophiles (including but not limited to hydrazine, hydrazide, hydroxylamine, semicarbazide) can react with the aldehyde or ketone groups present in the targeting domain to form hydrazones, oximes or semicarbazones (if applicable), which can be further reduced by treating with appropriate reducing agents in some cases. Alternatively, strong nucleophiles can be incorporated into the targeting domain via amino acids and used to preferentially react with the ketone or aldehyde groups present in the water-soluble polymer.

[0322] Any molecular weight of polymer can be used according to actual needs, including but not limited to about 0.1 Dalton (Da) to 2,500Da or higher. The molecular weight of polymer can be a wide range, including but not limited to between about 100Da and about 5000Da or larger. In some cases, polymer is 50-5000Da, 50-3000Da, 50-2500Da, 100-2500Da, 250-2500Da, 250-5000Da or 500-5000Da. Branched polymers, including but not limited to polymer molecules with a molecular weight range of 0.1-5kDa, 0.1-4kDa, 0.1-3kDa, 0.1-2.5kDa, 0.1-1.5kDa per chain.

[0323] Polymer can include polymer derivatives containing azide and acetylene, and it includes a water-soluble polymer backbone with an average molecular weight of about 800Da to about 100,000Da. The polymer backbone of a water-soluble polymer can be poly (ethylene glycol). However, it should be understood that various water-soluble polymers, including but not limited to poly (ethylene glycol) and other related polymers, including poly (dextran) and poly (propylene glycol), are also water-soluble, and the use of the term PEG or poly (ethylene glycol) is intended to cover and include all such molecules. The term PEG includes but is not limited to any form of poly (ethylene glycol), including bifunctional PEG, multi-arm PEG, derivatization PEG, bifurcated PEG, branched PEG, pendant PEG (i.e., PEG or related polymers with one or more functional groups pendant to the polymer backbone), or PEG with a degradable bond therein.

[0324] In addition to these forms of polymers, polymers can also be prepared with weak or degradable bonds in the backbone. For example, a polymer can be prepared with ester bonds in the polymer backbone, which undergo hydrolysis. This hydrolysis results in the cleavage of the polymer into lower molecular weight fragments as shown below: -Polymer-CO2-Polymer-+H2OàPolymer-CO2H+HO-Polymer-.

[0325] The connector can include polymers, such as those comprising a water-soluble backbone. In some embodiments, a water-soluble polymer backbone includes 2 to about 300 ends. Examples of suitable polymers include, but are not limited to, other poly(alkylene glycols), such as poly(propylene glycol) ("PPG"), copolymers thereof (including but not limited to copolymers of ethylene glycol and propylene glycol), terpolymers thereof, mixtures thereof, etc. Although the molecular weight of each chain of the polymer backbone can vary, it is generally in the range of about 800Da to about 100,000Da, generally in the range of about 6,000Da to about 80,000Da. The molecular weight of each chain of the polymer backbone may be between about 100 Da and about 100,000 Da, including but not limited to 100,000 Da, 95,000 Da, 90,000 Da, 85,000 Da, 80,000 Da, 75,000 Da, 70,000 Da, 65,000 Da, 60,000 Da, 55,000 Da, 50,000 Da, 45,000 Da, 40,000 Da, 35,000 Da, 3 In some embodiments, the molecular weight of each chain of the polymer backbone is between about 100Da and about 50,000Da. In some embodiments, the molecular weight of each chain of the polymer backbone is between about 100Da and about 40,000Da. In some embodiments, the molecular weight of each chain of the polymer backbone is between about 100Da and about 40,000Da. In some embodiments, the molecular weight of each chain of the polymer backbone is between about 1,000Da and about 40,000Da. In some embodiments, the molecular weight of each chain of the polymer backbone is between about 5,000 Da and about 40,000 Da. In some embodiments, the molecular weight of each chain of the polymer backbone is between about 10,000 Da and about 40,000 Da.

[0326] Suitable physiologically cleavable bonds include, but are not limited to, esters, carbonates, carbamates, sulfates, phosphates, acyloxyalkyl ethers, acetals and ketals. Such conjugates should have physiologically cleavable bonds that are stable during storage and administration. For example, the targeting domain or modified targeting domain connected to the polymer should maintain its integrity when the final pharmaceutical composition is manufactured, when dissolved in an appropriate delivery vehicle (if used), and when administered by any route.

[0327] The present invention also includes a phosphate-based connector with adjustable stability disclosed in US2017 / 0182181, for intracellular delivery of drug conjugates, which is incorporated herein by reference. A phosphate-based connector includes a monophosphate, diphosphate, triphosphate or tetraphosphate group (phosphate group) covalently connected to the distal end of a connector arm, and the connector arm includes an adjustable element, an optional spacer element and a reactive functional group from the distal end to the proximal end. The phosphate group of the phosphate-based connector can be conjugated with a payload, and the reactive functional group can be conjugated with a cell-specific targeting ligand (such as an antibody). The general structure of the phosphate-based connector is: phosphate group-adjustable element-optional spacer element-functional reactive group. The phosphate-based connector conjugated to a payload has a general structure: payload-phosphate group-adjustable element-optional spacer element-functional reactive group, and has a general structure when conjugated with a targeting ligand: payload-phosphate group-adjustable element-optional spacer element-targeting ligand. These phosphate-based linkers have differentiated and adjustable stability in the blood and in the intracellular environment (such as lysosomal compartments). The rate at which the phosphate group is cleaved in the intracellular environment to release the payload in natural or active form may be affected by the structure of the adjustable element, further affected by the substitution of the phosphate group and whether the phosphate group is monophosphate, diphosphate, triphosphate or tetraphosphate mediated. In addition, these phosphate-based linkers provide the ability to construct conjugates, such as antibody-drug conjugates, wherein the tendency of the conjugate to form aggregates is reduced compared to conjugates in which the same payload is conjugated to an antibody or a targeting ligand using a non-phosphate-based linker disclosed herein.

[0328] In some cases, the targeting domain is connected to the payload via a water-soluble polymer via the methods described herein. In some embodiments, the method includes contacting the separated targeting domain comprising a reactive amino acid side chain with a connector. In some cases, the conjugate is synthesized by reacting the functional groups present on the targeting domain with the reactive groups present on the connector. In some cases, the conjugate is synthesized by reacting the functional groups present on the connector with the reactive groups present on the payload. In some cases, the payload-connector portion is conjugated to the targeting domain. In some cases, the targeting domain-connector portion is conjugated to the payload. In some embodiments, the targeting domain is connected to a connector comprising a water-soluble polymer.

[0329] In other embodiments, the targeting domain is conjugated to the payload via a linker. In some cases, the linker comprises a polymer. In some embodiments, the targeting domain is directly or indirectly conjugated to a linker, a polymer, or a bioactive molecule. In some embodiments, the linker is a cleavable or non-cleavable linker.

[0330] In some embodiments, the linker is 0.1 kDa to 5 kDa. In other embodiments, the linker is 0.1 kDa to 2.5 kDa. In other embodiments, the linker or polymer is linear, branched, multimeric or dendritic macromolecule. In another embodiment, the linker or polymer is a bifunctional or multifunctional linker or a bifunctional or multifunctional polymer.

[0331] In other embodiments, the polymer is a water-soluble polymer. In other embodiments, the water-soluble polymer is polyethylene glycol (PEG). In some embodiments, the molecular weight of PEG is between 0.1kDa and 10kDa. In other embodiments, the molecular weight of PEG is between 0.1kDa and 5kDa. In other embodiments, the molecular weight of PEG is between 0.1kDa and 4kDa. In other embodiments, the molecular weight of PEG is between 0.1kDa and 3kDa. In other embodiments, the molecular weight of PEG is between 0.1kDa and 2kDa. In other embodiments, the molecular weight of PEG is between 0.1kDa and 2.5kDa. In some embodiments, the molecular weight of poly (ethylene glycol) molecule is about 0.1kDa to about 10kDa. In some embodiments, the molecular weight of poly (ethylene glycol) molecule is 0.1kDa to 50kDa. In some embodiments, the molecular weight of poly (ethylene glycol) is 0.1kDa to 2.5kDa, or 0.2 to 2.2kDa, or between 0.5kDa and 2kDa. For example, in some cases, the molecular weight of the poly(ethylene glycol) polymer is about 0.5 kDa, or about 1 kDa, or about 2 kDa, or about 2.5 kDa. For example, in some cases, the molecular weight of the poly(ethylene glycol) polymer is 0.1 kDa, or 0.5 kDa, or 1 kDa, or 2.5 kDa. In some embodiments, the poly(ethylene glycol) molecule is a branched PEG. In some embodiments, the poly(ethylene glycol) molecule is a branched 1K PEG. In some embodiments, the poly(ethylene glycol) molecule is a branched 2.5K PEG. In some embodiments, the poly(ethylene glycol) molecule is a branched 5K PEG. In some embodiments, the poly(ethylene glycol) molecule is a linear PEG. In some embodiments, the poly(ethylene glycol) molecule is a linear 2.5K PEG. In some embodiments, the poly(ethylene glycol) molecule is a linear 10K PEG. In some embodiments, the poly(ethylene glycol) molecule is a linear 2K PEG. In some embodiments, the poly(ethylene glycol) molecule is a linear 0.5K PEG. In some embodiments, the molecular weight of the poly(ethylene glycol) polymer is an average molecular weight. In certain embodiments, the average molecular weight is a number average molecular weight (Mn). The average molecular weight can be determined or measured using GPC or SEC, SDS-PAGE analysis, RP-HPLC, mass spectrometry, or capillary electrophoresis.

[0332] Treatment

[0333] The conjugates described herein can be used to treat conditions and / or diseases. In some cases, the disease includes a proliferative disease. In some cases, the proliferative disease includes cancer. In some cases, cancer includes one or more tumors. In some cases, cancer includes solid or liquid tumors. In some cases, the conjugate is administered to kill rapidly dividing cells (such as tumor cells) or inhibit the growth of rapidly dividing cells. In some cases, the method for treating a proliferative disease or condition of an object in need includes administering a therapeutically effective amount of the conjugate described herein to the object. In some embodiments, the proliferative disease or condition is cancer. In some embodiments, cancer is a solid tumor cancer. In some embodiments, solid tumor cancer is bladder cancer, bone cancer, brain cancer, breast cancer, colorectal cancer, esophageal cancer, eye cancer, head and neck cancer, kidney cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer or prostate cancer. In some instances, the disease includes PCa (prostate cancer), CRPCa (castration-resistant prostate cancer), solid tumors (neovasculature), NSCLC (non-small cell lung cancer), HNSCC (head and neck squamous cell carcinoma), ESCC (esophageal cancer), GC (gastric cancer), CRC (colorectal cancer), SCLC (small cell lung cancer), MPM (mesothelioma), PDAC (ductal pancreatic adenocarcinoma), ALL (acute lymphoblastic leukemia), AML (acute myeloid leukemia), MDS (myelodysplastic syndrome), MSI-high tumors, melanoma, DLBCL (diffuse large B-cell lymphoma), endometrial cancer, cervical cancer, bladder cancer, BrCa (breast cancer), TNBC (triple negative breast cancer), NE-PCa (neuroendocrine prostate cancer), GBM (glioblastoma) and RCC (renal cell carcinoma).

[0334] In some cases, the tumor cells targeted herein overexpress one or more targets. In some cases, the target comprises a surface marker or receptor. In some cases, the target is selected from PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPa, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3 rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, CD 73. ITGaVb3, ITGaVb6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD25, One or more of 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47 and EpCAM.In some cases, the target is selected from PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPa, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, CD73, ITGaVb3, and EGFRviii. b6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD25, 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47, and EpCAM. In some cases, the conjugate brings the payload to the tumor cell when the conjugate binds to one or more targets on the tumor cell and the payload kills the tumor cell, inhibits or slows the growth of the tumor cell.

[0335] In some cases, the conjugates described herein are used to image specific cells or cell groups. In some cases, the cells or cell groups are tumor cells, or are present in a tumor microenvironment. In some cases, when the conjugate is bound to one or more targets on a tumor cell and the payload is an imaging agent (such as a visual dye or a radioactive marker), the conjugate brings a payload to the tumor cell, and due to the binding of the conjugate to the tumor cell, the tumor cell is imaged.

[0336] The pharmaceutical composition is applied in a manner suitable for the disease to be treated (or prevented). The appropriate dosage, appropriate duration and frequency of application will be determined by factors such as the patient's condition, the type and severity of the patient's disease, the specific form of the active ingredient and the method of administration. In general, appropriate dosage and treatment regimen provide compositions in an amount sufficient to provide treatment and / or prevention benefits (e.g., improved clinical results), or to alleviate the severity of symptoms. The optimal dose is usually determined using experimental models and / or clinical trials. The optimal dose depends on the patient's body mass, weight or blood volume.

[0337] In one embodiment, the injectable pharmaceutical compositions described herein are used to prepare a medicament for treating a disease or condition in a mammal that would benefit from administration of any of the injectable pharmaceutical combinations of the disclosed conjugates. A method of treating any disease or condition described herein in a mammal in need of such treatment involves administering to the mammal a pharmaceutical composition comprising at least one compound described herein, or a pharmaceutically acceptable salt, active metabolite, prodrug, or pharmaceutically acceptable solvate thereof, in a therapeutically effective amount.

[0338] In certain embodiments, a composition containing a compound as described herein is administered for preventive and / or therapeutic treatment. In certain therapeutic applications, the composition is administered to a patient who has suffered from the disease or condition in an amount sufficient to cure or at least partially alleviate at least one symptom of the disease or condition. The effective amount of this usage depends on the severity and course of the disease or condition, previous treatment, the patient's health, body weight and response to the drug, and the judgment of the attending physician. The therapeutically effective amount is optionally determined by methods including but not limited to dose escalation and / or dose range clinical trials.

[0339] In preventive applications, compositions containing compounds described herein are administered to patients susceptible to or at risk of a particular disease, disorder or condition. Such an amount is defined as a "prophylactically effective amount or dose". In this use, the exact amount also depends on the patient's health, weight, etc. When used for a patient, the effective amount used will depend on the severity and course of the disease, disorder or condition, previous treatment, the patient's health and response to the drug, and the judgment of the attending physician. In one aspect, preventive treatment includes administering a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof to a mammal to prevent the recurrence of symptoms of a disease or condition, wherein the mammal has previously experienced at least one symptom of the disease being treated and is currently in remission.

[0340] In certain embodiments, the compound is administered chronically, ie, for an extended period of time, including throughout the duration of the patient's life, to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition.

[0341] Manufacturing method

[0342] The conjugates described herein can be synthesized using an in vivo or in vitro method or a combination of methods. In some cases, the method is an in vivo method. In some cases, the method is an in vitro method. In some cases, the targeting domain comprising an unnatural amino acid is synthesized in vivo and an in vitro chemical method is used to attach the payload.

[0343] In some cases, the method is an ex vivo method. In some cases, the conjugates described herein comprising natural amino acid mutations or non-natural amino acid mutations are recombinantly produced or chemically synthesized. In some cases, the targeting domains described herein are recombinantly produced, for example, by a host cell system or a cell-free system.

[0344] In general, methods for preparing target polypeptides comprising non-standard amino acids are known. In some cases, the aminoacyl tRNA synthetase / tRNA pair homologous to the non-natural amino acid is orthogonal to the cellular components of the cell in which it is used. The orthogonality (and therefore suitability) of the exogenous aminoacyl tRNA synthetase / tRNA pair depends on the type of host organism. Four major orthogonal aminoacyl tRNA synthetases have been developed for genetic code expansion: Methanococcus janaschii tyrosyl-tRNA synthetase (MjTyrRS) / tRNA synthetase (MjTyrRS) CUA Escherichia coli tyrosyl-tRNA synthetase (EcTyrRS) / tRNA CUA , Escherichia coli leucyl-tRNA synthetase (EcLeuRS) / tRNA CUA Pyrrolysyl-tRNA synthetase (PylRS) / tRNA from certain Methanosarcina species CUA Yes. PylRS / tRAN CUA The pairs are orthogonal in bacteria, eukaryotic cells, and animals (see, e.g., Chin, Jason W. "Expanding and reprogramming the genetic code of cells and animals." Annual review of biochemistry 83 (2014): 379-408).

[0345] In some cases, pyrrolysyl-tRNA synthetase (tRNA pyl ) is incorporated into the unnatural amino acid (UAA) provided herein. The unnatural amino acid (UAA) is introduced into the transfer RNA molecule (tRNA) so that it can be used for translation. However, the attachment of the unnatural amino acid to the tRNA is not necessarily accomplished by the naturally occurring aminoacyl-tRNA synthetase. Therefore, engineered aminoacyl tRNA synthetases such as those generated from tRNA pyl Engineered tRNAs prepared and selected from mutant libraries pyl Can be used to attach a desired UAA to a tRNA, thereby enabling the desired UAA to be incorporated by mutagenesis.

[0346] In some embodiments, an engineered mutant tRNA capable of attaching this UAA can be used pyl Variants attach a UAA provided herein (e.g., a UAA of Formula (IA)) to a tRNA. In some embodiments, the mutant tRNA pyl The variant introduces an amino acid mutation (i.e., incorporation of UAA). In other embodiments, the mutant tRNA pyl The variant introduces multiple amino acid mutations. In some embodiments, those skilled in the art prepare and screen tRNA pyl Variant library to select the appropriate tRNA pyl Variants are used to attach the desired UAA. In some embodiments, the tRNA used to introduce the UAA in the conjugates provided herein pyl Variants are tRNAs described in US 8,735,093, US 9,133,449, WO2020206341 pyl variants, each of which is incorporated herein by reference.

[0347] In various embodiments, a mutant pyrrolysyl-tRNA synthetase can be used. The mutant pyrrolysyl-tRNA synthetase can be derived from a pyrrolysyl-tRNA synthetase of Methanosarcina barkeri, Methanosarcina mazei, Methanosarcina alvus, or Methanosarcina jannaschii, or a variant thereof, or a chimera thereof.

[0348] In some embodiments, the mutant pyrrolysyl-tRNA synthetase provided herein comprises at least 5 amino acid residue replacements within the substrate binding site of the mutant pyrrolysyl-tRNA synthetase. In some embodiments, the mutant pyrrolysyl-tRNA synthetase comprises at least 5 amino acid residue replacements in the amino acid sequence of SEQ ID NO:90. In some embodiments, the substrate binding site includes 302 alanine, 305 leucine, 306 tyrosine, 309 leucine, 322 isoleucine, 346 asparagine, 348 cysteine, 384 tyrosine, 401 valine and 417 tryptophan residues set forth in the amino acid sequence of SEQ ID NO:90. In some embodiments, at least 5 amino acid residue replacements are selected from 302 alanine replacements, 346 asparagine replacements, 348 cysteine ​​replacements, 384 tyrosine replacements and 417 tryptophan replacements set forth in the amino acid sequence of SEQ ID NO:90. In some embodiments, at least 5 amino acid residues are replaced by alanine at position 302 replaced by isoleucine, asparagine at position 346 replaced by threonine, cysteine ​​at position 348 replaced by isoleucine, tyrosine at position 384 replaced by leucine, and tryptophan at position 417 replaced by lysine as set forth in the amino acid sequence of SEQ ID NO:90.

[0349] In some embodiments, the mutant pyrrolysyl-tRNA synthetase provided herein has an amino acid sequence of SEQ ID NO: 84. In some embodiments, the mutant pyrrolysyl-tRNA synthetase comprises an amino acid sequence of SEQ ID NO: 84. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with SEQ ID NO: 84 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with SEQ ID NO: 84 having at least 80% identity. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with SEQ ID NO: 84 having at least 80% identity. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with SEQ ID NO: 84 having at least 85% identity. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with SEQ ID NO: 84 having at least 90% identity. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 91% identical to SEQ ID NO: 84. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 92% identical to SEQ ID NO: 84. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 93% identical to SEQ ID NO: 84. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 94% identical to SEQ ID NO: 84. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 95% identical to SEQ ID NO: 84. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 96% identical to SEQ ID NO: 84. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 97% identical to SEQ ID NO: 84. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 98% identical to SEQ ID NO: 84. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 99% identical to SEQ ID NO: 84.

[0350] In some embodiments, the mutant pyrrolysyl-tRNA synthetase provided herein has an amino acid sequence of SEQ ID NO: 87. In some embodiments, the mutant pyrrolysyl-tRNA synthetase comprises an amino acid sequence of SEQ ID NO: 87. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with SEQ ID NO: 87 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with SEQ ID NO: 87 having at least 80% identity. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with SEQ ID NO: 87 having at least 80% identity. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with SEQ ID NO: 87 having at least 85% identity. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with SEQ ID NO: 87 having at least 90% identity. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with at least 91% identity to SEQ ID NO: 87. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with at least 92% identity to SEQ ID NO: 87. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with at least 93% identity to SEQ ID NO: 87. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with at least 94% identity to SEQ ID NO: 87. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with at least 95% identity to SEQ ID NO: 87. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with at least 96% identity to SEQ ID NO: 87. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with at least 97% identity to SEQ ID NO: 87. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 98% identical to SEQ ID NO: 87. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 99% identical to SEQ ID NO: 87.

[0351] In some embodiments, the mutant pyrrolysyl-tRNA synthetase provided herein is encoded by a nucleic acid sequence of SEQ ID NO: 85. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence comprising a SEQ ID NO: 85 sequence. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 85. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 80% identity to SEQ ID NO: 85. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 85% identity to SEQ ID NO: 85. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 90% identity to SEQ ID NO: 85. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 91% identity to SEQ ID NO: 85. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 92% identity to SEQ ID NO: 85. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 93% identity to SEQ ID NO: 85. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 94% identity to SEQ ID NO: 85. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 95% identity to SEQ ID NO: 85. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 96% identity to SEQ ID NO: 85. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence that is at least 97% identical to SEQ ID NO: 85. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence that is at least 98% identical to SEQ ID NO: 85. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence that is at least 99% identical to SEQ ID NO: 85.

[0352] In some embodiments, the mutant pyrrolysyl-tRNA synthetase provided herein is encoded by a nucleic acid sequence of SEQ ID NO: 88. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence comprising a SEQ ID NO: 88 sequence. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 88. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 80% identity to SEQ ID NO: 88. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 85% identity to SEQ ID NO: 88. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 90% identity to SEQ ID NO: 88. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 91% identity to SEQ ID NO: 88. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 92% identity to SEQ ID NO: 88. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 93% identity to SEQ ID NO: 88. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 94% identity to SEQ ID NO: 88. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 95% identity to SEQ ID NO: 88. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 96% identity to SEQ ID NO: 88. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence that is at least 97% identical to SEQ ID NO: 88. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence that is at least 98% identical to SEQ ID NO: 88. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence that is at least 99% identical to SEQ ID NO: 88.

[0353] In some embodiments, the mutant pyrrolysyl-tRNA synthetase provided herein has an amino acid sequence of SEQ ID NO: 92. In some embodiments, the mutant pyrrolysyl-tRNA synthetase comprises an amino acid sequence of SEQ ID NO: 92. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with SEQ ID NO: 92 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with at least 80% identity with SEQ ID NO: 92. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with at least 85% identity with SEQ ID NO: 92. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence with at least 90% identity with SEQ ID NO: 92. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 91% identical to SEQ ID NO: 92. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 92% identical to SEQ ID NO: 92. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 93% identical to SEQ ID NO: 92. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 94% identical to SEQ ID NO: 92. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 95% identical to SEQ ID NO: 92. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 96% identical to SEQ ID NO: 92. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence that is at least 97% identical to SEQ ID NO: 92. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence at least 98% identical to SEQ ID NO: 92. In some embodiments, the mutant pyrrolysyl-tRNA synthetase has an amino acid sequence at least 99% identical to SEQ ID NO: 87.

[0354] In some embodiments, the mutant pyrrolysyl-tRNA synthetase provided herein is encoded by a nucleic acid sequence of SEQ ID NO: 91. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence comprising a SEQ ID NO: 91 sequence. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 91. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 80% identity to SEQ ID NO: 91. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 85% identity to SEQ ID NO: 91. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 90% identity to SEQ ID NO: 91. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 91% identity to SEQ ID NO: 91. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 92% identity to SEQ ID NO: 91. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 93% identity to SEQ ID NO: 91. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 94% identity to SEQ ID NO: 91. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 95% identity to SEQ ID NO: 91. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence having at least 96% identity to SEQ ID NO: 91. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence that is at least 97% identical to SEQ ID NO: 91. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence that is at least 98% identical to SEQ ID NO: 91. In some embodiments, the mutant pyrrolysyl-tRNA synthetase is encoded by a nucleic acid sequence that is at least 99% identical to SEQ ID NO: 91.

[0355] In some cases, the sequences related to the mutant pyrrolysyl-tRNA synthetases herein are in Table 1B.

[0356] Table 1B

[0357]

[0358]

[0359]

[0360]

[0361]

[0362]

[0363]

[0364]

[0365]

[0366]

[0367]

[0368]

[0369] In some cases, the targeting domain is recombined by the host cell system. In some cases, the host cell is a eukaryotic cell (such as a mammalian cell, an insect cell, a yeast cell or a plant cell) or a prokaryotic cell (such as a gram-positive or gram-negative bacteria). In some cases, the eukaryotic host cell is a mammalian host cell. In some cases, the mammalian host cell is a stable cell line, or the genetic material of interest is incorporated into its own genome and can express the cell line of the product of the genetic material after multigenerational cell division. In other cases, the mammalian host cell is a transient cell line, or the genetic material of interest is incorporated into its own genome and does not have the cell line of the ability to express the genetic material product after multigenerational cell division.

[0370] Exemplary mammalian host cells include 293T cell lines, 293A cell lines, 293FT cell lines, 293F cells, 293H cells, A549 cells, MDCK cells, CHO DG44 cells, CHO-S cells, CHO-K1 cells, Expi293F cells, TM Cells, Flp-In TM T-REx TM 293 cell line, Flp-In TM -293 cell line, Flp-In TM -3T3 cell line, Flp-In TMBHK cell line, Flp-In TM -CHO cell line, Flp-In TM -CV-1 cell line, Flp-In TM The Jurkat cell line, FreeStyle TM 293-F cells, FreeStyle TM CHO-S cells, GripTite TM 293MSR cell line, GS-CHO cell line, Heparg TM Cells, T-REx TM Jurkat cell line, Per.C6 cell, T-REx TM -293 cell line, T-REx TM -CHO cell lines and T-REx TM HeLa cell line.

[0371] In some embodiments, the eukaryotic host cell is an insect host cell. Exemplary insect host cells include Drosophila S2 cells, Sf9 cells, Sf21 cells, and Cellular High Five TM cell.

[0372] In some embodiments, the eukaryotic host cell is a yeast host cell. Exemplary yeast host cells include Pichia pastoris strains such as GS115, KM71H, SMD1168H and X-33, and Saccharomyces cerevisiae strains such as INVSC1.

[0373] In some embodiments, the eukaryotic host cell is a plant host cell. In some cases, the plant cell includes a cell from algae. Exemplary plant cell lines include strains from Chlamydomonas reinhardtii 137c or Synechococcus elongatus PPC 7942.

[0374] In some embodiments, the host cell is a prokaryotic host cell. Exemplary prokaryotic host cells include BL21, BL21 (DE3), Mach1 TM 、DH10B TM 、TOP10、DH5α、DH10Bac TM 、OmniMax TM 、MegaX TM DH12S TM、INV110、TOP10F'、INVαF、TOP10 / P3、ccdB survival、PIR1、PIR2、Stbl2 TM 、Stbl3 TM or Stbl4 TM .

[0375] In some cases, suitable nucleic acid molecules or vectors for producing the targeting domains described herein include any suitable vector derived from a eukaryotic or prokaryotic source. Exemplary nucleic acid molecules or vectors include vectors from bacteria (e.g., Escherichia coli), insects, yeast (e.g., Pichia pastoris), algae, or mammalian sources. Bacterial vectors include, for example, pACYC177, pASK75, pBAD series vectors, pBADM series vectors, pET series vectors, pETM series vectors, pGEX series vectors, pHAT2, pMal-C2, pMal-p2, pQE series vectors, pRSET A, pRSET B, pRSET C, pTrcHis2 series, pZA31-Luc, pZE21-MCS-1, pFLAG ATS, pFLAG CTS, pFLAG MAC, pFLAG Shift-12C, pTAC-MAT-1, pFLAG CTC, or pTAC-MAT-2.

[0376] Insect vectors include, for example, pFastBac1, pFastBac DUAL, pFastBac ET, pFastBac HTa, pFastBac HTb, pFastBac HTc, pFastBac M30a, pFastBac M30b, pFastBac, M30c, pVL1392, pVL1393M 10, pVL1393M11, pVL1393M 12, FLAG vectors such as pPolh-FLAG1 or pPolh-MAT2, or MAT vectors such as pPolh-MAT1 or pPolh-MAT 2.

[0377] Yeast vectors include, for example, pDEST TM 14 vector, pDEST TM 15 vector, pDEST TM 17 vector, pDEST TM24 vector, pYES-DEST52 vector, pBAD-DEST49Target vector, pAO815 Pichia vector, pFLD1 Pichia vector, pGAPZA, Pichia C vector, Pichia pPIC3.5K vector, pPIC 6A, B and Pichia C vector, pPIC9K vector, pTEF1 / Zeo, pYES2 yeast vector, pYES2 / CT yeast vector, pYES2 / NT A, B and C yeast parents or pYES3 / CT yeast vector.

[0378] Algae vectors include, for example, pChlamy-4 vectors or MCS vectors.

[0379] Mammalian vectors include, for example, transient expression vectors or stable expression vectors. Exemplary mammalian transient expression vectors include p3xFLAG-CMV 8, pFLAG-Myc-CMV19, pFLAG-Myc-CMV 23, pFLAG-CMV 2, pFLAG-CMV 6a, b, c, pFLAG-CMV 5.1, pFLAG-CMV 5a, b, c, p3xFLAG-CMV 7.1, pF-CMV 20, p3xFLAG-Myc-CMV 24, pCMV-FLAG-MAT1, pCMV-FLAG-MAT2, pBICEP-CMV 3, or pBICCMV-4. Exemplary mammalian stable expression vectors include pFLAG-CMV 3, p3xFLAG-CMV 9, p3xFLAG-CMV 13, pFLAG-Myc-CMV 21, p3xFLAG-Myc-CMV 25, pFLAG-CMV 4, p3xFLAG-CMV 10, p3xFLAG-CMV14, pFLAG-Myc-CMV 22, p3xFLAG-Myc-CMV 26, pBICEP-CMV 1 or pBICEP-CMV 2. In some cases, a cell-free system is used to produce a targeting domain as described herein. In some cases, the cell-free system includes a mixture of cytoplasmic and / or nuclear components from a cell and is suitable for in vitro nucleic acid synthesis. In some cases, the cell-free system utilizes prokaryotic cell components. In other cases, the cell-free system utilizes eukaryotic cell components. Nucleic acid synthesis is achieved in a cell-free system based on, for example, fruit fly cells, clawed frog (Xenopus) eggs, archaea or HeLa cells. Exemplary cell-free systems include the E. coli S30 extract system, the E. coli T7 S 30 system, or XpressCF and XpressCF+.

[0380] Cell-free translation systems variously include ingredients, such as plasmids, mRNA, DNA, tRNA, synthetases, release factors, ribosomes, chaperones, translation initiation and elongation factors, natural and / or non-natural amino acids and / or other components for protein expression. These components are optionally modified to improve yield, increase synthesis rate, increase the fidelity of protein products or incorporate non-natural amino acids. In some embodiments, the targeting domain containing non-natural amino acids as described herein is synthesized using the cell-free translation system described in US8,778,631, US2017 / 0283469, US2018 / 0051065, US 2014 / 0315245 or US 8,778,631. In some embodiments, the cell-free translation system includes modified release factors, or even removes one or more release factors from the system. In some embodiments, the cell-free translation system includes reduced protease concentrations. In some embodiments, the cell-free translation system includes modified tRNAs with redistributed codons encoding non-natural amino acids. In some embodiments, the synthetases described herein for incorporating unnatural amino acids are used in a cell-free translation system. In some embodiments, the tRNA is pre-loaded with an unnatural amino acid using an enzymatic or chemical process before the tRNA is added to the cell-free translation system. In some embodiments, the components for the cell-free translation system are obtained from modified organisms, such as modified bacteria, yeast, or other organisms.

[0381] In some embodiments, the targeting domain is produced in a circular arrangement via an expression host system or by a cell-free system.

[0382] An orthogonal or amplified genetic code can be used to generate a targeting domain as described herein, wherein one or more specific codons present in the nucleic acid sequence of the targeting domain are assigned to encode an unnatural amino acid, such that it can be genetically incorporated into a conjugate (e.g., a targeting domain) by using an orthogonal tRNA synthetase / tRNA pair. An orthogonal tRNA synthetase / tRNA pair is capable of loading the tRNA with an unnatural amino acid and is capable of incorporating the unnatural amino acid into a polypeptide chain in response to a codon.

[0383] In some cases, the codon is an amber codon, an ochre codon, an opal codon, or a quadruple codon. In some cases, the codon corresponds to an orthogonal tRNA that will be used to carry an unnatural amino acid. In some cases, the codon is an amber codon. In other cases, the codon is an orthogonal codon.

[0384] In some cases, the codon is a quadruplet codon that can be decoded by an orthogonal ribosomal ribo-Q1. In some cases, the quadruplet codon is as described in Neumann et al., "Encoding multiple unnatural amino acid analysis of a quadruplet-decoding ribosome," Nature, 464(7287): 441-444 (2010).

[0385] In some cases, the codons used in the present disclosure are recoded codons, for example, synonymous codons or rare codons replaced by replacement codons. In some cases, the recoded codons are described in Napolitano et al., "Emergent rules for codon choice isolated by editing of a ray array code in Escherichia coli," PNAS, 113 (38): E5588-5597 (2016). In some cases, the recoded codons are described in Ostrov et al., "Design, synthesis, and testing translated a 57-codegene," Science 353 (6301): 819. sub. 822 (2016).

[0386] definition

[0387] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are amino acids encoded by the genetic code, as well as amino acids that are later modified, for example, hydroxyproline, g-carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as natural amino acids, i.e., carbon bound to hydrogen, carboxyl, amino, and R groups, for example, homoserine, norleucine, methionine sulfoxide, methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as natural amino acids. Amino acid mimetics refer to compounds that have a structure that is different from the general chemical structure of an amino acid, but function in a manner similar to a natural amino acid.

[0388] The terms "non-naturally occurring amino acid" and "unnatural amino acid" refer to amino acid analogs, synthetic amino acids, and amino acid mimetics that are not found in nature, such as amino acid residues containing arylamide, vinylsulfonamide, sulfonyl fluoride, arylsulfonyl fluoride, and 4-sulfotetrafluorophenyl (STP) ester.

[0389] Herein, amino acids may be referred to by either their common three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Similarly, nucleotides may also be referred to by their commonly accepted single-letter codes.

[0390] The term "amino acid side chain" refers to a functional substituent contained on an amino acid. For example, an amino acid side chain can be a side chain of a naturally occurring amino acid. Naturally occurring amino acids are amino acids encoded by the genetic code (e.g., alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine), as well as amino acids that are later modified, such as hydroxyproline, g-carboxyglutamate, and O-phosphoserine. In some aspects, an amino acid side chain can be a non-natural amino acid side chain. In some aspects, an amino acid side chain is H, In some embodiments, the unnatural amino acid side chain is In some embodiments, the unnatural amino acid side chain is

[0392] The term "non-natural amino acid side chain" or "unnatural amino acid side chain" or "Uaa" refers to a functional substitute for a compound having the same basic chemical structure as a natural amino acid, i.e., a carbon bound to a hydrogen, carboxyl, amino, and R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methylsulfonium, allylalanine, 2-aminoisobutyric acid. Non-natural amino acids are naturally occurring or chemically synthesized non-protein amino acids. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as natural amino acids.Non-limiting examples include exo-cis-3-aminobicyclo[2.2.1]hept-5-ene-2-carboxylic acid hydrochloride, cis-2-aminocycloheptanecarboxylic acid hydrochloride, cis-6-amino-3-cyclohexene-1-carboxylic acid hydrochloride, cis-2-amino-2-methylcyclohexanecarboxylic acid hydrochloride, cis-2-amino-2-methylcyclopentanecarboxylic acid hydrochloride, 2-(Boc aminomethyl), benzoic acid, 2-(Boc amino) suberic acid, Boc-4,5-dehydro-Leu-OH (dicyclohexyl ammonium salt), Boc-4-(Fmoc-amino)-L-phenylalanine, Boc-P-Homopyr-OH, Boc-(2-indenyl)-Gly-OH, 4-Boc-3-morpholineacetic acid, 4-Boc-3 -morpholineacetic acid, Boc pentafluoro-D-phenylalanine, Boc-pentafluoro-L-phenylalanine, Boc-Phe(2-Br)-OH, Boc-Phe(4-Br)-OH, Boc-D-Phe(4-Br)-OH, Boc-D-Phe(3-Cl)-OH, Boc-Phe(4-NH2)-OH, Boc-Phe(3-NH2)-OH, Boc-Phe(3,5-F2)-OH, 2-(4-Boc-piperazinyl)-2-(3,4-dimethoxyphenyl)acetic acid purum, 2-(4-Boc-piperazinyl)-2-(2-fluorophenyl)acetic acid purum, 2-(4-Boc-piperazinyl)-2-(3-fluorophenyl)acetic acid purum )acetic acid purum, 2-(4-Boc-piperazinyl)-2-(4-fluorophenyl)acetic acid purum, 2-(4-Boc-piperazinyl)-2-(4-methoxyphenyl)acetic acid purum, 2-(4-Boc-piperazinyl)-2-phenylacetic acid purum, 2-(4-Boc-piperazinyl)-2-(3-pyridyl)acetic acid purum, 2-(4-Boc-piperazinyl-2-[4-(trifluoromethyl)phenyl]acetic acid purum, Boc-P-(2-quinolyl)-Ala-OH, NBoc-1,2,3,6-tetrahydro-2-pyridinecarboxylic acid, Boc-P-(4-thiazolyl)-Ala-OH, Bo-b(2-thienyl)-D-Ala-OH , Fmoc-N-(4-Boc-aminobutyl)-Gly-OH, Fmoc-N-(2-Boc-aminoethyl)-Gly-OH, Fmoc-N-(2,4-dimethoxybenzyl)-Gly-OH, Fmoc-(2-diindenyl)-Gly-OH, Fmoc-pentafluoro-L-phenylalanine, Fmoc-Pen(Trt)-OH, Fmoc-Phe(2-Br)-OH, Fmoc-Phe(4-Br)-OH, FmocPhe(3,5-F2)-OH, Fmoc-P-(4-thiazolyl)-Ala-OH, Fmoc-P-(2-thienyl)-Ala-OH, 4-(hydroxymethyl)-D-phenylalanine.In some embodiments, the unnatural amino acid comprises Formula I:. In some embodiments, the non-natural amino acid comprises Formula II: In some embodiments, the non-natural amino acid is 2-amino-3-(4-(fluorosulfonyl)oxy)phenyl)propanoic acid: In some embodiments, the unnatural amino acid is fluorosulfonyltyrosine (FSY): In some embodiments, the unnatural amino acid is N6-(4-((fluorosulfonyl)oxy)benzoyl)lysine: In some embodiments, the unnatural amino acid is fluorosulfonyloxybenzoyl-L-lysine (FSK):

[0393] "Conservatively modified variants" apply to both amino acids and nucleic acid sequences. For a specific nucleic acid sequence, "conservatively modified variants" refer to those nucleic acids that encode the same or substantially the same amino acid sequence. Due to the degeneracy of the genetic code, many nucleic acid sequences will encode any given protein. For example, the codons GCA, GCC, GCG, and GCU all encode the amino acid alanine. Therefore, at each position where alanine is specified by a codon, the codon can be changed to any of the corresponding codons described without changing the encoded polypeptide. This nucleic acid variation is a "silent variation," which is a type of conservatively modified variation. Each nucleic acid sequence encoding a polypeptide herein also describes each possible silent variation of the nucleic acid. Those skilled in the art will recognize that each codon in the nucleic acid (except AUG and TGG, AUG is usually the only codon for methionine, and TGG is usually the only codon for tryptophan) can be modified to produce functionally identical molecules. Therefore, each silent variation of a nucleic acid encoding a polypeptide is implicit in each of the described sequences.

[0394] As for amino acid sequences, those skilled in the art will recognize that a single substitution, deletion or addition to a nucleic acid, peptide, polypeptide or protein sequence that alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant," wherein such alteration results in the replacement of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to, and do not exclude, polymorphic variants, interspecies homologs and alleles of the present disclosure.

[0395] The following eight groups each contain amino acids that are conservative substitutions for one another: (1) alanine (A), glycine (G); (2) aspartic acid (D), glutamic acid (E); (3) asparagine (N), glutamine (Q); (4) arginine (R), lysine (K); (5) isoleucine (I), leucine (L), methionine (M), valine (V); (6) phenylalanine (F), tyrosine (Y), tryptophan (W); (7) serine (S), threonine (T); and (8) cysteine ​​(C), methionine (M). (See, e.g., Creighton, Proteins (1984)).

[0396] In some embodiments, the pyrrolysyl-tRNA synthetase (tRNA pyl ) is an aminoacyl-tRNA synthetase that catalyzes the reaction required to attach the α-amino acid pyrrolysine or a similar unnatural amino acid to a cognate tRNA, thereby allowing the incorporation of pyrrolysine or a similar unnatural amino acid during protein production at an amber stop codon (i.e., UAG). Wild-type tRNA from Methanosarcina species pyl (which naturally incorporates pyrrolysine) is orthogonal to endogenous tRNAs and aminoacyl-tRNA synthetases in E. coli and eukaryotic cells. Using this pair and their synthetically evolved derivatives or variants, we and others have directed the efficient incorporation of unnatural amino acids, including post-translationally modified amino acids, chemical handles, and photocaged amino acids, at specific sites in desired proteins in E. coli, yeast, and mammalian cells.

[0397] In some embodiments, a tRNA described herein pyl Any recombinant or naturally occurring form of pyrrolysyl-tRNA synthetase or variant, homolog or isoform thereof that retains tRNA pyl activity (e.g., compared with wild-type tRNA pyl In some embodiments, the variant, homolog, or isoform has at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity over the entire sequence or a portion of the sequence (e.g., a 50, 100, 150, or 200 contiguous amino acid portion) compared to a naturally occurring pyrrolysyl-tRNA synthetase. In some embodiments, the mutant tRNA pyl Catalyzes the attachment of an unnatural amino acid (UAA) (e.g., a UAA of formula (IA), such as fluorosulfate L-tyrosine (FSY)) to a tRNA pyl , in order to incorporate unnatural amino acids.

[0398] In some embodiments, the tRNA provided herein pyl is a tRNA that can be engineered by a person skilled in the art pyl Derivatives or variants. In some embodiments, the tRNA provided herein pyl It is a single-stranded RNA molecule containing approximately 70 to 90 nucleotides, which folds through intrachain base pairing to form a characteristic cloverleaf structure that carries a specific amino acid (e.g., UAA of formula (IA), such as FSY) and matches it with the corresponding codon on mRNA during protein synthesis.

[0399] An "imaging ligand" or "detectable agent" is a composition detectable by appropriate means, such as spectroscopic, photochemical, biochemical, immunochemical, chemical, magnetic resonance imaging or other physical means. For example, useful detectable agents include 3 H. 14 C. 18 F. 33 P. 35 S. 45 Ti, 47 Sc, 52 Fe, 59 Fe, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 77 As, 86 Y. 90 Y. 89 Sr. 89 Zr, 94 Tc, 94 Tc, 99m Tc, 99 Mo, 105 Pd, 105 Rh, 111 Ag, 111 In, 112 In, 123 I. 124 I. 125 I. 131 I. 142 Pr, 143 Pr, 149 Pm, 153 Sm, 154-158 Gd, 161 Tb, 166 Dy, 166 HO, 169 2. 175 Lu, 177Lu 186 Re 188 Re 189 Re 194 Ir 198 Au 199 Au 211 At 211 Pb 212 Bi 212 Pb 213 Bi 223 Ra 225 Ac 153 Sm 177 Lu 86 Y 88 Y 90 Y 123 I 124 I 125 I 131 I 149 Tb 212 Pb / 212 Bi and 227 Th, Cr, V, Mn, Fe, Co, Ni, Cu, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu 32P, fluorophores (e.g., fluorescent dyes), electron-dense reagents, enzymes (e.g., commonly used in ELISA), biotin, digoxigenin, paramagnetic molecules, paramagnetic nanoparticles, ultrasmall superparamagnetic iron oxide ("USPIO") nanoparticles, USPIO nanoparticle aggregates, superparamagnetic iron oxide ("SPIO") nanoparticles, SPIO nanoparticle aggregates, single crystalline iron oxide nanoparticles, single crystalline iron oxide, nanoparticle contrast agents, liposomes or other delivery vehicles containing gadolinium chelate ("Gd chelate") molecules, gadolinium, radioisotopes, radionuclides (e.g., carbon-11, nitrogen-13, oxygen-15, fluorine-18, rubidium-82), fluorodeoxyglucose (e.g., fluorine-18 labeled), any gamma-ray emitting radioactive The invention relates to a method for detecting a target peptide or a combination of a radioactive nuclide, a positron emitting radionuclide, a radiolabeled glucose, a radiolabeled water, a radiolabeled ammonia, a biocolloid, a microbubble (e.g., a microbubble shell comprising albumin, galactose, a lipid and / or a polymer; a microbubble gas core comprising air, a heavy gas, a perfluorocarbon, nitrogen, octafluoropropane, a perfluorohexane lipid microsphere, a perfluoropropane, etc.), an iodinated contrast agent (e.g., iohexol, iodixanol, iofosmol, ioisophthalol, ioxilan, iopromide, diatrizoate, metrizoate and iocolic acid), barium sulfate, thorium dioxide, gold, gold nanoparticles, gold nanoparticle aggregates, fluorophores, two-photon fluorophores or haptens and proteins or other detectable entities, for example, by incorporating a radiolabel into a peptide or antibody that specifically reacts with a target peptide. The detectable portion is a monovalent detectable agent or a detectable agent that is capable of forming a bond with another composition.

[0400] According to embodiments of the present disclosure, radioactive substances (e.g., radioisotopes) that can be used as imaging agents and / or labeling agents include, but are not limited to 3 H. 14 C. 18 F. 33 P. 35 S. 45 Ti, 47 Sc, 52 Fe, 59 Fe, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 77 As, 86 Y. 90 Y. 89 Sr. 89 Zr, 94 Tc, 94 Tc, 99m Tc, 99 Mo, 105 Pd, 105Rh, 111 Ag, 111 In, 112 In, 123 I. 124 I. 125 I. 131 I. 142 Pr, 143 Pr, 149 Pm, 153 Sm, 154-158 Gd, 161 Tb, 166 Dy, 166 HO, 169 2. 175 Lu, 177 Lu, 186 Re, 188 Re, 189 Re, 194 Ir, 198 Au, 199 Au, 211 At 211 Pb, 212 Bi, 212 Pb, 213 Bi, 223 Ra, 225 Ac, 153 Sm, 177 Lu, 86 Y. 88 Y. 90 Y. 123 I. 124 I. 125 I. 131 I. 149 Tb, 212 Pb / 212 Bihe 227 Th. According to embodiments of the present disclosure, paramagnetic ions that may be used as additional imaging agents include, but are not limited to, transition metals and lanthanide metal ions (e.g., metals with atomic numbers 21-29, 42, 43, 44, or 57-71). These metals include ions of Cr, V, Mn, Fe, Co, Ni, Cu, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, and Lu.

[0401] The term "bond" or "connector" as used herein refers to a bond or chemical moiety formed by a chemical reaction between a functional group of a connector and another molecule. Such bonds may include, but are not limited to, covalent bonds and non-covalent bonds, and such chemical moieties may include, but are not limited to, esters, carbonates, imidophosphoesters, hydrazones, acetals, orthoesters, peptide bonds, and oligonucleotide bonds. Hydrolytically stable bonds mean that these bonds are substantially stable in water and will not react with water at useful pH values, including but not limited to extended periods of time under physiological conditions, possibly even indefinitely. Hydrolytically unstable or degradable bonds mean that these bonds are degradable in water or aqueous solutions (including, for example, blood). Enzymatically unstable or degradable bonds mean that the bond can be degraded by one or more enzymes. As an example only, PEG and related polymers may include degradable bonds in the linking group between a polymer backbone or a polymer backbone and one or more terminal functional groups of a polymer molecule. Such degradable bonds include, but are not limited to, ester bonds formed by the reaction of PEG carboxylic acid or activated PEG carboxylic acid with an alcohol group on a bioactive agent, wherein these ester groups are typically hydrolyzed under physiological conditions to release the bioactive agent. Other hydrolytically degradable bonds include, but are not limited to, carbonate bonds; imine bonds resulting from the reaction of amines and aldehydes; phosphate bonds formed by the reaction of alcohols with phosphate groups; hydrazone bonds, which are the reaction products of hydrazides and aldehydes; acetal bonds, which are the reaction products of aldehydes and alcohols; orthoester bonds, which are the reaction products of formate and alcohols; peptide bonds formed by amine groups, including but not limited to the ends of polymers such as PEG and the carboxyl groups of peptides; and oligonucleotide bonds formed by phosphoramidite groups, including but not limited to the phosphoramidite groups at the ends of polymers and the 5' hydroxyl groups of oligonucleotides. Connectors include, but are not limited to, short linear, branched, multi-armed or dendritic macromolecules, such as polymers. In some embodiments, the connector may be branched. In other embodiments, the connector may be a bifunctional connector. In some embodiments, the connector may be a trifunctional connector. The mechanism of release of the agent from these connector groups includes, for example, irradiation of photolabile bonds and acid-catalyzed hydrolysis. The length of the connector may be predetermined or selected based on the desired spatial relationship between the polypeptide and the molecule to which it is attached.

[0402] The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues, wherein in embodiments the polymer may be conjugated to a moiety that does not consist of amino acids. These terms apply to amino acid polymers in which one or more amino acid residues is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. "Fusion protein" refers to a chimeric protein encoding two or more separate protein sequences that are recombinantly expressed as a single part.

[0403] Amino acid or nucleotide base "positions" are represented by numbers that sequentially identify each amino acid (or nucleotide base) in the reference sequence based on its position relative to the N-terminus (or 5' terminus). Because deletions, insertions, truncations, fusions, etc. must be considered when determining the optimal alignment, in general, the number of amino acid residues in a test sequence determined by simple counting from the N-terminus is not necessarily the same as the number of its corresponding position in the reference sequence. For example, in the case where a variant has a deletion relative to the aligned reference sequence, there will be no amino acid in the variant that corresponds to the site of the deletion in the reference sequence. If there is an insertion in the aligned reference sequence, the insertion will not correspond to a numbered amino acid position in the reference sequence. In the case of truncations or fusions, a stretch of amino acids in the reference sequence or aligned sequence may not correspond to any amino acids in the corresponding sequence.

[0404] The terms "numbered with reference to" or "corresponding to" when used in the context of numbering a given amino acid or polynucleotide sequence means that the residues of the reference sequence are numbered as specified when comparing the given amino acid or polynucleotide sequence to the reference sequence.

[0405] When the amino acid residue in the protein occupies the same essential structural position as a given residue in the protein, it "corresponds" to a given residue. For example, when the selected residue has the same essential space or other structural relationship as Ala302 in the PylRS protein, the selected residue in the selected protein corresponds to Ala302 of the PylRS protein. In an embodiment, when the selected protein and the PylRS protein are compared for maximum homology, the position in the compared selected protein compared with Ala302 is considered to correspond to Ala302. In addition to the primary sequence comparison, a three-dimensional structure comparison can also be used, for example, the structure of the selected protein is aligned for maximum correspondence with the PylRS protein and the overall structure of the comparison. In this case, the amino acid that occupies the same essential position as Ala302 in the structural model is considered to correspond to the Ala302 residue.

[0406] "Percentage of sequence identity" is determined by comparing two optimally aligned sequences within a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may contain additions or deletions (i.e., gaps) compared to a reference sequence (which does not include additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the same nucleic acid base or amino acid residue occurs in the two sequences to produce the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window, and then multiplying the result by 100 to obtain the percentage of sequence identity.

[0407] In the context of two or more nucleic acids or polypeptide sequences, the term "identical" or "percentage of identity" refers to two or more sequences or subsequences that are identical or have a specified percentage of identical amino acid residues or nucleotides (i.e., about 60% identity on a specified region when maximum correspondence comparison and alignment are performed on a comparison window or a specified region, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher identity) measured using BLAST or BLAST 2.0 sequence comparison algorithms with the default parameters described below or by manual alignment and visual inspection (see, e.g., NCBI website ncbi.nlm.nih.gov / BLAST / , etc.). Such sequences are then referred to as "substantially identical". This definition also refers to or can be applied to the complementary sequence of a test sequence. The definition also includes sequences with deletions and / or additions, and sequences with replacements. As described below, preferred algorithms can take into account spaces, etc. Preferably, the identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.

[0408] "Antibodies" are large, complex proteins with a complex internal structure. Natural antibody molecules contain two pairs of identical polypeptide chains, each pair having a light chain and a heavy chain. Each light chain and heavy chain is composed of two regions: a variable ("V") region involved in binding to the target antigen, and a constant ("C") region that interacts with other components of the immune system. The light chain and heavy chain variable regions are gathered together in three-dimensional space to form a variable region that binds to an antigen (e.g., a receptor on the surface of a cell). Within each light chain or heavy chain variable region, there are three short segments (with an average length of 10 amino acids) called complementary determining regions ("CDRs"). The six CDRs in the antibody variable domain (three from the light chain and three from the heavy chain) are folded together in three-dimensional space to form an actual antibody binding site that docks with the target antigen. Kabat, E. et al., Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, 1983, 1987 precisely define the position and length of CDRs. The portion of the variable region not contained in the CDRs is called the framework ("FR"), which forms the environment of the CDRs.

[0409] The term "antibody" is used according to its well-known meaning in the art. Antibodies exist, for example, as complete immunoglobulins or as many well-characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests the antibody below the disulfide bond in the hinge region to produce F(ab)'2-a dimer of Fab, which itself is a light chain connected to VH-CH1 by a disulfide bond. F(ab)'2 can be reduced under mild conditions to destroy the disulfide bond in the hinge region, thereby converting the F(ab)'2 dimer into a Fab' monomer. Fab' monomers are essentially Fabs with a partial hinge region (see Fundamental Immunology (Pauled., 3d ed. 1993)). Although various antibody fragments are defined based on the digestion of complete antibodies, it will be appreciated by those skilled in the art that these fragments can be synthesized de novo chemically or by using recombinant DNA methods. Thus, the term antibody as used herein also includes antibody fragments produced by modification of whole antibodies or antibody fragments synthesized de novo using recombinant DNA methodologies (e.g., single-chain Fv) or antibody fragments identified using phage display libraries (e.g., McCafferty et al., Nature 348:552-554 (1990)).

[0410] Exemplary immunoglobulin (antibody) structural units include tetramers. Each tetramer is composed of two pairs of identical polypeptide chains, each pair having a "light" chain (about 25kD) and a "heavy" chain (about 50-70kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids that is primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light chains and heavy chains, respectively. Fc (i.e., fragment crystallizable region) is the "base" or "tail" of immunoglobulin, and is generally composed of two heavy chains, which contribute two or three constant domains, depending on the class of the antibody. By binding to specific proteins, the Fc region ensures that each antibody produces an appropriate immune response to a given antigen. The Fc region also binds to various cell receptors (such as Fc receptors) and other immune molecules (such as complement proteins).

[0411] Antibody " variant " provided herein refers to the polypeptide that can be bound to antigen and includes one or more domains of antibody or its fragment.Non-limiting examples of antibody variants include single domain antibody (nanobody), affibody (smaller than monoclonal antibody and can bind antigen with high affinity and mimic the polypeptide of monoclonal antibody (for example, about 6kDa)), monospecific Fab2, bispecific Fab2, trispecific Fab3, monovalent IgG, scFv, double characteristic double antibody, three characteristic three antibody, scFv-Fc, mini antibody, IgNAR, V-NAR, hcIgG, VhH or peptide body. " Peptide body " provided herein refers to the peptide part of the Fc domain attached to antibody (by covalent or non-covalent linker).Other non-limiting examples of antibody variants known in the art include antibodies produced by cartilaginous fish or camelids.General descriptions of antibodies and variable regions of camelids and their generation, separation and use methods can be found in references WO 97 / 49805 and WO 97 / 49805, which are incorporated herein by reference as a whole for all purposes. Likewise, antibodies and variable regions thereof from cartilaginous fish and methods of their production, isolation and use can be found in WO2005 / 118629, which is incorporated herein by reference in its entirety for all purposes.

[0412] "Single domain antibody" or "nanobody" refers to an antibody fragment with a single monomeric variable antibody domain. Like a complete antibody, it can selectively bind to a specific antigen. In some embodiments, the single domain antibody is a human or humanized single domain antibody. In some embodiments, the single domain antibody is a camelid single domain antibody. The single domain antibody can be an engineered single domain antibody and can contain unnatural amino acids.

[0413] The term "antigen" provided herein refers to a molecule that can be bound to an antibody binding domain provided herein. "Antigen binding domain" provided herein is a region in an antibody that binds to an antigen (epitope). As described above, the antigen binding domain may include a constant domain and a variable domain for each of a heavy chain and a light chain (VL, VH, CL and CH1, respectively). In an embodiment, the antigen binding domain includes a light chain variable domain and a heavy chain variable domain. In an embodiment, the antigen binding domain includes a light chain variable domain, and does not include a heavy chain variable domain and / or a heavy chain constant domain. The paratope or antigen binding site is formed at the N-terminus of the antigen binding domain. The two variable domains of the antigen binding domain can bind to the epitope of the antigen. For example, antibodies exist in the form of complete immunoglobulins or many well-characterized fragments produced by digestion with various peptidases. Therefore, for example, pepsin digests the antibody below the disulfide bond in the hinge region to produce F (ab) '2, which is a dimer of Fab, which itself is a light chain connected to VH-CH1 by a disulfide bond. F(ab)'2 can be reduced under mild conditions to destroy the disulfide bonds in the hinge region, thereby converting the F(ab)'2 dimer into a Fab' monomer. Fab' monomers are essentially antigen binding moieties with a partial hinge region (see Fundamental Immunology (Pauled., 3d ed. 1993)). Although various antibody fragments are defined based on the digestion of intact antibodies, it will be appreciated by those skilled in the art that these fragments can be synthesized de novo chemically or by using recombinant DNA methods. Therefore, the term antibody used herein also includes antibody fragments produced by modifying whole antibodies, or antibody fragments (e.g., single-chain Fv) synthesized de novo using recombinant DNA methods, or antibody fragments identified using phage display libraries (see, e.g., McCafferty et al., Nature 348: 552-554 (1990)).

[0414] Example

[0415] Example 1 - Identification of PSMA sdAb Coupling Sites

[0416] To evaluate the compatibility of PSMA as a target for coupling with a targeting molecule containing FSY using a single domain antibody (sdAb) C1 (SEQ ID NO: 1), FSY sites were screened by replacing each selected codon in the CDR1, CDR2, and CDR3 regions with a TAG stop codon and generating encoded proteins to incorporate FSY into the appropriate position. Approximately 19 potential sites were identified, most of which were clustered in the CDR1 and CDR3 regions. These TAG sites are located in CDR1 (sites 26-35: GYTDSNYYMS, SEQ ID NO: 5); CDR2 (50-66: VNTGRGSTSYADSVKG, SEQ ID NO: 6), CDR3 (99-116, excluding Cys101, Cys104 AACHFCDSLPKTQDEYIL, SEQ ID NO: 7). A similar evaluation was performed on the second sdAb C2 (SEQID NO: 2) for FSY modification sites. About 8 sites were found in C2 CDR as potential locations of FSY, most of which were concentrated in CDR2 and CDR3. These TAG sites are located in CDR1 (site 26-35RFMISEYSMH, SEQ ID NO: 8); CDR2 (50-65: TINPAGTTDYAESVKG, SEQ ID NO: 9), CDR3 (96-100DGYGY, SEQ ID NO: 10).

[0417] Example 2 - Expression of FSY-modified sdAb

[0418] The vector pBAD sequence (Invitrogen #43001) lacking the ORF insert was PCR amplified using forward primer (SEQ ID NO: 80) and reverse primer (SEQ ID NO: 81), respectively.

[0419] The resulting PCR amplified vector was gel extracted and purified using the Zymo PCR purification kit (Zymoclean Gel DNA Recovery Kit Cat#D4002). The dsDNA sequences of C2 WT His and C1 WT His were ligated to the PCR amplified pBAD backbone and transformed into E. coli DH10b chemically competent cells (Fisher Thermo Scientific TMDH10B competent cells; high efficiency; FEREC0113). The clones were miniprepped and sequence verified using the pBAD forward primer. The expression cassette also incorporated the PelB leader sequence and a His6 tag. The DNA sequences of C1 and C2 wt are SEQ ID NO:73 and SEQ ID NO:74, respectively. For constructs incorporating FSY residues, a TAG codon was engineered into the DNA sequence at the desired position for the amino acid replacement within the open reading frame of the sdAb or biparatopic construct.

[0420] Construction of C1 TAG library. Polynucleotides (dsDNA sequences) containing TAG codons were synthesized by IDT to replace each codon in the sites identified in the CDR region of C1 (see Example 1). These TAG sites are located in CDR1 (sites 26-35); CDR2 (50-66), CDR3 (99-116, excluding Cys101, Cys104). These sites are underlined in the following sequence:

[0421] QVQLQESGGGSVQAGGSLRLSCTAP GYTDSNYYMS WFRQAPGKERE

[0422] WV A GVNTGRGSTSYADSVKG RFTISQDNAKNTMFLQMNSLKPEDT

[0423] AIYYCAV AA C HF C DSLPKTQDEYIL WGQGTQVTVSSAAAYPYDVPDYG(SEQ ID NO:1)

[0424] Polynucleotides containing each of these TAG mutants were cloned into the pBAD backbone and sequence verified as described above.

[0425] Construction of C2 TAG library. A polynucleotide sequence containing a single TAG codon replacing each residue in the CDR region of C2 identified in Example 1 was synthesized by IDT. These regions in the amino acid sequence of the C2 WT His protein sequence are underlined in the following sequence:

[0426] EVQLVESGGGLVQPGGSLTLSCAAS RFMISEYSMH WVRQAPGKGLE

[0427] WVS TINPAGTTDYAESVKG RFTISRDNAKNTLYLQMNSLKPEDTAVYYC DG RGQGTQVTVSS (SEQ ID NO: 2)

[0428] Polynucleotides containing each of these TAG mutants were cloned into the pBAD backbone and sequence verified as described above.

[0429] Library strain generation. The pEVOL-FSYRS plasmid expressing the engineered Mb FSYRS aminoacyl-tRNA synthetase was synthesized by Genscript (Order No. U168NGE200; U168NGE200; Cat# SC1010) (reference: J. Am. Chem. Soc. 2018, 140, 15, 4995–4999) and transformed into chemically competent DH10b competent cells using standard methods to generate the parent strain FSYRS-DH10b. A single plasmid encoding each C1 CDR TAG or C2 CDRTAG variant was transformed into chemically competent FSYRS-DH10b using standard methods. A single colony was inoculated into 2xYT medium (Teknova #Y0166) containing 100ug / ml ampicillin and 34ug / ml chloramphenicol and grown overnight at 37°C with shaking at approximately 220rpm. Overnight cultures were mixed 1:1 with sterile 50% glycerol and stored at -80 °C.

[0430] Expression and purification. Strains carrying plasmids encoding sdAbs with a single CDR residue mutated to TAG in the FSYRS-DH10b parental background were cultured in 2xYT medium (Teknova #Y0166) in the presence of 100 ug / ml ampicillin and 34 ug / ml chloramphenicol. Cells were grown at 37°C prior to induction. At OD 600 At 0.6, the culture was supplemented with 1 mM FSY and induced by the addition of 0.2% arabinose. Upon induction, the culture was moved to 25°C with shaking at 220 RPM overnight for a total of 16 hours.

[0431] Expression was collected by pelleting the cells at 2200 x g for 30 minutes at 4°C. The supernatant was removed, and the cell pellet was weighed and stored at -80°C. The cell pellet was resuspended for lysis by adding B-PER protein extraction reagent (ThermoFisher #78243) at 4 mL / g of pellet. The resuspended pellet was lysed by placing the sample on an orbital shaker at medium speed for 15 minutes at room temperature. The lysed cells were then spun at 2200 x g for 30 minutes. The soluble portion of the supernatant was removed for further purification.

[0432] In order to purify the soluble part, HisPur-Ni-NTA resin (ThermoFisher #88222) is used to capture soluble substances from the lysate. Remove the resin storage buffer, and balance by washing in batches in wash buffer (40mM sodium phosphate, pH 7.2, 300mM NaCl, 20mM imidazole). Repeat batch washing, totaling 50x resin volume. The above-mentioned clarified lysate is added to the washed Ni-NTA resin, and combined with constant rotation for 1 hour at room temperature. After binding, the protein-bound resin is washed in batches with 50x resin volume in wash buffer to remove unbound pollutants. The protein-bound resin is then transferred to a centrifugal column, and rotated briefly at 700xg to remove remaining wash buffer. Then use the buffer with elution buffer (40mM sodium phosphate, 7.2, 300mM NaCl, 500mM imidazole) to elute the target protein. Elution buffer is added with 2x resin volume, and incubated at room temperature for 5 minutes. The samples were spun briefly and the eluted protein was collected in a new tube. The elution procedure was repeated twice using the same conditions. The eluted fractions were combined and eluted by A on a Nanodrop 2000. 280 Quantitation, blank control with elution buffer.Ni-NTA purified protein was then concentrated using 0.5 mL, 3 kDa MWCO PES spin filters (ThermoFisher #88512) and the buffer exchanged to 1x PBS via repeated dilutions at 8-10x volume of sample and concentration.

[0433] Example 3 - Covalent interaction between FSY-modified sdAb and PSMA

[0434] The semi-purified sdAb product from Example 2 was incubated with commercial PSMA (Sino Bio, cat#15877-H07H) in 1xPBS at a molar ratio of about 7:1 overnight at 37°C (sdAb:PSMA, PSMA final concentration was 0.125 mg / mL, 1.25 uM). Cross-linking was analyzed by reducing SDS-PAGE ( Figures 1A-1E ).

[0435] The sites evaluated in CDR1 and CDR3 of the C1 sdAb demonstrated a spectrum of cross-linking abilities to PSMA, as shown in Table 3 below.

[0436]

[0437] The site positions are listed relative to SEQ ID NO:1.

[0438] The cross-linking efficiency of the second PSMA-specific sdAb C2 was evaluated using a method similar to that of Example 1, except that the sdAb:PSMA molar ratio was about 8:1. Figure 2A-2C The sites evaluated in CDR2 and CDR3 of C2 sdAb demonstrated a spectrum of cross-linking abilities to PSMA, as shown in Table 4 below.

[0439]

[0440] The site positions are listed relative to SEQ ID NO:2.

[0441] Example 4 - Kinetics of Cross-linking

[0442] A subset of FSY-modified sdAbs was selected to evaluate the kinetics of PSMA cross-linking. The sdAbs were incubated with PSMA at a 5:1 molar ratio (PSMA final concentration was 0.125 mg / mL, 1.25 uM). Samples were taken at time points from 0 to 180 minutes, and the percentage of cross-linked PSMA was evaluated by SDS-PAGE. Figure 3A and 3B As shown, the modified sdAbs exhibited a range of coupling kinetics. The cross-linked band percentage was calculated by quantifying the sdAb PSMA cross-linked bands, and the PSMA band intensity was quantified using ImageJ.

[0443] Example 5 - PSMA-Targeting Constructs with Modified CDR3

[0444] The PSMA-targeted sdAb C1 construct was generated by modifying two cysteine ​​residues in CDR3 (SEQ ID NO: 7) of C1 (SEQ ID NO: 1) to alanine (C101A and C104A) to generate C39, removing these residues. The construct was then further modified to install FSY at residue 102 (C1-C101A / C104A / H102(FSY), SEQ ID NO: 4, hereinafter referred to as C39-102FSY). The diagrams of these sdAb constructs are shown in Figure 1. Figure 4 As shown. The constructs were synthesized using the pelB leader sequence (SEQ ID NO: 15) cleaved from the mature protein and His-Tag purified using six C-terminal histidines. The cross-linking ability of these constructs was evaluated using the method of Example 3. SDS-PAGE analysis showed that under these conditions, the cross-linking levels of all constructs were comparable.

[0445] As described in Example 2, the PSMA-targeted sdAb C39-FSY C1 containing FSY was cloned and expressed. A biparatopic construct (C1-C101A / C104A / H102(FSY)-L1-C1-C39, SEQ ID NO:21, hereinafter referred to as C40-FSY) was created by linking C39-FSY C1 with an additional copy of C1-C101A / C104A / H102H (SEQ ID NO:71, without FSY). The construct was designed by adding a GGGGSGGGGS linker between the two sdAb amino acid sequences. The biparatopic construct was then cloned into the pBAD vector and expressed as described in Example 2. The construct was synthesized with the pelB leader sequence (SEQ ID NO:15) cleaved from the mature protein and His-Tag purification was performed using six C-terminal histidines.

[0446] Cross-linking of monoparatopic sdAbs and biparatopic constructs to PSMA was assessed by SDS-PAGE and time course. SDS-PAGE analysis showed that the dimeric form C40-102FSY cross-linked at twice the rate of monomeric C39-102FSY (t1 / 2 maximum cross-linking time of about 30 minutes for the dimer, compared to about 60 minutes for the monomer).

[0447] ( Figure 5A-5B )

[0448] C39-102FSY amino acid sequence (* is the 102FSY position, SEQ ID NO: 4, alanine modification is underlined):

[0449] QVQLQESGGGSVQAGGSLRLSCTAPGYTDSNYYMSWFRQAPGKEREWVAGVNTGRGSTSYADSVKGRFTISQDNAKNTMFLQMNSLKPEDTAIYYCAVAA A *F A DSLPKTQDEYILWGQGTQVTVSSAAAYPYDVPDYGSCHHHHHHH

[0450] Example 6 - Synthesis of constructs

[0451] Site-specific conjugation via engineered C-terminal cysteine ​​residues. In order to achieve site-specific bioconjugation with sdAb compounds, additional Cys residues were designed near the C-terminus of the construct. sdAb-Cys compounds were prepared and formulated to 1mg / ml in 1xPBS, pH 7.4, 5mM EDTA. TCEP was added to 10mM for mild reduction and incubated at room temperature for 15 minutes. The sample was then buffer exchanged using a Zeba centrifugal column to remove TCEP and exchanged into 1xPBS, pH 7.4, 1mM EDTA. Maleimide-reactive payload compounds (such as AZDye647 maleimide cat#: 1122-5) were then added in 10x molar excess and incubated for 2 hours at 37°C, or for 16 hours at 4°C. Unreacted maleimide compounds were removed from the sample using size exclusion chromatography, desalting columns, dialysis or TFF. Samples were subjected to SDS-PAGE under reducing and non-reducing conditions to visualize labeling efficiency and analyzed using LC-MS to quantify the intact mass and relative ratios of labeled and unlabeled species.

[0452] Example 7 - Determination of cross-linking activity

[0453] The specific binding and cross-linking of the molecules to the target tumor antigens were determined. To evaluate the cell binding ability of the PSMA-targeted constructs, specific sdAbs containing FSY or Tyr were used to test the effect of covalent cross-linking on specific antigens of interest. These test articles were serially diluted and associated with prostate cancer cell lines LnCAP (PSMA+) and PC3 (PSMA-) cultured in vitro. After incubation at 37°C for different times, the cells were washed and the culture medium was replaced to remove unbound materials. The samples were analyzed by flow cytometry using anti-His tag antibodies or anti-VHH to measure the bound population as a function of input concentration. To measure the cross-linking efficiency and specificity, cells were collected, lysed, and Western blotted using anti-his or anti-VHH antibodies to measure the covalently bound population via gel shift and compared with gel shift Western blots using anti-PSMA antibodies to measure the total target antigen cross-linked to the sdAb test article.

[0454] The functional activity of the conjugate molecule was determined in addition, in this case, it refers to the ability to specifically deliver toxic payloads to tumor cells expressing target antigens in vitro. Using the general method described in Example 8, the construct containing the engineered C-terminal or proximal Cys residues is coupled to a cytotoxic payload, such as the highly cytotoxic compounds of MMAE or other categories. Dose response curves are generated, and samples are incubated in vitro with LnCAP and PC3 cells. After incubation for different times, cells are washed to remove free compounds, and cell viability is measured using assays (such as Promega CytoxGreen) or other assays to measure cell viability via reporter compound detection, detection of live cells by Presto Blue, CCK-8 or similar reagents, and / or via Annexin V-FITC, propidium iodide staining or similar reagents to measure apoptosis.

[0455] Example 8 - In vivo delivery

[0456] In order to measure the ability of the construct to deliver payload specifically to tumor tissue in vivo, and to compare the tumor exposure of the construct and the non-covalent sdAb conjugate, the fluorophore label is used as a representative payload to achieve tracking / biodistribution measurement over time. The sdAb construct (e.g., C1, C2, or C3) with a single residue replaced by Tyr or FSY provides maleimide chemistry via an engineered cysteine ​​residue and is conjugated to a chemical fluorophore (Alexa647 or the like), and is purified as described in Example 6. In male NSG mice carrying PSMA+ or - tumors, fluorophore-labeled sdADC conjugate molecules are administered via tail vein IV injection, and the biodistribution of the test product over time is observed using an AmiX imager or similar device via whole animal imaging. Tumor specificity and peripheral exposure are quantified via image density determination, and compared between FSY and Tyr versions of sdAb.

[0457] Example 9: Design of additional FSY-modified SdAbs

[0458] The C3 wt sequence (synthesized by IDT, SEQ ID NO: 3) was cloned into the digestion vector (synthesized by Genscript) using NdeI and HindIII restriction enzymes to construct the C3

[0459] wt anti-PSMA sdAb. The expression cassette also incorporated the PeIB leader sequence and His6 tag. The C3wt DNA sequence is shown in SEQ ID NO:75.

[0460] At the sites selected for FSY modification, the amino acid sequences of the CDR regions were changed to TAG codons in the plasmid. These TAG mutants in the ORF were prepared by Genscript via site-directed mutagenesis.

[0461] C3 CDR1(26-35: GWPYSTYSMN , SEQ ID NO:11); CDR2(50-65: GISSTMSGIIFAESKAG, SEQ ID NO: 12); CDR3 (99-113: RRDYSLSSSSDDFDY , SEQ ID NO:13).

[0462] Example 10 - Screening of FSY-modified sdAbs

[0463] As described in Example 2, the C3 construct from Example 9 was co-transformed with pEVOL FSYRS into DH10b competent cells. Single colonies were picked from the transformation and inoculated into 1 mL 2xYT in a 24-deep well plate supplemented with 100 ug / mL Amp + 34 ug / mL Cm, which was shaken at 220 rpm and 37 ° C. When the OD reached 0.5, the temperature was reduced to 25 ° C. Expression in each well was induced by adding 0.2% arabinose + 1 mM FSY. The product was expressed overnight at 25 ° C. After overnight, the cells were transferred to a 1.5 mL Eppendorf tube and centrifuged with a benchtop centrifuge. The supernatant was removed. The precipitate was treated with 50 uL B-per (ThermoFisher #78243) for cell lysis for 15 minutes. Afterwards, the cell lysate was spun at maximum speed with a 4 ° C benchtop centrifuge.

[0464] The cross-linking reaction was initiated by incubating 3uL of supernatant with 3uL PBS or 3uL 0.25mg / mL PSMA. The reaction was incubated at 37°C for a shorter time window of 3 hours. Afterwards, the incubation mixture was treated with 2X SDS-loading dye. The cross-linking was studied by running SDS-PAGE with Coomassie blue staining. The results are shown in Figure 2. Fig. 6A and 6B and are summarized in Table 5 below.

[0465]

[0466] The site positions are listed relative to SEQ ID NO:3.

[0467] Example 11 - Identification and Kinetics of FSK-Modified FAP sdAb

[0468] Sequence analysis (abYsis) was used to define the complementarity determining region (CDR) loop positions in the Fap antibody sequence. Libraries were constructed to replace each CDR residue individually with a TAG codon and express the resulting proteins under conditions in which the unnatural amino acid FSK was incorporated at each position.

[0469] C8 FAP library generation. To evaluate different FSK incorporation sites in sdAbs, the vector pBAD-C8WT (SEQ ID NO: 82) was constructed as follows: The C8 WT sequence (SEQ ID ID: 23) was codon-optimized for E. coli expression and synthesized by IDT. The pBAD-C8 WT vector was constructed by cloning the C8 WT gblock sequence (SEQ ID NO: 78) into the digested pBAD vector (Genscript) using NdeI and HindIII restriction enzymes.

[0470] Library strain generation. In order to express the corresponding synthetase, a pEVOL-FSKRS plasmid (Genscript) was synthesized, which encodes an engineered Ma FSKRS aminoacyl tRNA synthetase (SEQ ID NO: 87). pEVOL-FSKRS (SEQ ID NO: 89) was transformed into chemically competent DH10b competent cells to generate the parent strain FSKRS-DH10b. A single plasmid encoding each C8CDR TAG variant was transformed into a chemically competent FSKRS-DH10b cell. A single colony was inoculated into a Superbroth medium (Teknova # S1530) containing 100ug / ml ampicillin and 34ug / ml chloramphenicol and grown overnight at 37°C with shaking at about 220rpm.

[0471] Expression and purification.In the presence of 100ug / ml ampicillin and 34ug / ml chloramphenicol, the bacterial strain carrying the plasmid encoding sdAb was cultivated in Superbroth medium, and the sdAb had a single CDR residue that was mutated to TAG in the FSKRS-DH10b parental background. The single bacterium colony in each library was inoculated into the 5mL Superbroth medium containing the relevant antibiotics, and grown overnight at 37°C. On the second day, the cell was diluted to 30mL (3mL to 30mL dilution) Superbroth medium with a ratio of 1:10, and the medium contained 100ug / mL ampicillin and 34ug / mL chloramphenicol, 1mM FSK, 0.2% arabinose. At 30°C and 220rpm, cells were induced to carry out FSK and incorporated to 6 hours. After expression, the sdAb (C8-FSK) modified by FSK and purified according to the method described in Example 2.

[0472] Cross-linking kinetics. FAP receptor (Acrobiosystem #AP-H5263-100ug) was incubated with the combined antibody mixture (Table 6) at a molar ratio of approximately (antibody: receptor) 8:1 at 37°C, 1X PBS, pH 7.4 for 1 hour, 2 hours, or overnight. After incubation, the cross-linking reaction was stopped by adding 1X Laemmli sample buffer containing 100mM DTT. The samples were heated at 95°C for 5 minutes and then subjected to Tris-glcyne SDS-PAGE (4–20% TGX TM ). Relative band intensities were then quantified using ImageJ software. The results of FSK-merged translocation indicated that FAP receptors were translocated via cross-linking activity within pools 2 and 3 ( Fig. 7A ).

[0473] Table 6. CDR library designed for expressing C8 FSK mixtures

[0474] Library Number CDR Area 1 CDR1(26-35) 2 CDR2(50-57) 3 CDR2(58-65) 4 CDR3(98-106)

[0475] Identification of individual FSK sites responsible for crosslinking to FAP. To identify individual FSK sites responsible for crosslinking, each TAG mutant was co-transformed with pEVOL-FSKRS into DH10b cells, expressed and purified as described above. Each individual FSK mutant in the candidate pool was incubated with the FAP receptor for studies of gel shift ( Figure 7B ). Nine FSK mutants in CDR2 were found to crosslink with FAP (52, 53, 54, 55, 56, 58, 60, 62, 64). One site (56) was found to have the highest crosslinking yield of all crosslinking sites within 1 hour.

[0476] Measurement of the cross-linking kinetics of C8-FSK with FAP receptors. To evaluate the cross-linking kinetics of FSK, C8-54FSK and C8-56FSK were incubated with FAP receptors for 15, 30, 60, and 120 minutes, and the cross-linking yield was examined. It was found that the 56FSK site had the highest cross-linking rate compared to the other sites, indicating that C8-56FSK had the fastest cross-linking rate (>50% cross-linking within 2 hours) ( Figure 7C ).

[0477] Example 12 - Identification and kinetics of FSY-modified Her3-SdAb

[0478] C9 library generation. Sequence analysis (abYsis) was used to determine the complementary determining region (CDR) loop positions in the Her-3 antibody sequence. The library was constructed to replace each CDR residue individually with a TAG codon and expressed under conditions in which the unnatural amino acid FSY was incorporated at each position.

[0479] Constructed vector pBAD-C9 WT. C9 WT sequence (SEQ ID NO:24) was codon optimized for E. coli expression. C9-gblock sequence (SEQ ID NO:79) was cloned into pBAD vector (Genescript cat#SC1010) digested by NdeI and HindIII restriction enzymes to construct pBAD-C9 WT vector (SEQ ID NO:83). Create a library of C9-FSY variants as described in Example 2, except that pEVOL-FSYRS plasmid and single mutant pBAD-C9 mutants were transformed and expressed in BL21 cells instead of DH10b cells. The expression of C9-sdAb (C9-FSY) modified by FSY follows the method described in Example 2, except that C9-sdAb modified by FSY- is expressed and purified in parent strain FSYRS-BL21.

[0480] Identification of libraries responsible for crosslinking. To preliminarily identify CDR regions containing crosslink-compatible FSY sites, strains containing plasmids with TAG sites in multiple CDR regions were initially pooled (Table 7). Pooled strains were expressed and purified by Ni-NTA affinity as described in Example 2, concentrations were normalized, and crosslinking was assessed via SDS-PAGE gel shift. The C9-FSY library mixture was incubated with Her3 (Acrobiosystem #ER3-H5223-100ug) at a 3:1 ratio (3ug C9 FSY to 1ug Her3 receptor) at 37°C, 1XPBS, pH 7.4 overnight. Reactions were incubated at 4-20% TGX TM The results of the combined shift showed the Her3 receptor cross-linking activity in pools 2, 3, and 4 ( Fig. 8A ).

[0481] Table 7. CDR library designed for expression of C9 FSY mixture

[0482] Library Number CDR Area 1 CDR1(28-37) 2 CDR2(52-58) 3 CDR2(59-63) 4 CDR2(64-68) 5 CDR3(101-106) 6 CDR3(107-112) 7 CDR3(113-118)

[0483] Identification of individual FSY sites responsible for crosslinking to Her3. To identify each individual FSY site responsible for crosslinking, each TAG mutant was co-transformed with pEVOL-FSYRS into BL21 cells, expressed and purified as described above. Each FSY mutant in the candidate pool was incubated with the Her3 receptor overnight at 37°C. TGX TM Cross-linking was assessed by staining with Coomassie blue. Figure 8BEight C9-FSY mutants in CDR2 were found to support cross-linking with Her3 (53, 55, 56, 57, 58, 60, 64, 67). Two sites (55, 57) were found to have the highest cross-linking yields among all cross-linking sites.

[0484] Identification of C9-FSY crosslinking sites at the fastest rate. To identify FSY crosslinking sites at the fastest rate, C9 with the above identified FSY sites was incubated with Her3 receptor (Acrobiosystem) and the crosslinking yield was determined. C9-FSY mutants were incubated with Her3 receptor at a molar ratio of 8:1 in 1x PBS at pH 7.4. After 1 hour, the incubation was stopped by adding to a final 1X SDS loading dye containing 100 mM DTT and the crosslinking yield was determined by 4-20% Mini TGX TM The reaction was analyzed by Coomassie blue staining.

[0485] The unique 55FSY site was found to have the highest cross-linking yield (>50% within 1 h) compared to other sites, indicating that 55FSY has the fastest cross-linking rate ( Figure 8C ). C9-55FSY was further analyzed by incubating it with Her3 receptor and stopping the reaction during the time course of 0, 15, 30, 60, 120 and 180 minutes. Fig.8D As shown, cross-linking proceeded rapidly and was detectable within 15 min, with more than 50% cross-linking within 1 h.

[0486] Example 13 - Binding affinity of FSY-modified and unmodified C2 sdAbs

[0487] The C2 sdAb (C2-54FSY) with FSY at position 54 was selected to compare the binding affinity with the C2 sdAb (C2-54TYR) with tyrosine at the same position. Protein was prepared as described in Example 2, and then further purified via FPLC size exclusion chromatography (HiLoad16 / 600Superdex 200pg size exclusion column Cytiva#28989335). 1xDPBS was used as running buffer, and protein was collected by isocratic elution. For each C2sdAb, the monomer peak part was analyzed by reducing SDS-PAGE, and it was merged and dialyzed into anion exchange running buffer (20mM Tris, 7.5 and 20mMNaCl), overnight at 4°C. In order to remove endotoxin, the dialyzed sample pool was run in flow-through mode on HiTrap Q XL 1ml column (Cytiva#17515801), where endotoxin was bound to the column. The flow-through was collected and checked for endotoxin levels. Finally, the fully purified sample was dialyzed into 1x DPBS as the final formulation buffer. The sample was aliquoted and stored at -80°C.

[0488] Binding kinetics were measured using biolayer interferometry with an AHC sensor (Sartorius item #18-5060). PSMA (50 nM) with an Fc tag (Acrobiosystem PSA-H5264-100 ug) was loaded with C2-54FSY or C2-54TYR sdAb (protein concentration 400 nM, 200 nM, 100 nM, 50 nM). The steps for performing OCET measurements were as a baseline: 60 seconds; loading receptors: 300 seconds, elution of non-bound receptors: 300 seconds; loading associated sdAb: 100 seconds; dissociation: 600 seconds. The KD for C2-54TYR was 9.1 nM, and the KD for C2-54FSY was 10.9 nM, indicating that incorporation of FSY at position 54 instead of tyrosine did not change the binding affinity.

[0489] Example 14 - Cell Binding Assay

[0490] Flow cytometry was used to evaluate the binding of C2-54FSY and C2-54TYR sdAbs to human prostate tumor cell lines LNCaP (PSMA+) and PC3 (PSMA-). Proteins from Example 13 were prepared to 3 μM (1000 μL) in FACS buffer (1xPBS + 2% HI-FBS) and then serially diluted 5x (200 μL sdAb to 800 μL FACS buffer) to generate 8 concentration points for the assay, with the lowest concentration being 0.0000384 μM. Control sdAb (human Alexa Fluor Alexa 647-conjugated antibody) was prepared to 1 μM (450 μL) with FACS buffer (1×PBS+2% HI-FBS) and then serially diluted 3× (150 μL test article to 300 μL FACS buffer) with a minimum concentration of 0.00045 μM.

[0491] Binding assay. LNCaP and PC3 cell lines (ATCC) were maintained in RPMI-1640 and F12K culture medium supplemented with 10% heat-inactivated fetal bovine serum (Thermo Fisher) at 37°C and 5% CO2 in a humidified environment. Cells were harvested in the exponential growth phase, counted and aliquoted into v-bottom 96-well plates, 100 μL cells per well. Cells were precipitated by centrifugation. C2 sdAb and control sdAb samples were added to the cells and incubated on ice for one hour. For cells treated with C2 sdAb, after incubation, cells were washed twice with FACS buffer and incubated on ice for 30 minutes with 100 μL of ice-cold FACS buffer (AlexaFluor 647AffiniPure goat anti-alpaca IgG, VHH domain) containing 5 μg / mL secondary antibodies. Cells were then washed twice with FACS buffer and fixed for 30 minutes with 4°C fixation buffer (Thermofisher, Cat.No.0082249). For cells treated with control sdAb, after incubation, cells were washed twice with FACS buffer and fixed with fixation buffer (Thermofisher, Cat. No. 0082249) for 30 minutes at 4° C. After fixation, cells were washed twice and analyzed with Attune flow cytometry (ThermoFisher).

[0492] Analyze raw data (FCS files) (Flowjo 10.7.2). FSC-A and SSC-A are used to separate total cells, and intact cells are gated with FSC-A and SSC-A. FSC-A is then used to gate single peaks for FSC-H. Alexa Fluor-647 is used to separate single peaks. The geometric mean intensity of the Alexa Fluror-647 signal intensity of the sample is used for further analysis and drawing. The mean and STDEV values ​​of the geometric mean intensity of the Alexa Fluror-647 of the sample are calculated (for Microsoft 365MSOVersion 2202Build 16.0.14931.2012864-bit Curve fitting and plotting were performed using 'log(agonist) vs. response - variable slope (four parameters)' (GraphPad Prism 9.2.0).

[0493] C2-54TYR and C2-54FSY, which bound to LNCaP cells in a dose-dependent manner, did not show binding to PSMA-negative PC3 cells ( Fig. 9 The binding affinities of C2-54TYR and C2-54FSY were measured based on the EC50 values ​​after flow staining of LNCaP cells (Table 8).

[0494] Table 8. Binding affinity of C2 sdAb in LNCaP cells

[0495] C2-54TYR C2-54FSY EC50 14.88nM 12.25nM EC50 Range 8.83nM to 27.05nM 8.98nM to 16.88nM Square R 0.978 0.99

[0496] Example 15 - Cross-linking of FSY-modified sdAb to target cells

[0497] Compare the cross-linking effect of C2-54TYR, C2-54FSY and C3-101FSY on cell binding.LNCaP and PC3 cells were cultured as described in Example 14.Cells were plated in 6-well plates in their growth medium at a density of 500,000 cells / well.48 hours after inoculation, the culture medium was removed, and 0.8mL of culture medium containing sdAb was added at a specified concentration and time point (see Table 9 and Table 10).The cells were rinsed twice (1mL / well 1xPBS), and 0.2mL / well 0.25% EDTA-trypsin (Gibco, Cat.No.25200-056) was added.After incubation in an incubator for five minutes, 1ml of complete culture medium was added to neutralize trypsin.The cells were rinsed and precipitated.

[0498] Cells were lysed in RIPA buffer supplemented with a protease inhibitor cocktail (Santa Cruz Biotechnology, Cat. No. SC-24948A). Denatured samples were electrophoresed in 4-20% standard TGX gels (Bio-Rad, Cat. No. 5671095), followed by Western blotting using a kit (Bio-Rad, Cat. No. 1704271) and a Pierce Fast Western Blotting Kit (Thermo Scientific, Cat. No. 35060, 35061), and analyzed using primary antibodies anti-human PSMA (Invitrogen, Cat. No. 37-3900) or anti-alpaca VHH (Jackson ImmunoResearch, Cat. No. 128-035-232), internal standard anti-GAPDH (Cell Signaling Technology, Cat. No. CST-2118).

[0499] Images were collected by Azure Biosystem C600. GIMP 2.10.28 was used to process images. The density of bands in the western blot was determined using ImageJ 1.51j8 according to the instructions (imagej.nih.gov / ij / docs / guide / 146-30.html#infobox:Densitometry, Section 30.13). The percentage of cross-linked PSMA to total PSMA was calculated using the following formula: density of cross-linked PSMA / (density of cross-linked PSMA+density of uncross-linked PSMA) x 100%.

[0500] A major band (approximately 100 kD) detected with anti-PSMA antibody was observed in western blots of LNCaP cells ( Fig. 10A ), but no bands with similar molecular weight were detected in PC3 cells ( Fig. 10B ), which demonstrated the specificity of the anti-PSMA antibody and confirmed the specificity of PSMA expression in LNCaP cells. In LNCaP cells treated with C2-54FSY, an additional band above PSMA was detected. The intensity of the band increased in a time- and concentration-dependent manner, indicating specific cross-linking. However, in LNCaP cells treated with different concentrations of C2-54TYR for different times, a non-cross-linked PSMA band of similar intensity was observed, but no cross-linked band, indicating that the sdAb without FSY did not cross-link with PSMA in LNCaP cells ( Fig. 10B Quantification of cross-linking showed that C2-54TYR cross-linked with PSMA in a time- and dose-dependent manner in LNCaP cells. (Table 9 and Fig. 10C )

[0501] Table 9. Cross-linking kinetics of C2-54FSY and PSMA in LNCaP cells

[0502]

[0503] In LNCaP cells treated with C3-101FSY, a similar pattern was observed, with the intensity of the cross-linked band (PSMA-sdAb) increasing in a time- and concentration-dependent manner. Since the molecular weight of C3-101FSY is higher than that of C2-54FSY, the apparent molecular weight of the migrated cross-linked band is higher than that of the C2-54FSY cross-linked band ( Fig.11A The comparison of crosslinking kinetics of C2-54FSY and C3-101FSY is shown in Tables 10 and Fig. 11B shown.

[0504] Table 10. Cross-linking kinetics of C2-54FSY and C3-101FSY with PSMA in LNCaP cells

[0505]

[0506] Example 16 - In vivo cross-linking assay

[0507] This study evaluated the in vivo cross-linking, systemic and intratumoral exposure of C2-54TYR and C2-54FSY to PSMA in two mouse xenograft tumor models, LNCaP and PC3. LNCaP and PC3 cell lines (ATCC) were maintained in RPMI-1640 and F12K medium supplemented with 10% heat-inactivated fetal bovine serum (Thermo Fisher), respectively, at 37°C and 5% CO2 in a humidified environment. Cells were harvested during the exponential growth phase and centrifuged at 335xg in a refrigerated centrifuge, and the medium was aspirated. For cell inoculation, the cell pellet was resuspended in 100 μL of serum-free F-12K medium (for PC3) or RPMI (for LNCaP) plus 100 μL of Matrigel. 200 μL containing 5 million PC3 cells or 3 million LNCaP cells were implanted into the flank of male NSG mice (Jackson Labs). When the tumor size reached approximately 200 mm 3 At 1 hr, C2-54TYR and C2-54FSY were injected via the tail vein. Peripheral blood samples were collected by buccal bleeding. Six hours later, mice were sacrificed, and both peripheral blood samples and tumors were collected, weighed, and frozen at -80°C.

[0508] 1 ml of RIPA buffer (Santa Cruz Biotechnology, Cat. No. SC-24948A) containing a protease inhibitor cocktail was added to the tumor sample (approximately 30 to 40 mg) and then homogenized using a Qiagen Tissuelyser II sample crusher. After homogenization, the sample was centrifuged at 12,000 rpm for 10 minutes at 4°C. The supernatant was retained and the precipitate was discarded. The centrifugation process was repeated once (twice in total).

[0509] The protein concentration of tumor lysates was quantified using a BCA protein assay kit (Thermo Scientific, Cat. No. 23225). The samples were prepared to the same concentration with RIPA buffer and then heated at 100 ° C for 10 minutes after adding 6x reduction loading buffer (Alfa Aesar, Cat. No. J61337). Denatured samples were electrophoresed in a 4-20% standard TGX gel (Bio-Rad, Cat. No. 5671095), and then analyzed using anti-PSMA and anti-VHH for protein blotting (Bio-Rad, Cat. No. 1704271 and Thermo Scientific, Cat. No. 35060, 35061) to detect cross-linking and anti-GAPDH antibodies as loading controls. Images were collected by Azure Biosystem C600. GIMP 2.10.28 was used to process images. ELISA was performed on plasma, and the data was processed and plotted (GraphPad Prism 9.2.0). Means and STDEVs were calculated, and significance of plasma concentrations was assessed using an unpaired two-tailed Student's t-test.

[0510] Samples of LNCaP and PC3 tumors from animals administered C2-FSY or C2-TYR were prepared as described above and subjected to Western blotting with anti-VHH antibodies to detect non-cross-linked C2 compounds (15 kD region of the blot) and cross-linked C2 compounds (approximately 100 kD region above PSMA). In LNCaP tumor samples from animals administered C2-54FSY, anti-VHH Western blotting detected a band above the PSMA region (approximately 100 kD) in all samples, whereas no cross-linked bands were observed in C2-54TYR or vehicle samples ( Fig. 12A ), indicating that C2-54FSY has specific and repeatable cross-linking. No anti-VHH signal was observed in PC3 tumor samples, while different band patterns were observed in LNCaP samples treated with C2-54TYR and C2-54FSY. Uncrosslinked / free sdAb was shown in the approximately 15kD region of the blot, and both LNCaP samples treated with C2-54TYR and C2-54FSY showed bands of similar intensity, indicating that similar levels of uncrosslinked sdAb were present. In the LNCaP tumor tissue treated with C2-54FSY, an additional band was observed to migrate specifically at approximately 100kD, while in PC3 samples or LNCaP samples from C2-54TYR treated animals, no band was observed in this region, indicating that C2-54FSY is cross-linked with PSMA.

[0511] To estimate and compare the systemic exposure of the sdAbs, plasma concentrations of C2-54TYR and C2-54FSY were measured using ELISA at 30 minutes and 6 hours after dosing (Tables 11 and Fig. 12B ).

[0512] Table 11. Plasma concentrations of C2-54TYR and C2-54FSY (ng / ml)

[0513]

[0514] The results showed that after a single IV dose, C2-54TYR and C2-54FSY entered tumors and accumulated in a PSMA-dependent manner. However, in tumors, only C2-54FSY specifically cross-linked with PSMA.

[0515] Example 17 Construction of FSK-modified and FSY-modified sdAbs for target-specific cross-linking

[0516] The libraries and library strains were constructed, expressed and purified according to the general methods of Examples 2 and 11. To initially identify CDR regions containing sites compatible with FSY or FSK insertion, strains containing plasmids with TAG codons within the coding regions of the CDR regions were constructed. Table 12 shows the sdAb and CDR sequences used for screening.

[0517] Table 12: sdAbs with FSY and FSK insertions

[0518]

[0519]

[0520] Screening. The library was screened for strains containing plasmids with TAG codons within the coding regions of the CDR regions and cross-linking was determined following the general methods of Examples 11 and 12. The library that showed cross-linking activity against the target was further analyzed by evaluating the cross-linking of individual FSY or FSK mutants. Individual mutants that showed cross-linking are shown in Table 13.

[0521] Table 13: Identification of FSY and FSK insertions for cross-linking sdAbs

[0522]

[0523] Reagents for cross-linking targets of the assay. CEACAM5 was purchased from Acrobiosystem (#CE5-HF255-25μg) and Sinobiological (#11077-H02H-100μg). FAP receptor was purchased from Acrobiosystem (#AP-H5263-100ug). Human FolRa (folate receptor α) receptor was purchased from Acrobiosystem (#FO1-H5253-100ug). MSLN (mesothelin) was purchased from Sinobiological (Cat: 13128-HNCH, Cat: 13128-H01H-B) and Acrobiosystem (#MSN-H526x-100ug). Human MSLN extracellular domain was purchased from Acrobiosystem (#MSN-H5253-100ug, #MSN-HF223-25ug). The Her3 extracellular domain was purchased from Acrobiosystem (#ER3-H5223-100ug). The human CD123 protein extracellular domain was purchased from SinoBiological (#10518-H02H-50ug). The human 5T4 cell extracellular domain was purchased from Acrobiosystem (#TPG-H5253-100ug).

[0524] For C8 FSY sdAb, the cross-linking kinetics were analyzed according to the method of Example 11. Fig.13 Cross-linking of 0-180 minutes is shown. It was found that the C8-54 FSY site had the highest cross-linking rate compared to other sites (about 50% cross-linking within 2 hours). Similarly, the cross-linking rates of C18-FSY and C18-FSK sdAb and HER3 receptors were compared. Between positions 33, 101 and 103, it was observed that position 101FSY achieved the highest cross-linking efficiency and rate. For the C18 sdAb FSK variants at positions 30, 32, and 35, it was observed that position 35FSK achieved the highest cross-linking efficiency and rate for Her3. Evaluation of 3 sites in C20 FSY sdAb showed that position 57 achieved the highest cross-linking efficiency and rate for CD123.

[0525] Example 18 Identification and kinetics of FSY-modified DARPins

[0526] The Her2 binding DARPin (C15) was screened for its ability to be cross-linked by insertion of FSY amino acids. The library and library strains were constructed, expressed and purified according to the general methods of Example 2. The C15 WT sequence (SEQ ID NO 29) is shown in Table 14, the region screened by FSY insertion is shown in bold, and the amino acid positions replaced by FSY are shown in the second row of the table.

[0527] Table 14. Amino acid positions for substitution of FSY into HER2 DARPins

[0528]

[0529] Each individual C15-FSY mutant was incubated with the Her2 receptor for cross-linking efficiency according to the general method of Example 11. Sites 9, 12, 37, 66, and 68 in C15 showed cross-linking with the Her2 receptor, as shown in Fig.14 As shown. In order to identify FSY cross-linking sites at the fastest rate, DARPins with the above identified FSY sites were incubated with Fc-tagged Her2 (Acrobiosystem: Acrobiosystem: #HER2-H5253-100ug) and cross-linking was examined at 15 minutes and 30 minutes. It was found that the C15-66 FSY site had a higher cross-linking yield than other sites.

[0530] A biparatopic DARPin (C15-66FSY-C16, hereinafter referred to as C38-FSY) was constructed by fusing a copy of the DARPin without FSY replacing C16 (SEQ ID NO 30) to the C-terminus of C15-66FSY using a 5 amino acid GGGGS linker to prepare a fusion protein. The C38-FSY protein was incubated with Fc-tagged Her2 and cross-linking was examined according to the general method of Example 11. Biparatopic C38-FSY cross-linked Her2 in a time-dependent manner, with 50% cross-linking within 2.5 hours, as shown in Figure 11. Fig.15 shown.

[0531] Example 19 Cellular Binding with Targeted Imaging Payloads

[0532] C22-TYR and C22-FSY (SEQ ID No. 39 and 40, respectively) were expressed and purified according to the general method of Example 2, except that after elution from the Ni-NTA resin, the purified protein buffer was exchanged into anion exchange running buffer (20 mM Tris, 7.5 and 20 mM NaCl) and a dilution factor of 1:100 was used overnight at 4C. The dialyzed sample pool was passed through a HiTrap Q XL 5ml column (Cytiva#17515801) in a flow-through mode, where endotoxin was bound to the column. The sdAb monomer flow-through portion was analyzed by reducing SDS-PAGE and merged. The purified C22-TYR and C22-FSY were then conjugated with AZ Dye680 (Click Chemistry Tools, Catalog#1578-25).

[0533] AZ Dye680 (Click Chemistry Tools, Catalog #1578-25) was conjugated to C22-FSY and C22-TYR using sortase-mediated ligation to generate C23-TYR and C23-FSY. The sortase gblock sequence was codon optimized and sequenced by IDT, cloned into the pBAD vector, and prepared as described (PubMed: 21697512). To conjugate the sdAb construct to AZ Dye 680, 20 mg of protein purified in PBS at pH 7.4 was incubated with 1 mM CaCl2, 0.5 mM AZ Dye 680, and 2 mg sortase in an oscillator at 30°C (the final concentration of sdAb was about 0.7 mg / mL). After 2 hours, 2 mM MTSET was added to quench the reaction. The reaction of quenching is bound to 2mL (PBS balance) Ni resin in batches, to remove sortase and unconjugated material, rotate at room temperature 30 minutes. Rotate beads to promote the separation of resin and unbound part (700g x 10min, 20 ℃), and collect remaining protein by loading into glass column and washing beads with PBS, thus collect flow-through liquid. Flow-through liquid and washing solution are merged and concentrated (5K MWCO, 4k rcf, 10C, 1.5h), then loaded on HiLoad 26 / 600Superdex 75pg (Cytiva, #28-9893-34), to remove unconjugated dye. Collect each part, and analyze by SDS-PAGE, and merge, and store at-80 ℃.

[0534] The resulting conjugates C23-TYR and C23-FSY were evaluated by flow cytometry for binding to human epidermoid squamous cell carcinoma line A431 (EGFR+) and human colorectal cancer cell line COLO320DM (EGFR-). The protein was prepared to 30 μM (10x final concentration) with FACS buffer (1xPBS+2% HI-FBS+5mM EDTA), and then serially diluted 5x (20 μL sdAb to 80 μL FACS buffer) to generate 8 concentration points for determination, with a minimum concentration of 0.000384 μM (10x final concentration). Both A431 and COLO320DM cell lines (ATCC) were maintained in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum (Thermo Fisher) at 37°C and 5% CO2 in a humidified environment. Cells were harvested in the exponential growth phase, counted, and expressed as 1.1x10 6 / mL was resuspended in ice-cold FACS buffer and aliquoted into v-bottom 96-well plates (Corning 3897) at 90 μL / well. C23-TYR and C23-FSY proteins were added to A431 cells at 10uL / well to a final concentration of 1x. In order to control the specificity of binding to EGFR+ cells, the test products of the same dilution range were added to COLO320DM cells. After incubation on ice for 2 hours, the cells were precipitated at 2000rpm for two minutes, then washed twice with 200 μL FACS buffer, then resuspended in 100 μL ice-cold FACS buffer and analyzed with a NovoCyte flow cytometer (ACEA / Aglient).

[0535] Raw data (FCS files) were analyzed using FlowJo 10.7.2. Total intact cells were identified using FSC-A and SSC-A, and single peaks were then screened out using FSC-A versus FSC-H. The AZ680 geometric mean fluorescence intensity of the sample was used for further analysis and plotting. The geometric mean fluorescence intensity (GeoMean or GeoMFI) of the AZ680 channel was used to calculate the EC50 in GraphPad Prism (V9.3.1) using 'log (agonist) vs. response-variable slope (four parameters)'.

[0536] like Fig.16 As shown, C23-FSY and C23-TYR, which bound to A431 cells in a dose-dependent manner, did not show binding to EGFR-negative COLO320DM cells. As shown in Table 15, the binding affinity of C23-FSY and C23-TYR was measured based on the EC50 values ​​after staining of A431 cells and flow cytometry.

[0537] Table 15. Binding affinity of C23-FSY and C23-TYR AF680 conjugates to A431 cells

[0538] C23-TYR C23-FSY EC50(nM) 95 18 EC50 Range 415.2-613.1 444.7-618.2 Square R 0.99 1.00

[0539] Example 20 In vivo tumor targeting using targeted imaging payloads

[0540] This study evaluated the in vivo cross-linking of fluorescently labeled sdAbs. C22-FSY and C22-TYR were modified according to the method of Example 19 to produce AZ680 conjugates C23-FSY and C23-TYR (SEQ ID No. 42, 41, respectively). The in vivo cross-linking of C23-FSY and C23-TYR with EGFR was evaluated in the A431 epidermoid squamous cell carcinoma xenograft tumor model. The human colorectal cancer xenograft model COLO320DM was used as an EGFR control. The two cell lines were cultured according to the supplier's protocol (ATCC). On the day of injection, the cells were harvested, washed in serum-free medium, counted, and resuspended in cold serum-free medium. The A431 cell pellet was resuspended in 100 mL serum-free DMEM and COLO320DM 100 μL RPMI1640, and the cells were then mixed with 100 mL Matrigel to a final concentration of 5x 10 6 Live cells / 100 μL. A volume of 200 mL containing 10 million A431 or COLO 320DM cells was implanted into the right upper flank of 6-8 week old female Balb / c nude mice (Charles River). When the tumor size reached approximately 200 mm 3 At 100 mL / kg, 5 mg / kg of C23-FSY, C23-TYR or vehicle control (PBS) was injected via the tail vein. Peripheral blood samples were collected via cheek bleeding 0.5 hours after administration to confirm the accuracy of administration.

[0541] The biodistribution of the test article was studied at 2 different time points as shown in Table 16. Animals were euthanized and tumors were harvested, weighed and placed on ice for ex vivo IVIS imaging and then snap frozen for Western blot analysis.

[0542] Table 16. Time points for biodistribution analysis

[0543]

[0544] Tissue processing. Weigh a piece of tumor (about 30 to 50 mg) and cut it into small pieces with a razor blade. Place the excised tumor tissue in a CK28-R tube (Bertin Instruments, Cat. P000916LYSK0-A) and add 0.5 ml of T-PER buffer (ThermoScientific Cat. 78510) containing a mixture of Halt protease and phosphatase inhibitors (Thermo Scientific Cat. 78446). Then use a Precellys 24 tissue homogenizer to homogenize the tissue. After homogenization, the sample is centrifuged at 12,000 x rpm for 10 minutes at 4 ° C. Then retain the supernatant and discard the precipitate. Repeat the centrifugation process once more (a total of two times).

[0545] Gel imaging. The protein concentration of tumor lysates was quantified using the Pierce Rapid Gold BCA protein assay kit (Thermo Scientific Cat. A53225) according to the manufacturer's instructions. A 7-point 2-fold dilution of BSA starting with 1 mg / mL BSA from the kit was used as a standard. The samples were prepared to the same concentration (3.6 mg / mL) with T-PER buffer and then heated at 95°C for 10 minutes in 1x reduced loading buffer to produce a final concentration of 3 mg / mL. Next, 30ug of total protein from each sample was loaded onto a 4-20% standard TGX gel (Bio-Rad, Cat. 5671085) for electrophoresis. Images were collected by Azure Biosystem C600 using the NIR-700 channel. GIMP2.10.28 was used to process images.

[0546] Fig.17 Shown the time-dependent pattern of free and EGFR cross-linked sdAb in tumors in A431 (EGFR+) and COLO320DM (EGFR-). Free sdAb was detected in the approximately 15kD region (lower figure, labeled as free VHH), and EGFR cross-linked sdAb bands were detected in the approximately 175kD region (upper figure, labeled as VHH-EGFR cross-linking). In EGFR+A431 tumors, time-dependent cross-linking of EGFR with C23-FSY was observed, but time-dependent cross-linking with C23-TYR was not observed. Free sdAb retention was not observed in EGFR-COLO320DM tumors, and cross-linking was not observed.

[0547] Ex vivo IVIS imaging data analysis: Tumors were dissected and imaged with AMI HTX; imaging data were analyzed using Aura software (Spectral Instruments imaging, version 4.0.7). Mean radiant efficiency values ​​were obtained by creating ROIs around individual tumors (Ellipse ROI tool in Aura). Total emission (photons / s) was measured and recorded. Total emission values ​​were normalized to tissue weight (photons / s / g). Statistical significance was determined in Prism (v 9.1.0 (221)) using a paired T test (* = p ≤ 0.05, ** = p ≤ 0.005). Figure 18 shows ex vivo imaging of A431 and COLO320DM tumor tissues 8 hours and 24 hours after administration of C23-FSY and C23-TYR.

[0548] Fig.18A Photons / s / g tumor tissue in three biological replicates are shown. Values ​​from a single animal are shown, the center bar shows the mean intensity, and the error bars represent the SEM (* indicates p=0.024, ** indicates p=0.002 by paired t-test). At both the 8 and 24 hour time points, C23-FSY levels were significantly higher in A431 tumors compared to C23-TYR protein. After 24 hours, C23-TYR was observed at very low levels in A431 tumor tissue, while C23-FSY, especially the EGFR-VHH cross-linked species, was prominent ( Fig.17 , 18A). Since the test articles have similar affinities ( Fig.16 ), these results together suggest that the tumor AUC of FSY-containing sdAbs can be increased by covalency.

[0549] Fig.18B Quantitative ex vivo fluorescence intensity of A431 and COLO320DM tumors of animals administered C23-FSY at 8 hours and 24 hours after administration is shown. The figure shows the photons / s / g tumor tissue in three biological replicates. The values ​​from a single animal are shown, the center bar shows the average intensity, and the error bars represent the SEM. At the 8-hour and 24-hour time points, the level of C23-FSY in the A431 tumor was significantly higher than the amount in the EGFR-COLO320DM tumor, indicating the specificity of the tumor locking of the C23-FSY protein.

[0550] These results suggest that targeting domains (such as sdAbs) with cross-link-compatible unnatural amino acids can carry payloads (here, imaging dyes) to tumors with target specificity and can also improve retention of the payload at the target site compared to targeting domains without cross-link-compatible unnatural amino acids.

[0551] Example 21 In vivo PSMA tumor targeting using targeted imaging payloads

[0552] This study evaluated the in vivo PSMA cross-linking, systemic, and intratumoral exposure of fluorescently labeled sdAbs in the LNCaP mouse prostate cancer xenograft tumor model.

[0553] PSMA-targeted sdAbs conjugated to AZ Dye680 were prepared using C29-101TYR and C29-101FSY (SEQ ID NO: 53 or 54) (with TYR or FSY at position 101) according to the method of Example 19 to produce C30-TYR and C30-FSY (SEQ ID NO: 55, 56, respectively). LNCaP cells were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum at 37°C and 5% CO2 in a humidified environment. On the day of implantation, cells were harvested, washed in serum-free medium, counted, and resuspended in cold serum-free medium. The cell pellet was resuspended in 50 μL serum-free RPMI and mixed with 50 μL Matrigel to a final concentration of 5 x 10 6 A volume of 100 μL containing 5 million LNCaP cells was implanted into the right upper flank of male NU / J mice (Jackson Labs). When the tumor size reached approximately 200 mm 3 5mg / kg of C30-TYR or C30-FSY was injected into the tail vein at a volume of 10mL / kg. Peripheral blood samples were collected via cheek bleeding 0.5 hours after administration to confirm the accuracy of administration. As shown in Table 17, the biodistribution of the test article was studied at 8 different time points (before administration, 15 minutes, 1h, 6h, 24h, 48h, 72h and 96h after administration). After euthanasia, tumor tissue was harvested, weighed, IVIS ex vivo imaging, and then quickly frozen for Western blot analysis.

[0554] Table 17 PK sampling time points

[0555]

[0556] Tissue processing, protein quantification, and normalization were performed using the method of Example 20. To quantify free and PSMA-crosslinked sdAb test products, a 2-fold 16-point standard curve of C30-FSY was prepared starting from 500 ng / mL in T-PER buffer. The standards were heated at 95°C for 10 minutes in 1x reducing loading buffer. Different ranges of standards were used for different gels based on estimates of the concentration of the test product in the sample. Using the linear fit function in Excel, a standard curve was generated using the band area of ​​the standard relative to its concentration. The density of the band in the image was determined using ImageJ 1.51j8 as described (https: / / imagej.nih.gov / ij / docs / guide / 146-30.html#infobox:Densitometry, Section 30.13). After obtaining the area of ​​the sample band with ImageJ, the amount of TA in the lane was calculated using the formula derived from the linear fit of the standard curve. When 30 μg of total protein was loaded, the amount of TA in the lane was also the amount of TA in 30 μg of total protein. Tumor sdAb concentration (pg sdAb / mg tumor tissue) = sdAb amount in lane (pg) * (protein concentration (mg / ml) * (0.5ml*1000 / 30μg) / tumor tissue weight (mg). The resulting standard curve contained at least 5 points with R2>0.99. The area under the curve (AUC) was calculated using the trapezoidal rule using GraphPad Prism, where the area between two adjacent points was calculated as ΔX*([(Y1+Y2) / 2]-baseline] (https: / / www.graphpad.com / guides / prism / latest / statistics / stat_area_under_the_curve.htm). The AUC for C30-TYR was 1676, and the AUC for C30-FSY was 4902.

[0557] Fig.19 Fluorescence images of SDS-PAGE gels are shown, showing the time-dependent manner of free sdAb and PSMA-crosslinked sdAbs associated with tumors after application of C30-TYR and C30-FSY. At the specified time point after treatment, tumors were collected and processed for gel electrophoresis to detect sdAb test products conjugated with fluorophores. Free (non-crosslinked) sdAb-AF680 (bottom figure) was detected in the approximately 20kD region, and the PSMA-crosslinked sdAb-AF680 species of C30-FSY migrated in the 100kD region (top figure). Lanes marked with * show vehicle samples.

[0558] Fig. 20Quantitative analysis of tumor-associated free and PSMA cross-linked test products is shown. Fluorescence band intensities of free and PSMA cross-linked species bands from the above gels were quantified via densitometry and compared with standard curves. A graph of the total concentration of test products in the tumor (free and cross-linked PSMA, pg / mg tumor tissue) versus time (h) was plotted. Data points indicated with * represent samples below the limit of detection and quantification. Tumor exposure of C30-FSY increased to approximately 3x relative to non-covalent C30-TYR.

[0559] Example 22 Delivery of cytotoxic payloads

[0560] C25 and C27 sdAbs were prepared with and without FSY substitution to generate C25-54TYR, C25-54FSY, C27-101TYR and C27-101FSY (SEQ ID NOs: 45, 46, 49, 50, respectively). Proteins were expressed and purified according to the general method of Example 2, except that after elution from the Ni-NTA resin, the purified protein buffer was exchanged into anion exchange running buffer (20 mM Tris, 7.5 and 20 mM NaCl) at 4°C with a dilution factor of 1:100 overnight. The dialyzed sample pool was passed through HiTrap Q XL 5 ml columns (Cytiva #17515801) in flow-through mode, where endotoxin was bound to the column. The sdAb monomer flow-through portion was analyzed by reducing SDS-PAGE and merged.

[0561] The sdAb construct was conjugated to MC-PEG8-VC-PABC-MMAE (structure shown below) to form C26-54TYR, C26-54 FSY, C28-101TYR, and C28-101FSY. The sample was first reduced with 1 mM EDTA and 1.5 equivalents of TCEP (10 mM in deoxygenated water) and incubated at room temperature for 1 hour. After reduction, any residual TCEP was removed using a Zeba Spin desalting column (Thermo P / N89891, 7K MWCO), and 1 mM EDTA in 1X PBS was used as an equilibrium buffer. Propylene glycol (PG) and dimethylacetamide (DMA) were added to the reaction mixture (Cf = 10% v / v) to increase the solubility of the linker payload, and 1.5 equivalents of the linker payload were added. The reaction was gently vortexed and incubated overnight at 4°C. The conjugate mixture was added to a pre-hydrated dialysis cassette (approximately 1 ml sample: 3500 mL buffer volume) and dialyzed for at least 2 hours. The dialysis buffer was replaced and the sample was dialyzed overnight at 4 ° C before removal for analysis by A280 and analysis of SEC. The unconjugated linker payload was removed using a Cytiva PD-10 column (4.3 mL Sephadex G-25 adsorbent per column) according to the standard PD-10 rotation protocol (equilibrium buffer: 1xPBS, pH 7.4). After collecting the eluate, the column was rinsed with another 1 mL of 1X PBS at pH 7.4. After purification on PD-10, the sample was subjected to a final dialysis step using 50 mL 1xPBS using a Thermo Scientific Slide-A-Lyzer mini dialysis device (3.5k MWCO). All samples were passed through a 0.2 μm sterile PES filter and stored at -20 ° C.

[0562] MC-PEG8-VC-PABC-MMAE:

[0563]

[0564] To measure the ability of FSY-containing sdAb conjugates to specifically deliver cytotoxic payloads to immortalized PSMA-expressing tumor cell lines in vitro compared to non-covalent sdAb conjugates, the cell permeable payload monomethyl auristatin was conjugated to the sdAb at a drug-antibody ratio (DAR) of 1. PC3pip cell lines engineered to express PSMA and PC3 fluPSMA-negative cell lines (provided by Professor Xinning Wang and Professor Warren D. Heston of Case Western Reserve University, Cleveland, OH) were maintained at 37°C in a humidified atmosphere with 5% CO2 in growth medium consisting of RPMI-1640 (Thermo Scientific, 11875-903) supplemented with 10% heat-inactivated fetal bovine serum (Thermo Fisher, FB-12). Use TrypLE Express (Thermo Scientific, 14175-095) to harvest cells in the exponential growth phase and inoculate in 100 μ L growth medium with 800 cells / well in black 96-well flat transparent bottom plates (Costar, 3603). Then the cells were incubated overnight in a humidified environment of 37 ° C, 5% CO2 to allow the cells to adhere to the plate. The sdAb-MMAE conjugates listed in the following table were diluted to 50x final concentration in growth medium and diluted in 3 times increments to form a 10-point dilution series. Each 2 μ L volume of each 50x test article dilution series was added to the wells in triplicate to reach 1x final concentration (the highest concentration of each series indicated in Table 18).

[0565] Table 18. Test article conjugates

[0566] name Highest concentration in the dose response (1X) C26-54TYR 158nM C26-54FSY 137nM C28-101TYR 208nM C28-101FSY 127nM

[0567] The plates were returned to the incubator for 4 days, after which cell viability was assessed. CellTiter G1o (Promega, G5737) was added to all plates at 50 μL / well, and the plates were shaken at 1000 rpm for one minute at room temperature. Luminescence was then read on a Victor X5 plate reader (PerkinElmer) and reported as relative luminescence units (RLU). Viability was calculated in Excel (Microsoft 365MSO, Version 2202Build 16.0.14931.20128, 64-bit ), % viability = 100*(treated RLU / untreated RLU). Data were plotted in GraphPad Prism (V9.3.1) as % viability vs. concentration of test article, and IC50 was calculated using log [inhibitor] and response-variable slope (four parameters).

[0568] It was observed that the sdAb-PEG8-VC-PABC-MMAE conjugate had very low levels of cytotoxic activity against the PC3flU cell line, which is consistent with the lack of PSMA target expression on this cell line. The estimated affinity of C26-54TYR for PMSA was 14.9nM (as shown for the non-conjugated compound on LNCaP cells in Example 14), showing a dose-dependent increase in cytotoxicity against PC3pip cells, which is consistent with the targeted delivery of payloads via PSMA binding and internalization. As shown in Table 19, the efficacy of C26-54FSY in delivering payloads is 3.57x that of C26-54TYR, indicating that covalency enhances the cellular efficacy of single-domain antibody drug conjugates. In the second example, C28-101TYR, which has an affinity for PSMA>500nM, has low cytotoxic activity against PC3pip cells, while the cross-linking activity of C28-101FSY shifts the efficacy by more than 400x, confirming the effect of covalency on cellular efficacy. Fig.21A (C26 construct) and Fig.21B (C28 construct) shows a comparison of the cytotoxicity of the test articles, which shows the concentration of sdAb conjugated to MMAE and the cell viability rate curve. After incubation with sdAb-PEG8-VC-PABC-MMAE conjugate for 4 days, the viability of PSMA+PC3pip and PSMA-PC3flu cells was assessed by CellTiter-Glo assay. Dose response analysis was performed in triplicate, symbols represent mean values, and error bars represent STDEV.

[0569] Table 19. IC50 values ​​of cytotoxicity of sdAb-PEG8-VC-PABC-MMAE conjugates

[0570]

[0571] Example 23 Delivery of cytotoxic payloads to HER2 targets

[0572] HER2-targeted sdAb (C17; SEQ ID NO: 31) was evaluated to identify independent positions of FSY insertion that provide cross-linking with the HER2 target. The sdAb was generally cloned, expressed and purified according to the method of Example 2, except that a specific single site was selected for modification and testing, rather than using a combined screen. The selected sites for FSY insertion are shown in Table 20.

[0573] Table 20. Interesting FSY insertion sdAb library with target HER2

[0574]

[0575] Positions 52 and 54 were identified as cross-linking to the HER2 target. To evaluate the FSY cross-linking kinetics, the 52FSY and 54FSY variants of C17 were incubated with the Her2 receptor and the cross-linking efficiency was examined. Fig. 22 As shown, the 54FSY site was found to have the highest cross-linking rate, with >90% cross-linking within one hour, while 52FSY reached 90% cross-linking within 2 hours. These two constructs, and their non-FSY (TYR) counterparts, were selected for conjugation with cytotoxic payloads.

[0576] Table 21 Conjugates based on C17 variants

[0577] name C33-54FSY C33-52FSY C33-52TYR C33-54TYR

[0578] In order to conjugate the sdAb construct with GGG-PEG8-vc-PABC-MMAE, C32-54TYR, C32-54 FSY, C32-52TYR and C32-52FSY compounds were purified as described above. The compound was incubated in PBS at pH 7.4, incubated with 1mM CaCl2, 10 equivalents of linker payload (10mM stock solution in 10% DMA) and sortase (2mg sortase / 10mg sdAb), and incubated overnight at 4°C. The reaction was bound to 2mL (PBS balanced) Ni resin in batches to remove sortase and unconjugated materials, and rotated at room temperature for 30 minutes. The beads were rotated to facilitate the separation of the resin from the unbound portion (700g x10min, 20C), and the remaining protein was collected by loading into a glass column and washing the beads with PBS, and the flow-through was collected. The flow-through and washes were combined and concentrated (5K MWCO, 4k rcf, 10C, 1.5h) and loaded onto HiLoad 26 / 600 Superdex 75pg (Cytiva, #28-9893-34) to remove unconjugated dye. Fractions were collected and analyzed by SDS-PAGE, combined, and stored at -80°C.

[0579] GGG-PEG8-VC-PABC-MMAE:

[0580]

[0581] The binding of C33 conjugates containing TYR or FSY at positions 52 and 54 (Table 21) to the human breast cancer line BT-474 (HER2+) was evaluated. The protein was diluted to 3 μM (1× final) in FACS buffer (1×PBS+2% HI-FBS+5mM EDTA) and then serially diluted 3× to generate 8 concentration points for the assay, with the lowest concentration being 0.00384 μM (1× final).

[0582] BT-474 cell line (ATCC HTB-20) was maintained at 37°C in a humidified atmosphere with 5% CO2 in a growth medium consisting of RPMI-1640 (Thermo Scientific, 11875-903) supplemented with 10% heat-inactivated fetal bovine serum (Thermo Fisher, FB-12). Cells were harvested during the exponential growth phase and cultured at 1.0×10 6 / mL is resuspended in ice-cold FACS buffer (PBS pH6.0 / 2% FBS / 5mM EDTA) of pH 6.0 and aliquoted into v-bottom 96-well plates (Corning 3897) at 100 μL / well. The cells are precipitated at 2000rpm for 2 minutes and then resuspended in a titration of the test article in pH6.0 FACS buffer in duplicate, 100 μL / well. After incubation on ice for 2 hours, the cells are precipitated at 2000rpm for 2 minutes and then washed twice with 200 μL FACS buffer. The cells are then resuspended in 100 μL ice-cold FACS buffer (pH 7.4) containing AF488 goat anti-alpaca VHH antibody (Jackson ImmunoResearch 128-547-232) diluted 1:100. After incubation on ice for 30 minutes, cells were pelleted at 2000 rpm for two minutes, washed twice with 200 μL FACS buffer, then resuspended in 100 μL FACS buffer, pH 7.4, and analyzed using a NovoCyte flow cytometer (ACEA / Aglient).

[0583] FlowJo 10.7.2 is used to analyze raw data (FCS files). FSC-A and SSC-A are used to identify total intact cells, and then FSC-A is used for FSC-H gated single peak. The geometric mean fluorescence intensity of sample AF488 is used for further analysis and drawing. Using 'log (agonist) and response-variable slope (four parameters)', the geometric mean fluorescence intensity (GeoMean or GeoMFI) of AF488 channel is used to calculate EC50 in GraphPad Prism (V9.3.1). The test article is combined with BT-474 cells in a dose-dependent manner. As shown in Table 22, the binding affinity of the test article is measured according to the EC50 value after staining and flow cytometry of BT-474 cells.

[0584] Table 22. Binding affinity of BT-474 cells

[0585] Test article (conjugate) EC50(nM)pH6.0 C33-54FSY4 .6 C33-54TYR2 .5 C33-52FSY 49 C33-52TYR 160

[0586] The conjugate is then used for cell-based assays to measure the ability of covalent sdAb conjugates and non-covalent sdAb conjugates to specifically deliver cytotoxic payloads to immortalized HER2 expressing tumor cell lines in vitro. Maintain BT-474 cell line as described above. Cells were harvested in the exponential growth phase using TrypLE Express (Thermo Scientific, 14175-095) and inoculated with 5000 cells / well in 100 μL growth medium in black 96-well flat transparent bottom plates (Costar, 3603). The cells were then incubated overnight in a humidified environment at 37 ° C, 5% CO2, so that the cells adhered to the plate. The next day, a plate was analyzed by CTG to determine the background. The remaining plates were treated with C33-TYR and C33-FSY conjugates as follows: the conjugates listed in Table 23 were diluted to 11x final concentrations (1.1 μM) in growth medium, and then diluted in 5-fold increments to form a 10-point dilution series. Each of t...

Claims

1. A conjugate comprising a targeting domain and a payload, wherein the targeting domain comprises at least one unnatural amino acid (UAA) residue, wherein the targeting domain is configured to bind to a target, and wherein when the targeting domain binds, the UAA residue is sufficiently close to form a covalent bond with the target.

2. The conjugate of claim 1, wherein the payload is attached to an amino acid at position n+x relative to the UAA residue, wherein n is the position of the amino acid and x is at least 1.

3. The conjugate of claim 1, wherein the payload is attached to an amino acid at position nx relative to the UAA residue, wherein n is the position of the amino acid and x is at least 1.

4. The conjugate of any one of claims 1 to 3, wherein when the targeting domain binds to the target, the UAA residue is within 5-20 angstroms of the target.

5. The conjugate of claim 4, wherein the targeting domain binds to a cell surface molecule. The conjugate of claim 5 , wherein the cell surface molecule is a tumor-associated antigen.

7. The conjugate of any one of claims 1-6, wherein the UAA residue is configured to form a covalent bond with a histidine, lysine, or tyrosine residue of the target.

8. The conjugate of any one of claims 1-7, wherein the UAA residue comprises a fluorosulfate moiety.

9. The conjugate of any one of claims 1-7, wherein the UAA residue comprises an aryl fluorosulfate moiety.

10. The conjugate of claim 9, wherein the UAA residue comprises Formula I:

11. The conjugate of claim 9, wherein the UAA of the UAA residue has the structure:

12. The conjugate of claim 9, wherein the UAA of the UAA residue has the structure:

13. The conjugate of claim 9, wherein the UAA residue comprises Formula II:

14. The conjugate of claim 9, wherein the UAA of the UAA residue has the structure:

15. The conjugate of claim 9, wherein the UAA of the UAA residue has the structure:

16. The conjugate of claim 9, wherein the UAA residue comprises Formula III:

17. The conjugate of claim 9, wherein the UAA of the UAA residue has the structure:

18. The conjugate of claim 9, wherein the UAA of the UAA residue has the structure:

19. The conjugate of any one of claims 1-7, wherein the UAA of the UAA residue has a structure of Formula (IA): in, Each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; L is -(CH2) p -or-C(O)NH-(CH2) p -; p is an integer from 1 to 6; and When Y is -O- or -NR-, m is 1; when Y is -N=, m is 2.

20. The conjugate of claim 19, wherein the UAA of formula (IA) has formula (IA-a): structure.

21. The conjugate of claim 19, wherein the UAA of formula (IA) has formula (IA-b): structure.

22. The conjugate of claim 19, wherein the UAA of formula (IA) has a structure of formula (IB):

23. The conjugate of claim 19, wherein the UAA of formula (IA) has a structure of formula (IC):

24. The conjugate of claim 19, wherein the UAA of formula (IA) has a structure of formula (ID): in: Each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

25. The conjugate of claim 19, wherein the UAA of formula (IA) has a structure of formula (IE): in: Each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

26. The conjugate of claim 19, wherein the UAA of formula (IA) has the structure of formula (IIA): in: X is independently O or NR'; and When present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

27. The conjugate of claim 19, wherein the UAA of formula (IA) has the structure of formula (IIB): in: X is independently O or NR'; and When present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

28. The conjugate of any one of claims 1-7, wherein the UAA of the UAA residue has formula (IV) The structure, in, Each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; Ring A is a 5- to 6-membered aryl or heteroaryl group; Each R A are independently -OH, -OR X , halogen, NHR X 、N(R X )2 or optionally substituted alkyl; each R X is an optionally substituted alkyl group; L is -(CH2) p -or-C(O)NH-(CH2) p -; p is an integer from 1 to 6; and When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

29. The conjugate of any one of claims 1-28, further comprising at least one additional targeting domain.

30. The conjugate of any one of claims 1-29, wherein the payload comprises an imaging agent, a radioligand agent, or a cytotoxic agent.

31. The conjugate of claim 30, wherein the cytotoxic moiety comprises a small molecule drug or a chemotherapeutic drug.

32. The conjugate of claim 30, wherein the radioligand agent is selected from 35 S. 3 H. 111 In, 112 In, 14 C. 186 Re, 188 Re, 32 P. 153 Sm, 177 Lu, 86 Y. 88 Y. 90 Y. 131 I. 123 I. 124 I. 125 I. 149 Tb, 211 At 212 Pb / 212 Bi, 213 Bi, 223 Ra, 225 Ac, 64 Cu, 67 Cu and 227 Th.

33. The conjugate of claim 31 or claim 32, wherein the radioligand agent further comprises a chelating agent.

34. The conjugate of claim 30 or claim 33, wherein the radioligand agent is selected from 99m Tc, 131 I. 201 Tl, 111 In and 67 Ga.

35. The conjugate of any one of claims 1-34, wherein the payload is attached to the conjugate with a linker.

36. The conjugate of claim 35, wherein the linker comprises a polymer.

37. The conjugate of claim 35, wherein the linker is a cleavable or non-cleavable linker.

38. The conjugate of claim 35, wherein the linker is 0.01 kDa to 50 kDa.

39. The conjugate of claim 35, wherein the linker is 0.01 kDa to 10 kDa.

40. The conjugate of any one of claims 35-39, wherein the linker is linear, branched, polymeric or dendritic.

41. The conjugate of claim 40, wherein the linker is a bifunctional or multifunctional linker or a bifunctional or multifunctional polymer.

42. The conjugate of any one of claims 35-41, wherein the linker comprises a water soluble polymer.

43. The conjugate of claim 42, wherein the water soluble polymer is polyethylene glycol (PEG).

44. The conjugate of claim 43, wherein the molecular weight of the PEG is between 0.1 kDa and 2.5 kDa.

45. The conjugate of claim 43, wherein the PEG comprises 1-8 monomers.

46. ​​The conjugate of any one of claims 1-45, wherein the targeting domain comprises an antibody, an antibody fragment, or an antigen binding domain.

47. The conjugate of claim 46, wherein the targeting domain comprises an antigen binding domain, the conjugate comprises a CDR region, and the at least one UAA is within or near the CDR region.

48. The conjugate of claim 47, wherein the UAA is contained within the CDR region.

49. The conjugate of any one of claims 46-48, wherein the targeting domain comprises a single domain antibody (sdAb).

50. The conjugate of any one of claims 5-49, wherein the cell surface molecule is selected from PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPa, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3 rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, CD 73. ITGaVb3, ITGaVb6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD25, 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, EphA2, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47, and EpCAM.

51. A conjugate comprising (i) a payload and (ii) an engineered single domain antibody (sdAb), the engineered single domain antibody comprising a sdAb having a CDR region and at least one unnatural amino acid (UAA) residue within or near the CDR region, wherein the sdAb comprises any one of SEQ ID NO: 1-4 or 16-64.

52. The conjugate of claim 51, wherein the UAA residue comprises a fluorosulfate moiety.

53. The conjugate of claim 52, wherein the UAA residue comprises an aryl fluorosulfate moiety.

54. The conjugate of claim 53, wherein the UAA residue comprises Formula I:

55. The conjugate of claim 53, wherein the UAA of the UAA residues has the structure:

56. The conjugate of claim 53, wherein the UAA of the UAA residues has the structure:

57. The conjugate of claim 53, wherein the UAA residue comprises Formula II:

58. The conjugate of claim 53, wherein the UAA of the UAA residues has the structure:

59. The conjugate of claim 53, wherein the UAA of the UAA residues has the structure:

60. The conjugate of claim 53, wherein the UAA residue comprises Formula III:

61. The conjugate of claim 53, wherein the UAA of the UAA residues has the structure:

62. The conjugate of claim 53, wherein the UAA of the UAA residues has the structure:

63. The conjugate of claim 53, wherein the UAA of the UAA residue has a structure of Formula (IA): in, Each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; L is -(CH2) p -or-C(O)NH-(CH2) p -; p is an integer from 1 to 6; and When Y is -O- or -NR-, m is 1; when Y is -N=, m is 2.

64. The conjugate of claim 63, wherein the UAA of Formula (IA) has Formula (IA-a): structure.

65. The conjugate of claim 63, wherein the UAA of formula (IA) has formula (IA-b): structure.

66. The conjugate of claim 63, wherein the UAA of Formula (IA) has the structure of Formula (IB):

67. The conjugate of claim 63, wherein the UAA of Formula (IA) has the structure of Formula (IC):

68. The conjugate of claim 63, wherein the UAA of Formula (IA) has the structure of Formula (ID): in: Each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

69. The conjugate of claim 62, wherein the UAA of Formula (IA) has the structure of Formula (IE): in: Each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

70. The conjugate of claim 63, wherein the UAA of Formula (IA) has the structure of Formula (IIA): in: X is independently O or NR'; and When present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

71. The conjugate of claim 63, wherein the UAA of Formula (IA) has the structure of Formula (IIB): in: X is independently O or NR'; and When present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

72. The conjugate of claim 51, wherein the UAA of the UAA residue has formula (IIV) The structure, in, Each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; Ring A is a 5- to 6-membered aryl or heteroaryl group; Each R A are independently -OH, -OR X , halogen, NHR X 、N(R X )2 or optionally substituted alkyl; each R X is optionally substituted alkyl; and When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

73. The conjugate of any one of claims 51-72, wherein the engineered sdAb comprises SEQ ID NO: 1, and wherein the UAA is contained in any one of SEQ ID NOs: 5, 6, and 7.

74. The conjugate of claim 73, wherein the UAA is present at an amino acid position selected from 26, 28, 29, 30, 99, 102, 103, 105, 108, 110, 111, 112, 113, 114, and 115 relative to SEQ ID NO:

1.

75. The conjugate of any one of claims 51-72, wherein the engineered sdAb comprises SEQ ID NO: 2, and wherein the UAA is contained in any one of SEQ ID NOs: 8, 9, and 10.

76. The conjugate of claim 75, wherein the UAA is present at an amino acid position selected from 50, 52, 53, 54, 56, 58 and 100 relative to SEQ ID NO:

2.

77. The conjugate of any one of claims 51-72, wherein the engineered sdAb comprises SEQ ID NO:3, and wherein the UAA is contained in any one of SEQ ID NOs: 11, 12, and 13.

78. The conjugate of claim 77, wherein the UAA is present at an amino acid position selected from 58, 62, 101, 103 and 107 relative to SEQ ID NO:

3.

79. The conjugate of any one of claims 51-72, wherein the engineered sdAb comprises SEQ ID NO: 16, and wherein the UAA is present at amino acid position 109 relative to SEQ ID NO:

16.

80. The conjugate of any one of claims 51-72, wherein the engineered sdAb comprises SEQ ID NO:25, and wherein the UAA is present at an amino acid position selected from 52, 53, 54, 55, 56, 58, 60, 62, and 64 relative to SEQ ID NO:

23.

81. The conjugate of any one of claims 51-72, wherein the engineered sdAb comprises SEQ ID NO:26, and wherein the UAA is present at an amino acid position selected from 53, 55, 56, 57, 58, 60, 64, and 67 relative to SEQ ID NO:

24.

82. The conjugate of any one of claims 51-81, wherein the payload is not attached via the UAA side chain.

83. The conjugate of any one of claims 51-82, wherein the payload comprises an imaging agent, a radioligand agent, or a cytotoxic agent.

84. The conjugate of claim 83, wherein the cytotoxic moiety comprises a small molecule drug or a chemotherapeutic drug.

85. The conjugate of claim 83, wherein the radioligand agent is selected from 35 S. 3 H. 111 In, 112 In, 14 C. 186 Re, 188 Re, 32 P. 153 Sm, 177 Lu, 86 Y. 88 Y. 90 Y. 131 I. 123 I. 124 I. 125 I. 149 Tb, 211 At 212 Pb / 212 Bi, 213 Bi, 223 Ra, 225 Ac, 64 Cu, 67 Cu and 227 Th.

86. The conjugate of claim 83 or claim 85, wherein the radioligand agent further comprises a chelator.

87. The conjugate of claim 83, wherein the imaging agent comprises a fluorophore or is selected from 99m Tc, 131 I. 201 Tl, 111 In and 67 Ga radioligand reagent.

88. A method comprising administering the conjugate of any one of claims 1-87, wherein the conjugate covalently binds to a target on the surface of a cell.

89. The method of claim 88, wherein the cells comprise tumor cells.

90. The method of claim 89, wherein the conjugate kills the tumor cell or inhibits the growth of the tumor cell.

91. The method of any one of claims 88-90, wherein the target is a tumor-associated antigen.

92. The method of any one of claims 88-91, wherein the target is selected from PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPa, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, CD73, IT GaVb3, ITGaVb6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD25, 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, EphA2, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47 and EpCAM.

93. A method of treating a disease or condition comprising administering to a subject in need thereof a conjugate as described in any one of claims 1-92.

94. The method of claim 93, wherein the disease comprises PRAD (prostate adenocarcinoma), mCRPC (metastatic castration-resistant prostate cancer), solid tumors (neovasculature), LUAD (lung adenocarcinoma), LUSC (lung squamous cell carcinoma), HNSC (head and neck squamous cell carcinoma, THCA (thyroid cancer), ESCA (esophageal cancer), STAD (gastric adenocarcinoma), GIST (gastrointestinal stromal tumor), COAD (colon adenocarcinoma), READ (rectal adenocarcinoma), SARC (sarcoma), SCLC (small cell lung cancer), MESO (mesothelioma), PAAD (pancreatic adenocarcinoma), B cell malignancies, T cell malignancies, ALL (acute lymphoblastic leukemia), NHL (non-Hodgkin's lymphoma) , HL (Hodgkin's lymphoma), CLL (chronic lymphocytic leukemia), AML (acute myeloid leukemia), MDS (myelodysplastic syndrome), MSI-high tumors, SKCM (cutaneous melanoma), UVM (uveal melanoma), DLBC (diffuse large B-cell lymphoma), endometrial cancer, CESC (cervical cancer), bone cancer, BLCA (bladder urothelial carcinoma), BRCA (invasive breast cancer), TNBC (triple negative breast cancer), LIHC (hepatocellular carcinoma), OV (ovarian serous cystadenocarcinoma), UCEC (uterine corpus endometrial carcinoma), NE-PCa (neuroendocrine prostate cancer), GBM (glioblastoma multiforme) and KIRC (renal clear cell carcinoma).

95. A method of making the conjugate of any one of claims 1 to 87, comprising: (a) generating said targeting domain comprising at least one unnatural amino acid; and (b) conjugating the targeting domain to a payload, optionally via a linker.

96. The method of claim 95, wherein the targeting domain comprising at least one unnatural amino acid is synthesized in vivo.

97. The method of claim 96, wherein generating comprises using an orthogonal tRNA synthetase / suppressor tRNA pair.

98. The method of claim 97, wherein generating comprises the orthogonal tRNA synthetase / suppressor tRNA pair, which is derived from a pyrrolysine tRNA synthetase / tRNA Pyl .

99. The method of claim 97, wherein the orthogonal tRNA synthetase comprises SEQ ID NO: 84, 87, 92, or a variant thereof.

100. A method of delivering a cytotoxic payload to a cell, comprising administering a conjugate as described in any one of claims 30-33, 35-50, or 83-86, wherein the conjugate covalently binds to a target on the surface of the cell, thereby delivering the cytotoxic payload.

101. The method of claim 100, wherein the cell is a tumor cell.

102. The method of claim 100, wherein the cell is contained within a tumor microenvironment.

103. The method of claim 100, wherein the cell is contained within a mammalian subject.

104. The method of claim 100, wherein the cell is contained within a human subject.

105. The method of any one of claims 100-104, wherein the conjugate kills the tumor cell or inhibits the growth of the tumor cell.

106. The method of any one of claims 100-105, wherein the target is selected from PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPa, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3 rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, CD73, ITGaVb3, ITGaVb6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD 25, 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47, and EpCAM.

107. The method of any one of claims 100-106, wherein the human subject has or is diagnosed with a disease or condition selected from the group consisting of PCa (prostate cancer), CRPCa (castration-resistant prostate cancer), solid tumors (neovasculature), NSCLC (non-small cell lung cancer), HNSCC (head and neck squamous cell carcinoma), ESCC (esophageal cancer), GC (gastric cancer), CRC (colorectal cancer), SCLC (small cell lung cancer), MPM (mesothelioma), PDAC (ductal pancreatic adenocarcinoma), ALL (acute lymphoblastic leukemia), AML (acute myeloid leukemia), MDS (myelodysplastic syndrome), MSI-high tumors, melanoma, DLBCL (diffuse large B-cell lymphoma), endometrial cancer, cervical cancer, bladder cancer, BrCa (breast cancer), TNBC (triple negative breast cancer), NE-PCa (neuroendocrine prostate cancer), GBM (glioblastoma) and RCC (renal cell carcinoma).

108. A conjugate comprising (i) a first targeting domain, (ii) a second targeting domain, and optionally (iii) a payload, wherein the first targeting domain comprises at least one first unnatural amino acid (UAA), whereby the first targeting domain is capable of covalently binding to a first target at the site of the UAA, and the second targeting domain is configured to bind to a second target.

109. The conjugate of claim 108, wherein the first target and the second target are located on the same cell.

110. The conjugate of claim 108 or claim 109, wherein the first targeting domain comprises an antibody, antibody fragment, or an antigen binding domain.

111. The conjugate of claim 110, wherein the first targeting domain comprises a single domain antibody (sdAb).

112. The conjugate of any one of claims 108-111, wherein the first UAA is contained within or near a region of the first targeting domain that is adjacent to the first target.

113. The conjugate of any one of claims 108-112, wherein the second targeting domain comprises an antibody, an antibody fragment, or an antigen binding domain.

114. The conjugate of claim 113, wherein the second targeting domain comprises a single domain antibody (sdAb).

115. The conjugate of any one of claims 108-114, wherein the first targeting domain and the second targeting domain are linked to form a fusion protein.

116. The conjugate of any one of claims 108-114, wherein the first targeting domain and the second targeting domain are linked by chemical conjugation.

117. The conjugate of claim 115 or claim 116, wherein the first targeting domain and the second domain are connected by a linker.

118. The conjugate of any one of claims 108-117, wherein the first targeting domain and the second targeting domain bind to the same target.

119. The conjugate of claim 118, wherein the first targeting domain and the second targeting domain bind to different epitopes of the same target.

120. The conjugate of claim 118, wherein the first targeting domain and the second targeting domain bind to the same epitope of the same target.

121. The conjugate of any one of claims 118-120, wherein the same target is a monomer.

122. The conjugate of any one of claims 118-120, wherein the same target is a multimeric molecule.

123. The conjugate of any one of claims 108-117, wherein the first targeting domain and the second targeting domain bind different targets.

124. The conjugate of any one of claims 108-123, wherein the first target is a first cell surface molecule.

125. The conjugate of any one of claims 108-124, wherein the second target is a second cell surface molecule.

126. The conjugate of any one of claims 108-125, wherein the at least one first UAA comprises a fluorosulfate moiety.

127. The conjugate of any one of claims 108-125, wherein the at least one UAA comprises an aryl fluorosulfate moiety.

128. The conjugate of claim 127, wherein the at least one first UAA comprises Formula I:

129. The conjugate of claim 127, wherein the at least one first UAA has the structure:

130. The conjugate of claim 127, wherein the at least one first UAA has the structure:

131. The conjugate of claim 127, wherein the at least one first UAA comprises Formula II:

132. The conjugate of claim 127, wherein the at least one first UAA has the structure:

133. The conjugate of claim 127, wherein the at least one first UAA has the structure:

134. The conjugate of claim 127, wherein the at least one first UAA comprises Formula III:

135. The conjugate of claim 127, wherein the at least one first UAA has the structure:

136. The conjugate of claim 127, wherein the at least one first UAA has the structure:

137. The conjugate of any one of claims 108-125, wherein the at least one first UAA has a structure of Formula (IA): in, Each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; L is -(CH2) p -or-C(O)NH-(CH2) p -; p is an integer from 1 to 6; and When Y is -O- or -NR-, m is 1; when Y is -N=, m is 2.

138. The conjugate of claim 137, wherein the at least one first UAA has formula (IAa): structure.

139. The conjugate of claim 137, wherein the at least one first UAA has Formula (IAb): structure.

140. The conjugate of claim 137, wherein the at least one first UAA has a structure of Formula (IB):

141. The conjugate of claim 137, wherein the at least one first UAA has a structure of Formula (IC):

142. The conjugate of claim 137, wherein the at least one first UAA has a structure of Formula (ID): in: Each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

143. The conjugate of claim 137, wherein the at least one first UAA has a structure of Formula (IE): Each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

144. The conjugate of claim 137, wherein the at least one first UAA has a structure of Formula (IIA): in: X is independently O or NR'; and When present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

145. The conjugate of claim 137, wherein the at least one first UAA has a structure of Formula (IIB): in: X is independently O or NR'; and When present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

146. The conjugate of any one of claims 108-125, wherein the at least one first UAA has formula (IV) The structure, in, Each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; Ring A is a 5- to 6-membered aryl or heteroaryl group; Each R A are independently -OH, -OR X , halogen, NHR X 、N(R X )2 or optionally substituted alkyl; p is 0, 1, 2, 3 or 4; each R X is an optionally substituted alkyl group; L is -(CH2) p -or-C(O)NH-(CH2) p -; p is an integer from 1 to 6; and When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

147. The conjugate of any one of claims 124-146, wherein the first cell surface molecule is selected from PSMA, EGFR, HER2, HER3, PD-L1, EphA4, fibronectin ED-B, EpCAM, CCR4, CD25, VEGF, VEGFR2, endo180, LIV-1, PTK7, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3 rec, NaPi2b, DLK1, Muc16, cMET, CEA, LRP5, and LRP6.

148. The conjugate of any one of claims 125-147, wherein the second cell surface molecule is selected from PSMA, EGFR, HER2, HER3, PD-L1, EphA4, fibronectin ED-B, EpCAM, CCR4, CD25, VEGF, VEGFR2, endo180, LIV-1, PTK7, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3 rec, NaPi2b, DLK1, Muc16, cMET, CEA, LRP5, and LRP6.

149. The conjugate of any one of claims 108-148, wherein the second targeting domain comprises a second UAA, whereby the second targeting domain is capable of covalently binding to the second target at the site of the second UAA.

150. A conjugate as described in any claim 149, wherein the second UAA is different from the at least one UAA contained in the first targeting domain.

151. The conjugate of claim 149, wherein the second UAA is identical to the at least one UAA contained in the first targeting domain.

152. The conjugate of any one of claims 149-151, wherein the second UAA comprises a fluorosulfate moiety.

153. The conjugate of any one of claims 149-151, wherein the second UAA comprises an aryl fluorosulfate moiety.

154. The conjugate of claim 153, wherein the second UAA comprises Formula I:

155. The conjugate of claim 153, wherein the second UAA has the structure:

156. The conjugate of claim 153, wherein the second UAA has the structure:

157. The conjugate of claim 153, wherein the second UAA comprises Formula II:

158. The conjugate of claim 153, wherein the second UAA has the structure:

159. The conjugate of claim 153, wherein the second UAA has the structure:

160. The conjugate of claim 153, wherein the second UAA comprises Formula III:

161. The conjugate of claim 153, wherein the second UAA has the structure:

162. The conjugate of claim 153, wherein the second UAA has the structure:

163. The conjugate of any one of claims 149-151, wherein the second UAA has a structure of Formula (IA): in, Each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; L is -(CH2) p -or-C(O)NH-(CH2) p -; p is an integer from 1 to 6; and When Y is -O- or -NR-, m is 1; when Y is -N=, m is 2.

164. The conjugate of claim 163, wherein the second UAA has formula (IA-a): structure.

165. The conjugate of claim 163, wherein the second UAA has formula (IA-b): structure.

166. The conjugate of claim 163, wherein the second UAA has a structure of Formula (IB):

167. The conjugate of claim 163, wherein the second UAA has a structure of Formula (IC):

168. The conjugate of claim 163, wherein the second UAA has a structure of Formula (ID): in: Each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

169. The conjugate of claim 163, wherein the second UAA has a structure of Formula (IE): in: Each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; R 1 is hydrogen, fluorine or iodine; R 2 is hydrogen or methyl; and When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

170. The conjugate of claim 163, wherein the second UAA has the structure of Formula (IIA): in: X is independently O or NR'; and When present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

171. The conjugate of claim 163, wherein the second UAA has a structure of Formula (IIB): in: X is independently O or NR'; and When present, R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

172. The conjugate of any one of claims 149-151, wherein the second UAA has formula (IV) The structure, in, Each X is independently O or NR'; Y is a bond, -O-, -NR- or -N=; A is a bond or -(CH2) n -; m is 1 or 2; n is an integer from 1 to 4; When present, each R and R' is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl; Ring A is a 5- to 6-membered aryl or heteroaryl group; Each R A are independently -OH, -OR X , halogen, NHR X 、N(R X )2 or optionally substituted alkyl; p is 0, 1, 2, 3 or 4; each R X is an optionally substituted alkyl group; L is -(CH2) p -or-C(O)NH-(CH2) p -; p is an integer from 1 to 6; and When Y is a bond, -O- or -NR-, m is 1; when Y is -N=, m is 2.

173. The conjugate of any one of claims 108-172, wherein the first targeting domain comprises any one of SEQ ID NOs: 1-4 or 16-64.

174. The conjugate of any one of claims 108-172, wherein the first targeting domain comprises a sequence having at least 70% sequence identity to any one of SEQ ID NOs: 1-4 or 16-64.

175. The conjugate of any one of claims 108-173, wherein the second targeting domain comprises any one of SEQ ID NOs: 1-4, 16-64.

176. The conjugate of any one of claims 108-173, wherein the second targeting domain comprises a sequence at least 70% identical to any one of SEQ ID NOs: 1-4, 16-64.

177. The conjugate of any one of claims 1-87 or 108-172, wherein the conjugate comprises SEQ ID NOs: 65-72.

178. The conjugate of any one of claims 1-87 or 108-172, wherein the conjugate comprises a sequence having at least 70% sequence identity to SEQ ID NOs: 65-72.

179. The conjugate of any one of claims 1-87 or 108-172, wherein the conjugate comprises any one of SEQ ID NOs: 1-4, 16-64.

180. The conjugate of any one of claims 1-87 or 108-172, wherein the conjugate comprises a sequence having at least 70% sequence identity to any one of SEQ ID NOs: 1-4, 16-64.

181. The conjugate of any one of claims 1-87 or 108-172, wherein the conjugate comprises a sequence having at least 80% sequence identity to SEQ ID NOs: 65-72.

182. The conjugate of any one of claims 108-172, wherein at least one of the first targeting domain and the second targeting domain comprises SEQ ID NO:

1.

183. The conjugate of claim 182, wherein the UAA is present at an amino acid position selected from 26, 28, 29, 30, 99, 102, 103, 105, 108, 110, 111, 112, 113, 114, and 115 relative to SEQ ID NO:

1.

184. The conjugate of any one of claims 108-172, wherein at least one of the first targeting domain and the second targeting domain comprises SEQ ID NO:

2.

185. The conjugate of claim 184, wherein the UAA is present at an amino acid position selected from 50, 52, 53, 54, 56, 58 and 100 relative to SEQ ID NO:

2.

186. The conjugate of any one of claims 108-172, wherein at least one of the first targeting domain and the second targeting domain comprises SEQ ID NO:

3.

187. The conjugate of claim 186, wherein the UAA is present at an amino acid position selected from 58, 62, 101, 103 and 107 relative to SEQ ID NO:

3.

188. The conjugate of any one of claims 108-172, wherein at least one of the first targeting domain and the second targeting domain comprises SEQ ID NO:

16.

189. The conjugate of claim 188, wherein at least one of the first targeting domain and the second targeting domain comprising SEQ ID NO: 16 further comprises a non-natural amino acid at position 109 relative to SEQ ID NO:

16.

190. The conjugate of claims 108-172, wherein at least one of the first targeting domain and the second targeting domain comprises SEQ ID NO:

18.

191. The conjugate of any one of claims 108-190, wherein the payload comprises an imaging agent, a radioligand agent, or a cytotoxic agent.

192. The conjugate of claim 191, wherein the cytotoxic moiety comprises a small molecule drug or a chemotherapeutic drug.

193. The conjugate of claim 191, wherein the radioligand agent is selected from 35 S. 3 H. 111 In, 112 In, 14 C. 186 Re, 188 Re, 32 P. 153 Sm, 177 Lu, 86 Y. 88 Y. 90 Y. 131 I. 123 I. 124 I. 125 I. 149 Tb, 211 At 212 Pb / 212 Bi, 213 Bi, 223 Ra, 225 Ac, 64 Cu, 67 Cu and 227 Th.

194. The conjugate of claim 192 or claim 193, wherein the radioligand agent further comprises a chelator.

195. The conjugate of claim 192, wherein the radioligand agent is selected from 99m Tc, 131 I. 201 Tl, 111 In and 67 Ga.

196. The conjugate of any one of claims 108-195, wherein the payload is attached to the conjugate with a linker.

197. A method comprising administering the conjugate of any one of claims 108-196, wherein the conjugate covalently binds to the first target on the surface of a first cell.

198. The method of claim 197, wherein the conjugate binds to the second target on the surface of the first cell.

199. The method of claim 197 or claim 198, wherein the first targeting domain and the second targeting domain bind to the same target.

200. The method of claim 199, wherein the first targeting domain and the second targeting domain bind to the same epitope of the same target.

201. The method of claim 199, wherein the first targeting domain and the second targeting domain bind to different epitopes of the same target.

202. The method of claim 197 or claim 198, wherein the first targeting domain and the second targeting domain bind to different targets on the surface of the first cell.

203. The method of any one of claims 197-202, wherein the second domain comprises a second UAA, and wherein the second UAA is covalently bound to the second target.

204. The method of any one of claims 197-203, wherein the first cell is a tumor cell.

205. The method of claim 204, wherein the conjugate kills the tumor cell or inhibits the growth of the tumor cell when bound to the first target.

206. The method of claim 204, wherein the conjugate kills the tumor cell or inhibits the growth of the tumor cell when bound to the second target.

207. The method of claim 204, wherein the conjugate kills the tumor cell or inhibits the growth of the tumor cell when bound to the first target and the second target.

208. The method of any one of claims 197-207, wherein the first target is selected from PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPa, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3 rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, CD 73. ITGaVb3, ITGaVb6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD25, 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, EphA2, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47, and EpCAM.

209. The method of any one of claims 197-208, wherein the second target is selected from PSMA, EGFR, EGFRviii, MSLN, CEA, DLL3, FAP, CD33, HER3, PD-L1, EphA2, EphA4, HER2, SIRPa, DLK1, Muc16, LRP5, LRP6, endo180, LIV-1, SLAMF7, PTK7, GPR20, CDH6, CSP-1, CD71, PRLR, SEZ6, DLL1, NOTCH3 rec, NaPi2b, CD16, GCC, SSTR2, CAIX, CAXII, MC1R, CXCR4, B1R, GRPR, STEAP1, CD70, CD46, CD166, CLL-1, ADAM9, cKIT, CD36, CD 73. ITGaVb3, ITGaVb6, GPC-1, CD38, CD51, FGFR3, Ly6E, CD44v6, ENPP3, CXCR3, CXCR5, FcRH5, VEGF, VEGFR2, CD45, CCR4, CD25, 5T4, ROR1, TROP-2, NECTIN4, cMET, CD19, CD22, CD30, CD33, CD123, BCMA, CD79b, AXL, RON, B7-H3, B7-H4, KAAG1, Muc1, ADAM-9, GPNMB, EDB fibronectin, tissue factor, GPNMB, FolRa, EphA2, ALPP, ALPPL2, MT1-MMP, CLDN18.2, CLDN6, CLDN9, p-cadherin, CEACAM6, CD47, and EpCAM.

210. The method of any one of claims 197-209, wherein the payload is a radiolabeling agent or a cytotoxic agent.

211. The method of any one of claims 198-209, wherein the payload is an imaging agent.

212. The method of claim 211, wherein when the conjugate binds to the first target and the second target on the first cell, the method images or identifies the first cell.

213. A method of making the conjugate of any one of claims 108-196, comprising: (a) synthesizing in vivo the first targeting domain comprising at least one unnatural amino acid; and (b) optionally conjugating the payload to the first targeting domain or the second targeting domain via a linker.

214. The method of claim 213, further comprising synthesizing the second targeting domain in vivo as a fusion protein with the first targeting domain.

215. The method of claim 213 or claim 214, wherein synthesizing comprises using an orthogonal tRNA synthetase / suppressor tRNA pair.

216. The method of claim 215, wherein the synthesis comprises the orthogonal tRNA synthetase / suppressor tRNA pair, which is derived from a pyrrolysine tRNA synthetase / tRNA Pyl .

Citation Information

Cited By

  • Non-natural amino acid as well as preparation method and application thereof

    CN119462442A

  • Non-natural amino acid modified anti-CCL5 nano antibody

    CN119613545A

  • Unnatural amino acid-modified anti-CCL5 nanobodies

    CN119613545B